



## **XIX International Workshop on Chronic Lymphocytic Leukemia September 2021**

### **Accepted Abstract Title Release (List does include Late Breaker abstracts)**

**1082515**

#### **Incidence of Cardiovascular and Bleeding Events in Chronic Lymphocytic Leukemia Patients (CLL) Treated with Ibrutinib – a Swedish Single-center Experience**

MARIA ANDERSSON,<sup>1</sup>SALLA MAUNO,<sup>2</sup>ANDERS ÖSTERBORG,<sup>3</sup>AGNETA MÅNSSON-  
BROBERG,<sup>4</sup>LOTTA HANSSON,<sup>3</sup>MARZIA PALMA,<sup>3</sup>

<sup>1</sup> Department of Oncology-Pathology, Karolinska Institutet, Stockholm, Sweden, Department of Hematology, Karolinska University Hospital, Stockholm, Sweden, Solna, Sweden

<sup>2</sup> Karolinska institutet, Stockholm, Sweden, Stockholm, Sweden

<sup>3</sup> Department of Oncology-Pathology, Karolinska Institutet, Stockholm, Sweden, Department of Hematology, Lymphoma Unit, Karolinska University Hospital Solna, Stockholm, Sweden, Solna, Sweden

<sup>4</sup> Department of Medicine Huddinge, Karolinska Institutet, Stockholm, Sweden, Department of Cardiology, Karolinska University Hospital, Stockholm, Sweden, Stockholm, Sweden

**1082531**

#### **First-in-human Study of Lisoftoclax (APG-2575), a Novel BCL-2 Inhibitor, in Patients with Relapsed/refractory (R/R) Chronic Lymphocytic Leukemia (CLL) and Other Hematologic Malignancies (HMs)**

SIKANDER AILAWADHI,<sup>1</sup>ASHER CHANAN-KHAN,<sup>2</sup>ANEEL PAULUS,<sup>1</sup>ZI CHEN,<sup>3</sup>BO  
HUANG,<sup>3</sup>MARINA KONOPLEVA,<sup>4</sup>DANIELLE BRANDER,<sup>5</sup>DAVID RIZZIERI,<sup>5</sup>MASA  
LASICA,<sup>6</sup>CONSTANTINE TAM,<sup>6</sup>COSTAS YANNAKOU,<sup>7</sup>HENRY PRINCE,<sup>7</sup>MATTHEW  
DAVIDS,<sup>8</sup>ZHICONG HE,<sup>9</sup>MING LU,<sup>10</sup>MOHAMMAD AHMAD,<sup>10</sup>MINGYU LI,<sup>10</sup>ERIC LIANG,<sup>10</sup>BOYD  
MUDENDA,<sup>10</sup>DAJUN YANG,<sup>11</sup>YIFAN ZHAI,<sup>10</sup>

<sup>1</sup> Mayo Clinic Florida, Jacksonville, Florida, United States

<sup>2</sup> Mayo Clinic Jacksonville, Jacksonville, Florida, United States

<sup>3</sup> Ascentage Pharma (Suzhou) Co., Ltd., Suzhou, China (People's Republic)

**XIX International Workshop on CLL**

16 – 20 September 2021, Virtual

[www.iwcll2021.org](http://www.iwcll2021.org) • 1-888-476-9129



<sup>4</sup> The University of Texas MD Anderson Cancer Center, Houston, Texas, United States

<sup>5</sup> Duke Cancer Institute, Duke University Medical Center, Durham, North Carolina, United States

<sup>6</sup> St. Vincent's Hospital and University of Melbourne, Melbourne, Australia

<sup>7</sup> Epworth Healthcare, Freemasons Hospital and University of Melbourne, East Melbourne, Australia

<sup>8</sup> Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, United States

<sup>9</sup> Jiangsu Ascentage Pharma Pty Ltd., Sydney, Australia

<sup>10</sup> Ascentage Pharma Group, Rockville, Maryland, United States

<sup>11</sup> Ascentage Pharma (Suzhou) Co., Ltd. and State Key Laboratory of Oncology in South China Collaborative Innovation Center for Cancer Medicine, Sun Yat-Sen University Cancer Center, Suzhou, China (People's Republic)

#### **1082565**

#### **A Phase I Trial of Nedd8-Activating Enzyme (NAE) Inhibitor, Pevonedistat (PEVO) in Combination with Ibrutinib in Patients with Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia (CLL) and Non-Hodgkin Lymphoma (NHL)**

PALLAWI TORKA,<sup>1</sup>SWETHA KAMBHAMPATI,<sup>2</sup>LU CHEN,<sup>2</sup>ALEXANDRA MUIR,<sup>2</sup>KIRSTEN ORAND,<sup>2</sup>LYNNE SMITH,<sup>2</sup>ALEX HERRERA,<sup>2</sup>FRANCISCO HERNANDEZ-ILIZALITURRI,<sup>1</sup>LIONEL LEWIS,<sup>3</sup>ALEXEY DANILOV,<sup>2</sup>

<sup>1</sup> Roswell Park Comprehensive Cancer Center, Buffalo, New York, United States

<sup>2</sup> City of Hope National Medical Center, Duarte, California, United States

<sup>3</sup> Dartmouth-Hitchcock Medical Center, Lebanon, New Hampshire, United States

#### **1082648**

#### **A Real-world Study to Assess the Association of Cardiovascular Adverse Events with Ibrutinib as First-line (1L) Treatment for Patients with Chronic Lymphocytic Leukemia (CLL) in the United States**

ANTHONY MATO,<sup>1</sup>BOXIONG TANG,<sup>2</sup>SORAYA AZMI,<sup>2</sup>KERI YANG,<sup>2</sup>YI HAN,<sup>2</sup>XIAOWEI ZHANG,<sup>2</sup>NICOLA WALLIS,<sup>3</sup>JENNIFER STERN,<sup>4</sup>ERIC HEDRICK,<sup>4</sup>JANE HUANG,<sup>3</sup>JEFF SHARMAN,<sup>5</sup>

<sup>1</sup> Memorial Sloan Kettering Cancer Center, New York, New York, United States

<sup>2</sup> BeiGene, Ltd., Emeryville, California, United States

**XIX International Workshop on CLL**

16 – 20 September 2021, Virtual

[www.iwcll2021.org](http://www.iwcll2021.org) • 1-888-476-9129



<sup>3</sup> BeiGene USA, Inc., San Mateo, California, United States

<sup>4</sup> BeiGene, Ltd., Cambridge, Massachusetts, United States

<sup>5</sup> Willamette Valley Cancer Institute, Eugene, Oregon, United States

### **1082736**

**A First-in-human, Phase 1/2 Study of NVG-111, a Novel ROR1xCD3 Bispecific Antibody, in Patients with Debulked, Relapsed/refractory Chronic Lymphocytic Leukaemia (CLL), Small Lymphocytic Lymphoma (SLL) and Mantle Cell Lymphoma (MCL)**

PARAG JASANI,<sup>1</sup>PETER PHILLIPS,<sup>2</sup>SARAH COOK,<sup>2</sup>SATYEN GOHIL,<sup>3</sup>FIONA GERMASCHEWSKI,<sup>4</sup>TOBY BATTEN,<sup>5</sup>MITTAL SHAH,<sup>6</sup>RUTH LOCK,<sup>7</sup>KIERAN O'DONOVAN,<sup>2</sup>AMIT NATHWANI,<sup>8</sup>

<sup>1</sup> Royal Free London NHS Trust and University College London NHS Trust, Essex, United Kingdom

<sup>2</sup> NovelGen Ltd, London, United Kingdom

<sup>3</sup> University College Hospital London, London, United Kingdom

<sup>4</sup> Delos Consultancy Ltd., BEDFORDSHIRE, United Kingdom

<sup>5</sup> Veramed Ltd., Twickenham, United Kingdom

<sup>6</sup> NovalGen Ltd, London, United Kingdom

<sup>7</sup> Aucuba Sciences Ltd, Canterbury, United Kingdom

<sup>8</sup> University College London, London, United Kingdom

### **1082745**

**Ebi3/IL-27 Depleted Microenvironment Favours Tumour Progression in Chronic Lymphocytic Leukaemia**

IRIA CARMEN FERNANDEZ BOTANA,<sup>1</sup>GIULIA MARIA PAGANO,<sup>1</sup>MARINA WIERZ,<sup>1</sup>JEROME PAGGETTI,<sup>1</sup>ETIENNE MOUSSAY,<sup>1</sup>

<sup>1</sup> Luxembourg Institute of Health, Luxembourg, Luxembourg



1082765

**LncRNA Landscape Analysis Identified LncRNA LEF-AS1 as an Oncogene That Upregulates LEF1 and Promotes Survival in Chronic Lymphocytic Leukemia**

HAILING LIU,<sup>1</sup>XINYI DU,<sup>1</sup>XIAO SHI,<sup>1</sup>LEI CAO,<sup>1</sup>XIAOLI ZHAO,<sup>1</sup>YI MIAO,<sup>1</sup>HUAYUAN ZHU,<sup>1</sup>LI WANG,<sup>1</sup>WEI XU,<sup>1</sup>JIANYONG LI,<sup>1</sup>LEI FAN,<sup>1</sup>

<sup>1</sup> Jiangsu Province Hospital, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China (People's Republic)

1082856

**Outcome of SARS-CoV-2 Infected Polish Patients with Chronic Lymphocytic Leukemia**

BARTOSZ PUJA,<sup>1</sup>EWA PIETRUSZA,<sup>2</sup>KATARZYNA PRUSZCZYK,<sup>1</sup>MARTA MORAWSKA,<sup>3</sup>WERONIKA PISZCZEK,<sup>4</sup>ELŻBIETA KALICIŃSKA,<sup>5</sup>AGNIESZKA SZEREMET,<sup>5</sup>JAGODA TRYC-SZPONDER,<sup>6</sup>JOANNA DROZD-SOKOŁOWSKA,<sup>7</sup>HELENA KRZEMIEŃ,<sup>8</sup>ALEKSANDRA REJUS,<sup>9</sup>MAŁGORZATA GAJEWSKA,<sup>10</sup>KAMIL WIŚNIEWSKI,<sup>11</sup>MACIEJ WYSOCKI,<sup>11</sup>ALAN MAJERANOWSKI,<sup>12</sup>EWA PASZKIEWICZ-KOZIK,<sup>13</sup>PAWEŁ STECKIEWICZ,<sup>14</sup>ŁUKASZ SZUKALSKI,<sup>15</sup>ŁUKASZ BOŁKUN,<sup>16</sup>MONIKA DŁUGOSZ-DANECKA,<sup>2</sup>EWA LECH-MARAŃDA,<sup>17</sup>IWONA HUS,<sup>1</sup>

<sup>1</sup> Department of Hematology, Institute of Hematology and Transfusion Medicine, Warsaw, Poland, Warsaw, Poland

<sup>2</sup> Maria Skłodowska-Curie National Research Institute of Oncology, Cracow, Poland

<sup>3</sup> Experimental Hematooncology Department, Medical University, Lublin, Poland; Department of Hematology, St. John's Cancer Center, Lublin, Poland; Lublin, Poland

<sup>4</sup> Department of Hematology, Copernicus Hospital, Torun, Poland, Torun, Poland

<sup>5</sup> Department and Clinic of Hematology, Blood Neoplasms and Bone Marrow Transplantation, Wrocław Medical University, Wrocław, Poland, Wrocław, Poland

<sup>6</sup> Department of Hematology and Bone Marrow Transplantation, Poznan University of Medical Sciences, Poznan, Poland, Poznan, Poland

<sup>7</sup> 8 Department of Hematology, Transplantation and Internal Medicine, Medical University, Warsaw, Poland, Warsaw, Poland

<sup>8</sup> Department of Hematology and Bone Marrow Transplantation, Medical School of Silesia, Silesian Medical University, Katowice, Poland, Katowice, Poland

**XIX International Workshop on CLL**

16 – 20 September 2021, Virtual

[www.iwcll2021.org](http://www.iwcll2021.org) • 1-888-476-9129



<sup>9</sup> Department of Hematology, Regional Clinical Hospital No 1, Rzeszow, Poland, Rzeszow, Poland

<sup>10</sup> Department of Internal Medicine and Hematology, Military Institute of Medicine, Warsaw, Poland, Warszawa, Poland

<sup>11</sup> Department of Hematology, Institute of Hematology and Transfusion Medicine, Warsaw, Poland, Warszawa, Poland

<sup>12</sup> Department of Cell Biology and Immunology, Intercollegiate Faculty of Biotechnology, University of Gdańsk and Medical University of Gdańsk; Department of Hematology and Transplantology, Medical University, Gdansk, Poland, Gdansk, Poland

<sup>13</sup> Department of Lymphoid Malignancies, Maria Skłodowska-Curie National Research Institute of Oncology, Warszawa, Poland, Warszawa, Poland

<sup>14</sup> Jan Kochanowski University, Collegium Medicum, Kielce, Poland; Department of Hematology, Holy Cross Cancer Center, Kielce, Poland, Kielce, Poland

<sup>15</sup> Department of Hematology, Collegium Medicum in Bydgoszcz, Nicolaus Copernicus University in Torun, Poland, Bydgoszcz, Poland

<sup>16</sup> Department of Hematology, Medical University, Bialystok, Poland, Bialystok, Poland

<sup>17</sup> Department of Hematology, Institute of Hematology and Transfusion Medicine, Warsaw, Poland; Department of Hematology and Transfusion Medicine, Centre of Postgraduate Medical Education, Warsaw, Poland, Warsaw, Poland

## **1082908**

### **Results from the informCLL™ Prospective Observational Registry: Real-World Prognostic Biomarker Testing, Treatment Patterns, and Dosing Among 1462 Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)**

ANTHONY MATO,<sup>1</sup>JACQUELINE BARRIENTOS,<sup>2</sup>JEFF SHARMAN,<sup>3</sup>DANIELLE BRANDER,<sup>4</sup>MEGHAN GUTIERREZ,<sup>5</sup>KAREN KADISH,<sup>6</sup>ISRAEL ARANGO-HISIJARA,<sup>7</sup>SANDHYA UPASANI,<sup>7</sup>JENNIFER HAN,<sup>8</sup>QING HUANG,<sup>8</sup>REETHI IYENGAR,<sup>7</sup>NILANJAN GHOSH,<sup>9</sup>

<sup>1</sup> Memorial Sloan Kettering Cancer Center, New York, New York, United States

<sup>2</sup> Donald & Barbara Zucker School of Medicine at Hofstra/Northwell, Lake Success, New York, United States

<sup>3</sup> Willamette Valley Cancer Institute, Eugene, Oregon, United States

<sup>4</sup> Duke Cancer Institute, Duke University Medical Center, Durham, North Carolina, United States

<sup>5</sup> Lymphoma Research Foundation, New York, New York, United States

<sup>6</sup> New England Cancer Specialists, Portsmouth, New Hampshire, United States

**XIX International Workshop on CLL**

16 – 20 September 2021, Virtual

[www.iwcll2021.org](http://www.iwcll2021.org) • 1-888-476-9129





<sup>7</sup> Pharmacyclics LLC, an AbbVie Company, Sunnyvale, California, United States

<sup>8</sup> Janssen Scientific Affairs, LLC, Horsham, Pennsylvania, United States

<sup>9</sup> Department of Hematology, Lymphoma Division, Levine Cancer Institute, Charlotte, North Carolina, United States

**1082910**

**CD160+CD8+ Effector T Cells Are Expanded and Display Impaired Effector Functions in Chronic Lymphocytic Leukemia**

NAJMEH BOZORGMEHR,<sup>1</sup> ANTHEA PETERS,<sup>1</sup> SHOKROLLAH ELAHI,<sup>1</sup>

<sup>1</sup> University of Alberta, Edmonton, Canada

**1083141**

**Differences in Availability of Targeted Inhibitors and Use of Chemoimmunotherapy in the First – Line Therapy of Chronic Lymphocytic Leukemia. a European Survey**

LUKÁŠ SMOLEJ,<sup>1</sup> DARKO ANTIC,<sup>2</sup> EDUARDA COUTO,<sup>3</sup> ALEXANDER EGGLE,<sup>4</sup> MICHAEL GREGOR,<sup>5</sup> HOA THI TUYET TRAN,<sup>6</sup> OZREN JAKSIC,<sup>7</sup> ANN JANSSENS,<sup>8</sup> ARNON KATER,<sup>9</sup> SANDRA LEJNIECE,<sup>10</sup> MATTIAS MATTSSON,<sup>11</sup> ZOLTÁN MÁTRAI,<sup>12</sup> EVA MIKUŠKOVÁ,<sup>13</sup> STEFANO MOLICA,<sup>14</sup> CAROL MORENO,<sup>15</sup> CARSTEN NIEMANN,<sup>16</sup> EUGENE NIKITIN,<sup>17</sup> REGINA PILECKYTĚ,<sup>18</sup> TADEUSZ ROBAK,<sup>19</sup> KOSTAS STAMATOPOULOS,<sup>20</sup> MATEVŽ ŠKERGET,<sup>21</sup> ELISABETH VANDENBERGHE,<sup>22</sup> LOIC YSEBAERT,<sup>23</sup> MIHNEA ZDRENGHEA,<sup>24</sup> BARBARA EICHHORST,<sup>25</sup> PETER HILLMEN,<sup>26</sup>

<sup>1</sup> 4th Department of Internal Medicine - Hematology, University Hospital and Charles University Faculty of Medicine, Hradec Králové, Czech Republic, Hradec Králové, Czech Republic

<sup>2</sup> University of Belgrade, School of Medicine, Clinic for Hematology, Belgrade, Serbia, Serbia

<sup>3</sup> Instituto Português de Oncologia do Porto, Porto, Portugal, Portugal

<sup>4</sup> University Clinic of Internal Medicine III, Paracelsus Medical University Salzburg, Austria, Austria

<sup>5</sup> Department of Hematology, Cantonal Hospital Lucerne, Switzerland, Switzerland

<sup>6</sup> Department Of Hematology, Akershus University Hospital, Norway, Norway

<sup>7</sup> University Hospital Dubrava, Zagreb, Croatia, Zagreb, Croatia

**XIX International Workshop on CLL**

16 – 20 September 2021, Virtual

[www.iwcll2021.org](http://www.iwcll2021.org) • 1-888-476-9129



- <sup>8</sup> Department of Hematology, University Hospitals Leuven, Belgium, Belgium
- <sup>9</sup> Amsterdam University Medical Centers, Amsterdam, on behalf of Hovon, Amsterdam, Netherlands
- <sup>10</sup> Department of Internal Diseases, Riga Stradins University, Riga, Latvia, Latvia
- <sup>11</sup> Department of Hematology, Uppsala University Hospital, Uppsala, Sweden, Sweden
- <sup>12</sup> Department of Hematology and SCT South-Pest Central Hospital, Semmelweis University, Budapest, Hungary, Hungary
- <sup>13</sup> National Oncology Institute, Bratislava, Slovakia, Slovakia
- <sup>14</sup> Dipartimento Onco-Ematologico, Azienda Ospedaliera Pugliese - Ciaccio, CATANZARO, Italy
- <sup>15</sup> Hematology Department, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain, Spain
- <sup>16</sup> Department of Hematology, Copenhagen University Hospital, Copenhagen, Denmark, Blegdamsvej, Denmark
- <sup>17</sup> S. P. Botkin's city hospital, Moscow, Russia, Москва, Russia
- <sup>18</sup> Hematology, Oncology and Transfusiology Center, Vilnius University Hospital, Vilnius, Lithuania, Lithuania
- <sup>19</sup> Medical University of Lodz, Lodz, Poland
- <sup>20</sup> Centre for Research and Technology Hellas, Institute of Applied Biosciences and Karolinska Institutet, Sweden
- <sup>21</sup> Department of Hematology, University Medical Centre Ljubljana, Faculty of Medicine, University of Ljubljana, Slovenia, Slovenia
- <sup>22</sup> Department of Haematology, St James's Hospital, Dublin, Ireland, Ireland
- <sup>23</sup> IUCT-Oncopole, Toulouse, France
- <sup>24</sup> Department of Hematology, Iuliu Hatieganu University of Medicine and Pharmacy, Cluj - Napoca, Romania, Romania
- <sup>25</sup> Department of Internal Medicine, University of Cologne, Cologne, Germany, Germany
- <sup>26</sup> Leeds Institute of Medical Research at St James's, Leeds, United Kingdom



**1083188**

**A Retrospective Analysis of Patients with Chronic Lymphocytic Leukemia (CLL) Treated with Venetoclax in the Real-life Setting in Spain (venares)**

CHRISTELLE FERRA,<sup>1</sup>DIANA MORENO,<sup>2</sup>PATRICIA BALTASAR,<sup>3</sup>MARIA JOSE TEROL,<sup>4</sup>SANTIAGO OSORIO,<sup>5</sup>JAVIER LOSCERTALES,<sup>6</sup>JOSE GARCÍA MARCO,<sup>7</sup>MACARENA ORTIZ,<sup>8</sup>SANDRA IRAHETA,<sup>9</sup>ALICIA SMUCLER,<sup>10</sup>

<sup>1</sup> Institut Català d'Oncologia-H. Germans Trias i Pujol, Badalona, Badalona, Spain

<sup>2</sup> Departamento Médico-Hematología Abbvie Spain, S.L.U., Madrid affiliations, MADRID, Spain

<sup>3</sup> H. U. La Paz, Madrid, madrid, Spain

<sup>4</sup> H.U. Clínico de Valencia, Valencia, valencia, Spain

<sup>5</sup> H. General U. Gregorio Marañón, Madrid, madrid, Spain

<sup>6</sup> H. U. de La Princesa, Madrid, madrid, Spain

<sup>7</sup> Hospital Universitario Puerta de Hierro-Majadahonda, Majadahonda, Spain

<sup>8</sup> H. U. Carlos Haya, Málaga, Malaga, Spain

<sup>9</sup> H. Universitario de Canarias, Tenerife, Santa Cruz de Tenerife, Spain

<sup>10</sup> H. del Bierzo, León, León, Spain

**1083193**

**Prognostic Impact of Somatic Mutations on Time to First Treatment and Overall Survival: Results of Targeted Next-generation Sequencing in 211 Patients with Early Stage Chronic Lymphocytic Leukemia**

CATERINA CRISTINELLI,<sup>1</sup>MARZIA VARETTONI,<sup>2</sup>ESTER ORLANDI,<sup>2</sup>SILVIA ZIBELLINI,<sup>2</sup>MARIANNA ROSSI,<sup>2</sup>MASSIMO GENTILE,<sup>3</sup>ELENA FLOSPERGHER,<sup>1</sup>VIRGINIA VALERIA FERRETTI,<sup>4</sup>ETTORE RIZZO,<sup>5</sup>MATTEO GIOVANNI DELLA PORTA,<sup>6</sup>SARA RATTOTTI,<sup>2</sup>CHIARA CAVALLONI,<sup>2</sup>FABIO BERGAMINI,<sup>1</sup>NICOLE FABBRI,<sup>1</sup>ANNA GALLI,<sup>1</sup>LUCA ARCAINI,<sup>2</sup>

<sup>1</sup> Department of Molecular Medicine, University of Pavia, Pavia, Italy

<sup>2</sup> Division of Hematology, Fondazione IRCCS Policlinico San Matteo, Pavia, Pavia, Italy

<sup>3</sup> Department of Onco-Hematology, Hematology Unit AO of Cosenza, Cosenza, Cosenza, Italy

<sup>4</sup> Service of Clinical Epidemiology and Biometry, Fondazione IRCCS Policlinico San Matteo, Pavia, Pavia, Italy

**XIX International Workshop on CLL**

16 – 20 September 2021, Virtual

[www.iwcll2021.org](http://www.iwcll2021.org) • 1-888-476-9129





<sup>5</sup> EnGenome s.r.l, Pavia, Italy

<sup>6</sup> Cancer Center, IRCCS Humanitas Research Hospital & Humanitas University, Rozzano, Rozzano, Italy

**1083217**

**Mcl-1 and Bcl-xL Levels Predict Responsiveness to Dual MEK/Bcl-2 Inhibition in B Cell Malignancies**

KATRINE MELVOLD,<sup>1</sup>MARIASERENA GILIBERTO,<sup>1</sup>LINDA KARLSEN,<sup>1</sup>PILAR AYUDA-DURÁN,<sup>1</sup>ROBERT HANES,<sup>1</sup>TORIL HOLIEN,<sup>2</sup>JORRIT ENSERINK,<sup>1</sup>JENNIFER BROWN,<sup>3</sup>GEIR TJØNNFJORD,<sup>4</sup>KJETIL TASKÉN,<sup>1</sup>SIGRID SKÅNLAND,<sup>4</sup>

<sup>1</sup> Institute for Cancer Research, Oslo University Hospital, Oslo, Norway

<sup>2</sup> NTNU, Trondheim, Norway

<sup>3</sup> Dana-Farber Cancer Institute, Boston, Massachusetts, United States

<sup>4</sup> Oslo University Hospital, Oslo, Norway

**1083226**

**Low - Dose FCR Compared to BR for the First - Line Treatment of Chronic Lymphocytic Leukemia Patients Without TP53 Aberration: A Retrospective Real - World Analysis by the Czech CLL Study Group**

LUKÁŠ SMOLEJ,<sup>1</sup>YVONA BRYCHTOVÁ,<sup>2</sup>PETRA OBRTLÍKOVÁ,<sup>3</sup>EDUARD CMUNT,<sup>3</sup>PAVEL VODÁREK,<sup>4</sup>ZUZANA KUBOVÁ,<sup>5</sup>RENATA URBANOVÁ,<sup>5</sup>JANA ZUCHNICKÁ,<sup>6</sup>JANA MIHÁLYOVÁ,<sup>6</sup>DAN LYSÁK,<sup>7</sup>MARTIN BREJCHA,<sup>8</sup>MARTIN ŠIMKOVIČ,<sup>9</sup>MARTIN ŠPAČEK,<sup>10</sup>MICHAEL DOUBEK,<sup>11</sup>

<sup>1</sup> 4th Department of Internal Medicine - Hematology, University Hospital and Charles University Faculty of Medicine, Hradec Králové, Czech Republic, Hradec Králové, Czech Republic

<sup>2</sup> Department of Internal Medicine – Hematology and Oncology, University Hospital, Brno, Czech Republic, Brno, Czech Republic

<sup>3</sup> First Department of Internal Medicine - Hematology, General University Hospital, Prague, Czech Republic, Czech Republic

<sup>4</sup> 4th Department of Internal Medicine - Hematology, University Hospital and Faculty of Medicine, Hradec Králové, Czech Republic, Czech Republic

<sup>5</sup> Department of Hematooncology, University Hospital, Olomouc, Czech Republic, Czech Republic

<sup>6</sup> Department of Hematooncology, University Hospital, Ostrava, Czech Republic, Czech Republic

**XIX International Workshop on CLL**

16 – 20 September 2021, Virtual

[www.iwcll2021.org](http://www.iwcll2021.org) • 1-888-476-9129



<sup>7</sup> Department of Hematooncology, University Hospital, Pilsen, Czech Republic, Czech Republic

<sup>8</sup> Department of Hematology, Hospital Agel, Nový Jičín, Czech Republic, Czech Republic

<sup>9</sup> 4th Department of Internal Medicine - Hematology, University Hospital and Charles University Faculty of Medicine, Hradec Králové, Czech Republic, Czech Republic

<sup>10</sup> First Department of Internal Medicine - Hematology, General University Hospital, Prague, Czech Republic, Praha 2, Czech Republic

<sup>11</sup> Department of Internal Medicine – Hematology and Oncology, University Hospital, Brno, Czech Republic, Czech Republic

### **1083230**

#### **The Chronic Lymphocytic Leukemia Comorbidity Index (CLL-CI), a Disease-specific Comorbidity Scale Validated in Two Independent Cohorts**

MAX GORDON,<sup>1</sup> ANDY KAEMPF,<sup>2</sup> EMELIE ROTBAIN,<sup>3</sup> ANDREA SITLINGER,<sup>4</sup> GEOFFREY SHOUSE SHOUSE,<sup>5</sup> MATHEW MEI,<sup>5</sup> DANIELLE BRANDER,<sup>6</sup> TAREQ SALOUS,<sup>7</sup> BRIAN T. HILL,<sup>7</sup> MICHAEL CHOI,<sup>8</sup> JONATHON COHEN,<sup>9</sup> DEBORAH STEPHENS,<sup>10</sup> DANIEL PERSKY,<sup>11</sup> KRISH PATEL,<sup>12</sup> MAZYAR SHADMAN,<sup>13</sup> BYUNG PARK,<sup>14</sup> CARSTEN NIEMANN,<sup>15</sup> ALEXEY DANILOV,<sup>16</sup>

<sup>1</sup> University of Texas MD Anderson, Houston, Texas, United States

<sup>2</sup> Oregon Health and Science, Portland, Oregon, United States

<sup>3</sup> University South Denmark, Odense, Denmark

<sup>4</sup> Duke, Durham, North Carolina, United States

<sup>5</sup> City of Hope, Duarte, California, United States

<sup>6</sup> Duke Cancer Institute, Duke University Medical Center, Durham, North Carolina, United States

<sup>7</sup> Cleveland Clinic, Cleveland, Ohio, United States

<sup>8</sup> UCSD, La Jolla, California, United States

<sup>9</sup> Emory, Atlanta, Georgia, United States

<sup>10</sup> University of Utah, Salt Lake, Utah, United States

<sup>11</sup> University of Arizona, Tucson, Arizona, United States

<sup>12</sup> Swedish, Seattle, Washington, United States

<sup>13</sup> Fred Hutchinson Cancer Research Center, University of Washington, Clinical Research Division, Seattle, WA, USA, Seattle, Washington, United States

**XIX International Workshop on CLL**

16 – 20 September 2021, Virtual

[www.iwcll2021.org](http://www.iwcll2021.org) • 1-888-476-9129



<sup>14</sup> OHSU, Portland, Oregon, United States

<sup>15</sup> Department of Hematology, Copenhagen University Hospital, Copenhagen, Denmark, Blegdamsvej, Denmark

<sup>16</sup> City of Hope National Medical Center, Duarte, California, United States

### 1083240

**Utilizing serial Minimal Residual Disease (MRD) assessments: Long-term outcomes and insights from modeling MRD growth by Next-Generation Sequencing (NGS) within the randomized CLL14 study evaluating fixed-duration therapy with venetoclax and obinutuzumab.**

OTHMAN AL-SAWAF,<sup>1</sup>CAN ZHANG,<sup>2</sup>TONG LU,<sup>3</sup>MICHAEL LIAO,<sup>3</sup>ANESH PANCHAL,<sup>4</sup>SANDRA ROBRECHT,<sup>5</sup>TRAVERS CHING,<sup>6</sup>MANEESH TANDON,<sup>4</sup>ANNA-MARIA FINK,<sup>7</sup>EUGEN TAUSCH,<sup>8</sup>MATTHIAS RITGEN,<sup>9</sup>SEBASTIAN BÖTTCHER,<sup>10</sup>KARL KREUZER,<sup>2</sup>BRENDA CHYLA,<sup>11</sup>DALE MILES,<sup>3</sup>CLEMENS WENDTNER,<sup>12</sup>BARBARA EICHHORST,<sup>13</sup>STEPHAN STILGENBAUER,<sup>14</sup>YANWEN JIANG,<sup>3</sup>MICHAEL HALLEK,<sup>2</sup>KIRSTEN FISCHER,<sup>5</sup>

<sup>1</sup> University Hospital, Cologne, Germany

<sup>2</sup> University Hospital of Cologne, Germany

<sup>3</sup> Genentech, United States

<sup>4</sup> Roche, United States

<sup>5</sup> Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf (CIO ABCD), German CLL Study Group, University Hospital Cologne, University of Cologne, Cologne, Germany, Germany

<sup>6</sup> Adaptive, United States

<sup>7</sup> University of Cologne, Germany

<sup>8</sup> Department of Internal Medicine III, University of Ulm, Ulm, Germany, Germany

<sup>9</sup> University Hospital Kiel, Germany

<sup>10</sup> University Hospital Rostock, Germany

<sup>11</sup> AbbVie, United States

<sup>12</sup> Muenchen Klinik, Germany

<sup>13</sup> Department of Internal Medicine, University of Cologne, Cologne, Germany, Germany

<sup>14</sup> Department of Internal Medicine III, Ulm University, Ulm, Germany, Ulm, Germany

**XIX International Workshop on CLL**

16 – 20 September 2021, Virtual

[www.iwcll2021.org](http://www.iwcll2021.org) • 1-888-476-9129



**1083334**

**Treatment in the First 24 Months from Diagnosis Predicts Shorter Survival in Binet A Stage Patients with Chronic Lymphocytic Leukemia. A CLL Campus Study**

ANDREA VISENTIN,<sup>1</sup>GIANLUIGI REDA,<sup>2</sup>FRANCESCO AUTORE,<sup>3</sup>STEFANO PRAVATO,<sup>4</sup>ANNAMARIA TOMASSO,<sup>5</sup>VALERIA RUOCCO,<sup>4</sup>ALESSANDRO CELLINI,<sup>4</sup>RAMONA CASSIN,<sup>6</sup>MONICA FACCO,<sup>4</sup>FEDERICA FREZZATO,<sup>4</sup>FILIPPO SEVERIN,<sup>4</sup>FRANCESCO PIAZZA,<sup>4</sup>ROBIN FOA,<sup>7</sup>ANTONIO CUNEO,<sup>8</sup>LUCA LAURENTI,<sup>5</sup>FRANCESCA ROMANA MAURO,<sup>7</sup>LIVIO TRENTIN,<sup>4</sup>

<sup>1</sup> Hematology and clinical immunology unit, Department of Medicine, University of Padova, Padova, Italy

<sup>2</sup> Hematology Unit, Fondazione IRCCS Ca' Granda Ospedale Maggiore, MILANO, Italy

<sup>3</sup> Sezione di Ematologia, Dipartimento di Diagnostica per Immagini, Radioterapia Oncologica ed Ematologia, Fondazione Policlinico Universitario A. Gemelli IRCCS, Roma, Italy., Rome, Italy

<sup>4</sup> Hematology and Clinical Immunology Unit, Department of Medicine, University of Padova, Padova, Italy

<sup>5</sup> Hematology Institute, Fondazione Policlinico Universitario Agostino Gemelli IRCSS, Rome, Italy

<sup>6</sup> Hematology Unit, Fondazione IRCCS Ca' Granda Ospedale Maggiore, Milan, Italy

<sup>7</sup> Department of Translational and Precision Medicine, Hematology unit, 'Sapienza' University, Rome, Italy

<sup>8</sup> Hematology Section, Department of Medical Sciences, Azienda Ospedaliera-Universitaria, Arcispedale S. Anna, University of Ferrara, Ferrara, Italy

**1083343**

**Orelabrutinib Monotherapy in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma: Updated Efficacy and Safety Results of Phase II Study**

WEI XU,<sup>1</sup>YONGPING SONG,<sup>2</sup>TINGYU WANG,<sup>3</sup>SHENMIAO YANG,<sup>4</sup>LIHONG LIU,<sup>5</sup>YU HU,<sup>6</sup>WEI ZHANG,<sup>7</sup>JIANFENG ZHOU,<sup>8</sup>SUJUN GAO,<sup>9</sup>KAIYANG DING,<sup>10</sup>HUILAI ZHANG,<sup>11</sup>ZUNMIN ZHU,<sup>12</sup>SHUNQING WANG,<sup>13</sup>BING XU,<sup>14</sup>JIANDA HU,<sup>15</sup>TING LIU,<sup>16</sup>CHUNYAN JI,<sup>17</sup>ZHONGJUN XIA,<sup>18</sup>YAN LI,<sup>19</sup>XIN WANG,<sup>20</sup>BIN ZHANG,<sup>21</sup>RENBIN ZHAO,<sup>22</sup>JIANYONG LI,<sup>23</sup>

<sup>1</sup> Pukou CLL Center, The First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital, Collaborative Innovation Center for Cancer Personalized Medicine, Hematology Department, Nanjing, China, nanjing, China (People's Republic)

<sup>2</sup> Affiliated Cancer Hospital of Zhengzhou University, Hematology Department, Zhengzhou, China, China (People's Republic)

**XIX International Workshop on CLL**

16 – 20 September 2021, Virtual

[www.iwcll2021.org](http://www.iwcll2021.org) • 1-888-476-9129



- <sup>3</sup> Blood Disease Hospital, Chinese Academy of Medical Science, Tianjin, China, Tianjin, China (People's Republic)
- <sup>4</sup> Peking University People's Hospital, Hematology Department, Beijing, China, China (People's Republic)
- <sup>5</sup> The Fourth Hospital of Hebei Medical University, Hematology Department, Shijiazhuang, China, Shijiazhuang, China (People's Republic)
- <sup>6</sup> Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Hematology Department, Wuhan, China, China (People's Republic)
- <sup>7</sup> Peking Union Medical College Hospital, Hematology Department, Beijing, China, China (People's Republic)
- <sup>8</sup> Tongji Hospital, Tongji Medical College, Wuhan, China, China (People's Republic)
- <sup>9</sup> The First Hospital, Jilin University, Hematology Department, Jilin, China, China (People's Republic)
- <sup>10</sup> The First Affiliated Hospital of University of Science and Technology of China, Hematology Department, Hefei, China, China (People's Republic)
- <sup>11</sup> Tianjin Medical University Cancer Institute & Hospital, Lymphoma, Tianjin, China, China (People's Republic)
- <sup>12</sup> Henan Provincial People's Hospital, Hematology Department, Zhengzhou, China, China (People's Republic)
- <sup>13</sup> Guangzhou First People's Hospital, Hematology Department, Guangzhou, China, China (People's Republic)
- <sup>14</sup> The First Affiliated Hospital of Xiamen University, Hematology Department, Xiamen, China, Xiamen, China (People's Republic)
- <sup>15</sup> Fujian Institute of Hematology, Fujian Provincial Key Laboratory on Hematology, Fujian Medical University Union Hospital, Fuzhou, China, China (People's Republic)
- <sup>16</sup> West China Hospital Sichuan University, Hematology Department, Chengdu, China, China (People's Republic)
- <sup>17</sup> Qilu Hospital, Cheeloo College of Medicine, Shandong University, Hematology Department, Jinan, China, China (People's Republic)
- <sup>18</sup> Sate Key Laboratory of Oncology in South China, Collaborative Innovation of Cancer Medicine, Sun Yat-sen University Cancer center, Department of Hematologic Oncology, Guangzhou, China, China (People's Republic)
- <sup>19</sup> The First Affiliated Hospital of China Medical University, Hematology Department, Shenyang, China, China (People's Republic)
- <sup>20</sup> School of Medicine, Shandong University, Hematology, Jinan, China, China (People's Republic)
- <sup>21</sup> Beijing InnoCare Pharma Tech Co., Ltd., China (People's Republic)
- <sup>22</sup> Beijing InnoCare Pharma Tech Co., Ltd, China (People's Republic)

**XIX International Workshop on CLL**

16 – 20 September 2021, Virtual

[www.iwcll2021.org](http://www.iwcll2021.org) • 1-888-476-9129





<sup>23</sup> Pukou CLL Center, The First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital, Collaborative Innovation Center for Cancer Personalized Medicine, Hematology Department, Nanjing, China, China (People's Republic)

**1083347**

**Prognosis of Chronic Lymphocytic Leukaemia in Japanese Patients: Results from the CLLRSG-01 Study**

JUN TAKIZAWA,<sup>1</sup>RITSURO SUZUKI,<sup>2</sup>GO YAMAMOTO,<sup>3</sup>TORU KIGUCHI,<sup>4</sup>ATAE UTSUNOMIYA,<sup>5</sup>HIDEKI ASAOKU,<sup>6</sup>EIICHI OHTSUKA,<sup>7</sup>KENGO TAKEUCHI,<sup>8</sup>KOJI IZUTSU,<sup>9</sup>NAOYA NAKAMURA,<sup>10</sup>KOICHI OHSHIMA,<sup>11</sup>SADAO AOKI,<sup>12</sup>JUNJI SUZUMIYA,<sup>13</sup>

<sup>1</sup> Niigata University Faculty of Medicine, Niigata, Japan

<sup>2</sup> Shimane University, Izumo, Japan

<sup>3</sup> Toranomon Hospital, Minato-ku, Japan

<sup>4</sup> Chugoku Central Hospital, Fukuyama, Japan

<sup>5</sup> Imamura General Hospital, Kagoshima, Japan

<sup>6</sup> Hiroshima Red Cross Hospital & Atomic-bomb Survivors Hospital, Hiroshima, Japan

<sup>7</sup> Oita Prefectural Hospital, Oita, Japan

<sup>8</sup> The Cancer Institute Of JFCR, Koto-ku, Japan

<sup>9</sup> National Cancer Center Japan, Chuo-ku, Japan

<sup>10</sup> Tokai University, Isehara, Japan

<sup>11</sup> Kurume University, Kurume, Japan

<sup>12</sup> NIIGATA UNIVERSITY OF PHARMACY AND APPLIED LIFE SCIENCES., Niigata, Japan

<sup>13</sup> Koga hispital, Yaidu, Japan

**1083349**

**The Use of Ibrutinib in Italian CLL Patients Treated in a Real-World Setting (EVIDENCE): A Preliminary Report**

FRANCESCA ROMANA MAURO,<sup>1</sup>POTITO ROSARIO SCALZULLI,<sup>2</sup>LYDIA SCARFO,<sup>3</sup>ATTILIO GUARINI,<sup>4</sup>ROBERTA MURRU,<sup>5</sup>PAOLO SPORTOLETTI,<sup>6</sup>FERDINANDO FRIGERI,<sup>7</sup>FRANCESCO ALBANO,<sup>8</sup>NICOLA DI RENZO,<sup>9</sup>ALESSANDRO SANNA,<sup>10</sup>IDANNA INNOCENTI,<sup>11</sup>

**XIX International Workshop on CLL**

16 – 20 September 2021, Virtual

[www.iwcll2021.org](http://www.iwcll2021.org) • 1-888-476-9129



MASSIMO MASSAIA,<sup>12</sup> MARTA COSCIA,<sup>13</sup> ELSA PENNESE,<sup>14</sup> CATERINA PATTI,<sup>15</sup> GIANLUIGI REDA,<sup>16</sup> AGOSTINO TAFURI,<sup>17</sup> ANNA GRUGNETTI,<sup>18</sup> VALERIA MAGAROTTO,<sup>18</sup> STEFANO MOLICA,<sup>19</sup>

- <sup>1</sup> Department of Translational and Precision Medicine, Hematology unit, 'Sapienza' University, Rome, Italy
- <sup>2</sup> Department of Hematology and Bone Marrow Transplant, IRCCS Casa Sollievo della Sofferenza Hospital Foundation, SAN GIOVANNI ROTONDO (FOGGIA), Italy
- <sup>3</sup> Strategic Research Program on CLL and Laboratory of B-cell Neoplasia, Università Vita-Salute San Raffaele and IRCCS Ospedale San Raffaele, MILANO, Italy
- <sup>4</sup> Hematology Unit, IRCCS Istituto Tumori "Giovanni Paolo II, BARI, Italy
- <sup>5</sup> SC Ematologia e CTMO, Ospedale Oncologico A. Businco, ARNAS "G. Brotzu", CAGLIARI, Italy
- <sup>6</sup> Department of Medicine and Surgery, Institute of Hematology and Center for Hemato-Oncological Research, Ospedale S. Maria della Misericordia, PERUGIA, Italy
- <sup>7</sup> Hematology-Oncology Unit Azienda Ospedaliera Sant'Anna e San Sebastiano, CASERTA, Italy
- <sup>8</sup> Department of Emergency and Organ Transplantation (D.E.T.O.) - Hematology and Stem Cell Transplantation Unit, University of Bari 'Aldo Moro', BARI, Italy
- <sup>9</sup> Hematology and SCT Unit, Vito Fazzi Hospital, LECCE, Italy
- <sup>10</sup> Division of Hematology, AOU Careggi, FIRENZE, Italy
- <sup>11</sup> Sezione di Ematologia, Dipartimento di Diagnostica per Immagini, Radioterapia Oncologica ed Ematologia, Fondazione Policlinico Universitario A. Gemelli IRCCS, Roma, Italy., ROMA, Italy
- <sup>12</sup> Division of Hematology, AO S.Croce e Carle, CUNEO, Italy
- <sup>13</sup> Department of Molecular Biotechnology and Health Sciences, University of Torino and Division of Hematology, A.O.U. Città della Salute e della Scienza di Torino, TORINO, Italy
- <sup>14</sup> UOSD Centro Diagnosi e Terapia dei Linfomi, Dipartimento Oncologico-Ematologico PO "Spirito Santo", PESCARA, Italy
- <sup>15</sup> Division of Oncohematology Azienda Ospedali Riuniti Villa Sofia-Cervello, PALERMO, Italy
- <sup>16</sup> Hematology Unit, Fondazione IRCCS Ca' Granda Ospedale Maggiore, MILANO, Italy
- <sup>17</sup> Azienda Ospedaliera Universitaria "Sant'Andrea" - Sapienza Università di Roma University Hospital "Sant'Andrea" - Sapienza, University of Rome, ROMA, Italy
- <sup>18</sup> JANSSEN, COLOGNO MONZESE (MILANO), Italy
- <sup>19</sup> Dipartimento Onco-Ematologico, Azienda Ospedaliera Pugliese - Ciaccio, CATANZARO, Italy

**XIX International Workshop on CLL**

16 – 20 September 2021, Virtual

[www.iwcll2021.org](http://www.iwcll2021.org) • 1-888-476-9129



**1083357**

**Tumor Microenvironment-dependent Transcription Factors AHR and HIF-1 $\alpha$  Are Dispensable for Leukemogenesis in the E $\mu$ -TCL1 Mouse Model of CLL**

SUSANNE GONDER,<sup>1</sup>JEROME PAGGETTI,<sup>1</sup>ETIENNE MOUSSAY,<sup>1</sup>

<sup>1</sup> Luxembourg Institute of Health, Luxembourg, Luxembourg

**1083359**

**Ibrutinib Followed by Ofatumumab Consolidation in Previously Untreated Patients with Chronic Lymphocytic Leukemia (CLL): GELLC-7 Trial from the Spanish Group of CLL (GELLC)**

PAU ABRISQUETA,<sup>1</sup>EVA GONZÁLEZ-BARCA,<sup>2</sup>CHRISTELLE FERRA,<sup>3</sup>EDUARDO RÍOS,<sup>4</sup>MARGARITA FERNÁNDEZ DE LA MATA,<sup>5</sup>JULIO DELGADO,<sup>6</sup>RAFAEL ANDREU,<sup>7</sup>JOSÉ ÁNGEL HERNÁNDEZ-RIVAS,<sup>8</sup>MARIA JOSE TEROL,<sup>9</sup>MARCOS GONZÁLEZ,<sup>10</sup>M BELÉN VIDRIALES,<sup>10</sup>PATRICIA BALTASAR,<sup>11</sup>JAVIER DE LA SERNA,<sup>12</sup>ÁNGEL RAMÍREZ,<sup>13</sup>CARMEN BALLESTER,<sup>14</sup>CAROL MORENO,<sup>15</sup>JOSE GARCÍA MARCO,<sup>16</sup>RAÚL CÓRDOBA,<sup>17</sup>LUCRECIA YÁÑEZ,<sup>18</sup>LUÍS FELIPE CASADO,<sup>19</sup>FRANCESC BOSCH,<sup>1</sup>

<sup>1</sup> Vall d'Hebron Institute of Oncology (VHIO), Hospital Universitari Vall d'Hebron, Barcelona, Spain

<sup>2</sup> Institut Català D'Oncologia, Hospital Duran i Reynals, IDIBELL, Universitat de Barcelona, L'Hospitalet de Llobregat, Spain

<sup>3</sup> Institut Català d'Oncologia-H. Germans Trias i Pujol, Badalona, Badalona, Spain

<sup>4</sup> Hospital Nuestra Señora de Valme, Sevilla, Spain

<sup>5</sup> Hospital Universitario Reina Sofía, Córdoba, Spain

<sup>6</sup> Servicio de Hematología, Hospital Clínic, IDIBAPS, Barcelona, Spain, Barcelona, Spain

<sup>7</sup> Hospital Universitario La Fe, Valencia, Spain

<sup>8</sup> Hospital Infanta Leonor, Madrid, Spain

<sup>9</sup> H.U. Clínico de Valencia, Valencia, valencia, Spain

<sup>10</sup> Hospital Universitario de Salamanca-IBSAL, CIC- IBMCC (USAL-CSIC) CIBERONC., Salamanca, Spain

<sup>11</sup> H. U. La Paz, Madrid, madrid, Spain

<sup>12</sup> Hospital Universitario 12 de Octubre, Madrid, Spain

<sup>13</sup> Hospital Universtiaro Central de Asturias, Oviedo, Spain

**XIX International Workshop on CLL**

16 – 20 September 2021, Virtual

[www.iwcll2021.org](http://www.iwcll2021.org) • 1-888-476-9129



- <sup>14</sup> Hospital Universitari Son Espases, Palma, Spain
- <sup>15</sup> Hospital de la Santa Creu i Sant Pau, Barcelona, Spain
- <sup>16</sup> Hospital Universitario Puerta de Hierro-Majadahonda, Majadahonda, Spain
- <sup>17</sup> Fundación Jiménez Díaz, Madrid, Spain
- <sup>18</sup> Hospital Universitario Marqués de Valdecilla, Santander, Spain
- <sup>19</sup> Hospital Virgen de la Salud, Toledo, Spain

**1083368**

**Final Results of IDELA PASS: A Prospective Non-interventional Post Authorization Safety Study of Idelalisib in Germany**

MANUELA HOECHSTETTER,<sup>1</sup> WOLFGANG KNAUF,<sup>2</sup> SILVIA DAMBACHER,<sup>3</sup> NIKE HUCKE,<sup>4</sup> ANNA VAN TROOSTENBURG,<sup>4</sup> HERIBERT RAMROTH,<sup>5</sup> WOLFGANG ABENHARDT,<sup>6</sup> MATHIAS RUMMEL,<sup>7</sup>

- <sup>1</sup> München Klinik Schwabing, München, Germany
- <sup>2</sup> Centrum Haematologie / Onkologie Bethanien, Frankfurt, Germany
- <sup>3</sup> Gilead Sciences GmbH, Martiensried bei München, Germany
- <sup>4</sup> Gilead Sciences GmbH, Martinsried bei München, Germany
- <sup>5</sup> Gilead Sciences GmbH, London, United Kingdom
- <sup>6</sup> Onco Consult Gilching, Gilching, Germany
- <sup>7</sup> Universitätsklinikum Giessen, Gießen, Germany

**1083370**

**Significant Reduction in the Incidence of Bacterial Infections During the covid-19 Pandemic: A Side Effect of Lockdown**

ANDREI PETRENKO,<sup>1</sup> ELENA DMITRIEVA,<sup>1</sup> MARIA KISLOVA,<sup>2</sup> KONSTANTIN NIKITIN,<sup>3</sup> ANCHA BARANOVA,<sup>4</sup> VADIM PTUSHKIN,<sup>1</sup> EUGENE NIKITIN,<sup>5</sup>

- <sup>1</sup> S. P. Botkin's city hospital, Moscow, Russia, Moscow, Russia
- <sup>2</sup> Sechenov First Moscow State Medical University (Sechenov University), Moscow, Russia, Moscow, Russia

**XIX International Workshop on CLL**

16 – 20 September 2021, Virtual

[www.iwcll2021.org](http://www.iwcll2021.org) • 1-888-476-9129



<sup>3</sup> Moscow Institute of Physics and Technology, Department of Radio Engineering and Cybernetics, Moscow, Russia, Москва, Russia

<sup>4</sup> School of Systems Biology, George Mason University, Fairfax, Virginia, USA, Fairfax, Virginia, United States

<sup>5</sup> S. P. Botkin's city hospital, Moscow, Russia, Москва, Russia

### 1083381

#### **COVAXID – a Prospective Clinical Trial on mRNA Vaccination (BNT162b2) Against SARS-CoV-2 in Patients with Immunodeficiency: Results from the CLL Cohort**

LOTTA HANSSON,<sup>1</sup>LISA BLIXT,<sup>2</sup>GORDANA BOGDANOVIC,<sup>3</sup>MARCUS BUGGERT,<sup>4</sup>PURAN CHEN,<sup>4</sup>KATIE HEALY,<sup>5</sup>SOPHIA HOBER,<sup>6</sup>HANS-GUSTAF LJUNGREN,<sup>4</sup>PER LJUNGMAN,<sup>7</sup>PETER NILSSON,<sup>6</sup>ELISA PIN,<sup>6</sup>EDVARD C.I. SMITH,<sup>8</sup>MARGARET SÄLLBERG CHEN,<sup>9</sup>DAVID WULLIMANN,<sup>10</sup>RULA ZAIN,<sup>11</sup>SOO ALEMAN,<sup>12</sup>ANDERS ÖSTERBERG,<sup>1</sup>MIRA AKBER,<sup>13</sup>OLA BLENNOW,<sup>14</sup>STEPHAN MIELKE,<sup>15</sup>GUNNAR SÖDERDAHL,<sup>16</sup>PETER BERGMAN,<sup>17</sup>PIOTR NOWAK,<sup>18</sup>

<sup>1</sup> Department of Oncology-Pathology, Karolinska Institutet, Stockholm, Sweden, Department of Hematology, Lymphoma Unit, Karolinska University Hospital Solna, Stockholm, Sweden, Solna, Sweden

<sup>2</sup> Dept of Hematology, Karolinska University Hospital Solna and Dept of Oncology-Pathology, Karolinska Institutet, Stockholm, Sweden

<sup>3</sup> Dept of Microbiology, Karolinska University Hospital, Stockholm, Sweden

<sup>4</sup> Center for Infectious Medicine, Dept of Medicine Huddinge, Karolinska Institutet, Stockholm, Sweden

<sup>5</sup> Dept of Dental Medicine, Karolinska Institutet, Huddinge, Stockholm, Sweden

<sup>6</sup> Dept of Protein Science, SciLifeLab and KTH Royal Institute of Technology, Stockholm, Sweden

<sup>7</sup> Dept of Hematology, Karolinska University Hospital Solna, Stockholm, Sweden

<sup>8</sup> Dept of Laboratory Medicine, Karolinska Institutet, Stockholm, Sweden

<sup>9</sup> Dept of Dental Medicine, Karolinska Institutet, Stockholm, Sweden

<sup>10</sup> Center for Infectious Medicine, Dept of Medicine Huddinge, Stockholm, Sweden

<sup>11</sup> Dept of Laboratory Medicine, Karolinska Institutet and Centre for Rare Diseases, Department of Clinical Genetics, Karolinska University Hospital, Stockholm, Sweden

<sup>12</sup> Department of Medicine Huddinge, Karolinska Institutet and Division of Infectious Diseases, Karolinska University Hospital, Stockholm, Sweden

**XIX International Workshop on CLL**

16 – 20 September 2021, Virtual

[www.iwcll2021.org](http://www.iwcll2021.org) • 1-888-476-9129





<sup>13</sup> Center for Infectious Medicine, Dept of Medicine Huddinge, Karolinska Institutet, Stockholm, Sweden, Sweden

<sup>14</sup> Division of Infectious Diseases, Karolinska University Hospital, Dept of Transplantation, Karolinska University Hospital, Department of Medicine Huddinge, Karolinska Institutet, Stockholm, Sweden, Sweden

<sup>15</sup> Dept. of Cellular Therapy and Allogeneic Stem Cell Transplantation, Karolinska University Hospital Huddinge, Department of Medicine Huddinge, Karolinska Institutet, Stockholm, Sweden, Sweden

<sup>16</sup> Dept of Transplantation, Karolinska University Hospital, Dept of Clinical Science, Intervention and Technology, Karolinska Institutet, Stockholm, Sweden, Sweden

<sup>17</sup> Centre for Rare Diseases, Department of Clinical Genetics, Karolinska University Hospital, Dept of Laboratory Medicine, Karolinska Institutet, Stockholm, Sweden, Sweden

<sup>18</sup> Division of Infectious Diseases, Karolinska University Hospital, Center for Infectious Medicine, Dept of Medicine Huddinge, Karolinska Institutet, Stockholm, Sweden, Sweden

#### **1083425**

#### **Clinical Impact of Recurrent Gene Mutations in Chronic Lymphocytic Leukemia: A Retrospective, Multi-center Cohort Study by ERIC, the European Research Initiative on CLL, in Harmony**

LARRY MANSOURI,<sup>1</sup>BIRNA THORVALDSDOTTIR,<sup>1</sup>LESLEY-ANN SUTTON,<sup>2</sup>MANJA MEGGENDORFER,<sup>3</sup>HELEN PARKER,<sup>4</sup>FERRAN NADEU,<sup>5</sup>CHRISTIAN BRIEGHEL,<sup>6</sup>STAMATIA LAIDOU,<sup>7</sup>RICCARDO MOIA,<sup>8</sup>DAVIDE ROSSI,<sup>9</sup>MARK CATHERWOOD,<sup>10</sup>JANA KOTASKOVA,<sup>11</sup>JULIO DELGADO,<sup>12</sup>ANA RODRÍGUEZ-VICENTE,<sup>13</sup>GIAN MATTEO RIGOLIN,<sup>14</sup>SILVIA BONFIGLIO,<sup>15</sup>LYDIA SCARFO,<sup>16</sup>ZADIE DAVIS,<sup>17</sup>INMACULADA RAPADO,<sup>18</sup>FATIMA MIRAS,<sup>18</sup>JOAQUÍN MARTINEZ-LOPEZ,<sup>18</sup>JESÚS MARÍA HERNÁNDEZ RIVAS,<sup>19</sup>PATRICK THORNTON,<sup>20</sup>MARÍA JOSÉ LARRÁYOZ,<sup>21</sup>MARÍA JOSÉ CALASANZ,<sup>21</sup>ZOLTÁN MÁTRAI,<sup>22</sup>CSABA BÖDÖR,<sup>23</sup>KARIN EKSTRÖM SMEDBY,<sup>2</sup>BLANCA ESPINET,<sup>24</sup>ANNA PUIGGROS,<sup>24</sup>RITU GUPTA,<sup>25</sup>LARS BULLINGER,<sup>26</sup>FRANCESC BOSCH,<sup>27</sup>BÁRBARA TAZÓN-VEGA,<sup>27</sup>FANNY BARAN-MARSZAK,<sup>28</sup>DAVID OSCIER,<sup>29</sup>FLORENCE NGUYEN-KHAC,<sup>30</sup>THORSTEN ZENZ,<sup>31</sup>MARIA JOSE TEROL,<sup>32</sup>ANTONIO CUNEO,<sup>14</sup>MARÍA HERNÁNDEZ-SÁNCHEZ,<sup>13</sup>SARKA POSPISILOVA,<sup>33</sup>KEN MILLS,<sup>34</sup>GIANLUCA GAIDANO,<sup>35</sup>CARSTEN NIEMANN,<sup>36</sup>ELIAS CAMPO,<sup>37</sup>JONATHAN STREFFORD,<sup>4</sup>PAOLO GHIA,<sup>15</sup>KOSTAS STAMATOPOULOS,<sup>38</sup>RICHARD ROSENQUIST,<sup>2</sup>

<sup>1</sup> Karolinska Institutet, Solna, Sweden

<sup>2</sup> Karolinska Institutet, United States

**XIX International Workshop on CLL**

16 – 20 September 2021, Virtual

[www.iwcll2021.org](http://www.iwcll2021.org) • 1-888-476-9129



- <sup>3</sup> MLL Munich Leukemia Laboratory, United States
- <sup>4</sup> University of Southampton, United Kingdom
- <sup>5</sup> Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain; Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Madrid, Spain, Spain
- <sup>6</sup> Rigshospitalet, Copenhagen University Hospital, United States
- <sup>7</sup> Centre for Research and Technology Hellas, Institute of Applied Biosciences, United States
- <sup>8</sup> University of Eastern Piedmont, Italy
- <sup>9</sup> Institute of Southern Switzerland, Sweden
- <sup>10</sup> Queens University Belfast, United States
- <sup>11</sup> University Hospital Brno and Faculty of Medicine, Masaryk University, United States
- <sup>12</sup> Servicio de Hematología, Hospital Clínic, IDIBAPS, Barcelona, Spain, Barcelona, Spain
- <sup>13</sup> University of Salamanca, United States
- <sup>14</sup> University of Ferrara, United States
- <sup>15</sup> Università Vita Salute San Raffaele and IRCCS Ospedale San Raffaele, United States
- <sup>16</sup> Strategic Research Program on CLL and Laboratory of B-cell Neoplasia, Università Vita-Salute San Raffaele and IRCCS Ospedale San Raffaele, MILANO, Italy
- <sup>17</sup> Royal Bournemouth Hospital, United States
- <sup>18</sup> Hospital Universitario 12 Octubre Madrid, Spain
- <sup>19</sup> University of Salamanca, Spain
- <sup>20</sup> Beaumont Hospital Dublin, United States
- <sup>21</sup> Servicio de Citogenética y Genética Hematológica, Departamento de Genética, Universidad de Navarra, Pamplona, Spain, Spain
- <sup>22</sup> Department of Hematology and SCT South-Pest Central Hospital, Semmelweis University, Budapest, Hungary, Hungary
- <sup>23</sup> Semmelweis University, United States
- <sup>24</sup> Servei de Patologia, Hospital del Mar, Barcelona, Spain; Grup de Recerca Translacional en Neoplàsies Hematològiques, Programa de Recerca en Càncer, Institut Hospital del Mar d'Investigacions Mèdiques (IMIM), Barcelona, Spain, Barcelona, Spain
- <sup>25</sup> All India Institute of Medical Sciences, United States
- <sup>26</sup> Charité University Medicine, United States

**XIX International Workshop on CLL**

16 – 20 September 2021, Virtual

[www.iwcll2021.org](http://www.iwcll2021.org) • 1-888-476-9129



- <sup>27</sup> Hospital Universitari Vall d'Hebron (HUVH), Vall d'Hebron Institute of Oncology (VHIO), Universitat Autònoma de Barcelona, Spain
- <sup>28</sup> Laboratoire d'hématologie, Hôpital Avicenne, Assistance Publique-Hôpitaux de Paris, Paris, France
- <sup>29</sup> Department of Haematology, Royal Bournemouth Hospital, Bournemouth, United Kingdom
- <sup>30</sup> Sorbonne Université, United States
- <sup>31</sup> University Hospital and University of Zurich, Germany
- <sup>32</sup> H.U. Clínico de Valencia, Valencia, valencia, Spain
- <sup>33</sup> Central European Institute of Technology (CEITEC), Masaryk University; Department of Internal Medicine – Hematology and Oncology, University Hospital Brno and Faculty of Medicine, Masaryk University, Czech Republic
- <sup>34</sup> Patrick G. Johnston Centre for Cancer Research, Queen's University Belfast, Belfast, United Kingdom, Belfast, United Kingdom
- <sup>35</sup> University of Eastern Piedmont, United States
- <sup>36</sup> Department of Hematology, Copenhagen University Hospital, Copenhagen, Denmark, Blegdamsvej, Denmark
- <sup>37</sup> Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain; Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Madrid, Spain; Hospital Clinic de Barcelona, Universitat de Barcelona, Barcelona, Spain, Spain
- <sup>38</sup> Centre for Research and Technology Hellas, Institute of Applied Biosciences and Karolinska Institutet, Sweden

## 1083511

### **Final Results of a Phase 1/2 Study of SYK Inhibitor Entospletinib in Combination with Obinutuzumab in Patients with Relapsed/refractory (R/R) Chronic Lymphocytic Leukemia (CLL)**

ALEXEY DANILOV,<sup>1</sup> VI LAM,<sup>2</sup> BRIA THURLOW,<sup>3</sup> BYUNG PARK,<sup>4</sup> STEPHEN SPURGEON,<sup>3</sup> ADAM KITTAL,<sup>5</sup>

<sup>1</sup> City of Hope National Medical Center, LA CANADA FLINTRIDGE, California, United States

<sup>2</sup> City of Hope National Medical Center, DUARTE, California, United States

<sup>3</sup> Oregon Health and Science University, Portland, Oregon, United States

<sup>4</sup> OHSU, Portland, Oregon, United States

<sup>5</sup> Ohio State University, Columbus, Ohio, United States

**XIX International Workshop on CLL**

16 – 20 September 2021, Virtual

[www.iwcll2021.org](http://www.iwcll2021.org) • 1-888-476-9129



**1083515**

**Comparison of Subcutaneous and Intravenous Immunoglobulins in Patients with Chronic Lymphocytic Leukemia and Secondary Immunodeficiency. a Real- world Evidence Study**

ANDREA VISENTIN,<sup>1</sup>FRANCESCA ROMANA MAURO,<sup>2</sup>FRANCESCO MALFONA,<sup>2</sup>SILVIA IMBERGAMO,<sup>3</sup>STEFANO PRAVATO,<sup>4</sup>LEILA ROMANO GARGARELLA,<sup>5</sup>MONICA FACCO,<sup>4</sup>FEDERICA LESSI,<sup>5</sup>CARMELA GURRIERI,<sup>5</sup>FABRIZIO VIANELLO,<sup>5</sup>FRANCESCO PIAZZA,<sup>4</sup>MAURIZIO MARTELLI,<sup>2</sup>LIVIO TRENTIN,<sup>4</sup>

<sup>1</sup> Hematology and clinical immunology unit, Department of Medicine, University of Padova, Padova, Italy

<sup>2</sup> Department of Translational and Precision Medicine, Hematology unit, 'Sapienza' University, Rome, Italy

<sup>3</sup> Hematology and Clinical Immunology Unit, Department of Medicine, University of Padua, Padova, Italy

<sup>4</sup> Hematology and Clinical Immunology Unit, Department of Medicine, University of Padova, Padova, Italy

<sup>5</sup> Hematology and clinical immunology unit, Department of Medicine, University of Padua, Padova, Italy

**1083519**

**Pharmacologic Inhibition of SUMO-activating Enzyme Potentiates Interferon Response and T Cell-mediated Anti-tumor Immunity in Chronic Lymphocytic Leukemia (CLL) and Lymphoma Models**

VI LAM,<sup>1</sup>XIAO GUANG WANG,<sup>1</sup>SCOTT BEST,<sup>2</sup>NUR BRUSS,<sup>2</sup>TINGTING LIU,<sup>1</sup>ALLISON BERGER,<sup>3</sup>NATHAN PENNOCK,<sup>2</sup>ALEXEY DANILOV,<sup>4</sup>

<sup>1</sup> City of Hope National Medical Center, DUARTE, California, United States

<sup>2</sup> Oregon Health and Science University, Portland, Oregon, United States

<sup>3</sup> Takeda, Cambridge, Massachusetts, United States

<sup>4</sup> City of Hope National Medical Center, LA CANADA FLINTRIDGE, California, United States

**1083523**

**PHASE I/II STUDY of UMBRALISIB (TGR- 1202), UBLITUXIMAB (TG-1101), and PEMBROLIZUMAB in PATIENTS with RELAPSED or REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA and RICHTER'S TRANSFORMATION: 5-YEAR FOLLOW-UP**

LINDSEY E. ROEKER,<sup>1</sup>MAZYAR SHADMAN,<sup>2</sup>JAKUB SVOBODA,<sup>3</sup>ELINE T. LUNING PRAK,<sup>4</sup>STEPHEN J. SCHUSTER,<sup>3</sup>PATRICIA Y. TSAO,<sup>4</sup>COLLEEN DORSEY,<sup>1</sup>GAIL PANTON,<sup>1</sup>

**XIX International Workshop on CLL**

16 – 20 September 2021, Virtual

[www.iwcll2021.org](http://www.iwcll2021.org) • 1-888-476-9129



SUNITA D. NASTA,<sup>3</sup>DANIEL J. LANDSBURG,<sup>3</sup>BETH MORRIGAN,<sup>5</sup>JILL ELWELL,<sup>5</sup>KAITLIN KENNARD,<sup>3</sup>ANDREW D. ZELENETZ,<sup>1</sup>MICHELLE PURDOM,<sup>6</sup>DANA PASKALIS,<sup>6</sup>PETER SPORTELLI,<sup>6</sup>HARI P. MISKIN,<sup>6</sup>MICHAEL S. WEISS,<sup>6</sup>ANTHONY MATO,<sup>7</sup>

<sup>1</sup> CLL Program, Leukemia Service, Division of Hematologic Oncology, Memorial Sloan-Kettering Cancer Center, New York, New York, United States

<sup>2</sup> Fred Hutchinson Cancer Research Center, University of Washington, Clinical Research Division, Seattle, WA, USA, Seattle, Washington, United States

<sup>3</sup> Lymphoma Program, Abramson Cancer Center, University of Pennsylvania, Philadelphia, Pennsylvania, United States

<sup>4</sup> Department of Pathology and Laboratory Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, United States

<sup>5</sup> Fred Hutchinson Cancer Research Center, Seattle, Washington, United States

<sup>6</sup> TG Therapeutics Inc., New York, New York, United States

<sup>7</sup> Memorial Sloan Kettering Cancer Center, New York, New York, United States

**1083548**

### **Unraveling Functional Consequences of AID Off-target Mutations in CLL**

AMPARO RICO,<sup>1</sup>JORGE PUELMA,<sup>2</sup>NOE SEIJA,<sup>1</sup>JULIETA SEPULVEDA,<sup>2</sup>PABLO MORANDE,<sup>1</sup>XIAO-JIE YAN,<sup>3</sup>FLORENCIA PALACIOS,<sup>1</sup>MARÍA ELENA MARQUEZ,<sup>1</sup>RITA URIA,<sup>1</sup>GIMENA DOS SANTOS,<sup>4</sup>ANA INÉS LANDONI,<sup>5</sup>NICHOLAS CHIORAZZI,<sup>6</sup>MARCELO NAVARRETE,<sup>2</sup>PABLO OPPEZZO,<sup>7</sup>

<sup>1</sup> Institut Pasteur de Montevideo, Montevideo, Uruguay

<sup>2</sup> Universidad de Magallanes, Punta Arena, Chile

<sup>3</sup> The Feinstein Institutes for Medical Research, New York, New York, United States

<sup>4</sup> Institut Pasteur de Montevideo and Dept of Hematology of the University Hospital, Montevideo, Uruguay

<sup>5</sup> Unit of Hematology and Transplant of hematopoietic precursors, Hospital Maciel, Montevideo, Uruguay

<sup>6</sup> Karches Center for Oncology Research, The Feinstein Institutes for Medical Research, Northwell Health, Manhasset, NY, USA, New York, New York, United States

<sup>7</sup> Institut Pasteur de Montevideo, Montevideo, Uruguay

**XIX International Workshop on CLL**

16 – 20 September 2021, Virtual

[www.iwcll2021.org](http://www.iwcll2021.org) • 1-888-476-9129





**1083553**

**A Phase 2 Study of the Efficacy and Safety of MK-1026 in Patients with Hematologic Malignancies**

ARVIND CHAUDHRY,<sup>1</sup> MOHAMMED FAROOQUI,<sup>2</sup> LI-AN LIN,<sup>2</sup> JING YANG,<sup>2</sup> SETH THOMPSON,<sup>2</sup> PATRICIA MARINELLO,<sup>2</sup>

<sup>1</sup> Summit Cancer Centers, Spokane Valley, Washington, United States

<sup>2</sup> Merck & Co., Inc., Kenilworth, New Jersey, United States

**1083568**

**Comparison of Clinical and Laboratory Features, Drug Availability, and Outcomes of CLL Patients Treated in Public or in Private Hospitals in Brazil: A Retrospective Analysis of the Brazilian Registry of CLL**

VERENA PFISTER,<sup>1</sup> FERNANDA MARQUES,<sup>1</sup> MIHOKO YAMAMOTO,<sup>1</sup> RODRIGO SANTUCCI,<sup>2</sup> VALERIA BUCCHERI,<sup>3</sup> RAPHAEL MELO,<sup>4</sup> ALITA AZEVEDO,<sup>5</sup> YANA NOVIS,<sup>6</sup> SERGIO FORTIER,<sup>7</sup> LAURA FOGLIATTO,<sup>8</sup> LEILA PEROBELLI,<sup>9</sup> GLACIANO RIBEIRO,<sup>10</sup> GERMISON LOPES,<sup>11</sup> VERA FIGUEIREDO,<sup>12</sup> MATHEUS GONÇALVES,<sup>1</sup> CARLOS CHIATTONE,<sup>7</sup> CELSO ARRAIS-RODRIGUES,<sup>1</sup>

<sup>1</sup> Universidade Federal de Sao Paulo, Sao Paulo, Brazil

<sup>2</sup> Hemomed Instituto de Oncologia e Hematologia, Sao Paulo, Brazil

<sup>3</sup> ICESP - Faculdade de Medicina da USP, Sao Paulo, Brazil

<sup>4</sup> Instituto do Câncer do Estado de São Paulo, Sao Paulo, Brazil

<sup>5</sup> Hemope - Fundação de Hematologia e Hemoterapia de Pernambuco, Recife, Brazil

<sup>6</sup> Hospital Sirio Libanes, Sao Paulo, Brazil

<sup>7</sup> Santa Casa de Misericórdia de São Paulo, Sao Paulo, Brazil

<sup>8</sup> Hospital de Clínicas de Porto Alegre, Porto Alegre, Brazil

<sup>9</sup> Hospital Brigadeiro, Sao Paulo, Brazil

<sup>10</sup> Universidade Federal de Minas Gerais, Belo Horizonte, Brazil

<sup>11</sup> Universidade Federal do Ceará, Fortaleza, Brazil

<sup>12</sup> Hospital do Servidor Público Estadual, Sao Paulo, Brazil

**XIX International Workshop on CLL**

16 – 20 September 2021, Virtual

[www.iwcll2021.org](http://www.iwcll2021.org) • 1-888-476-9129



**1083588**

**Longitudinal antibody Levels and T- cell Response Following BNT162b mRNA Covid19 Vaccine in Patients with Chronic Lymphocytic Leukemia. on Behalf of the Israeli CLL Study Group**

OHAD BENJAMINI,<sup>1</sup> LIOR ROKACH,<sup>2</sup> GILAD ITCHAKI,<sup>3</sup> EREZ BAR-HAIM,<sup>4</sup> ANDREI BRAESTER,<sup>5</sup> LEV SHVIDEL,<sup>6</sup> NETA GOLDSCHMIDT,<sup>7</sup> SHIRLEY SHAPIRA,<sup>8</sup> NAJIB DALLY,<sup>9</sup> RIVA FINEMAN,<sup>10</sup> OSNAT BAIREY,<sup>11</sup> AARON POLLIACK,<sup>7</sup> TAMAR TADMOR,<sup>12</sup>

<sup>1</sup> Chaim Sheba Medical Center, Tel-Hashomer, Tel Aviv, Israel

<sup>2</sup> 3Department of Software and Information Systems Engineering, Ben-Gurion University of the Negev, Beer Sheva, Israel

<sup>3</sup> Institute of Hematology, Davidoff Cancer Center, Rabin Medical Center, Petah Tikva, Petah Tikva, Israel

<sup>4</sup> institute of technology, 74100, Israel

<sup>5</sup> Galilee Medical Center, Nahariya,, Nahariya,, Israel

<sup>6</sup> Kaplan Medical Center, Rehovot, Rehovot, Israel

<sup>7</sup> Hadassah Medical Center, Jerusalem, Israel

<sup>8</sup> 8Health Division, Maccabi Healthcare Services, Tel Aviv, Tel Aviv, Israel

<sup>9</sup> Ziv Medical Center, Safed, Safed, Israel

<sup>10</sup> Rambam Health Care Campus, Haifa, Israel

<sup>11</sup> Davidoff Cancer Center, Petah Tikva, Israel

<sup>12</sup> Bnai Zion Medical Center, Haifa, Israel

**1083625**

**BCL3 Gene Rearrangement at IgH Locus, t(14;19), Identifies an Aggressive Subset of Chronic Lymphocytic Leukemia. an ERIC and Italian CLL Campus Study**

ANDREA VISENTIN,<sup>1</sup> PANAGIOTIS BALIAKAS,<sup>2</sup> LAURA BONALDI,<sup>3</sup> CLAUDIA HAFERLACH,<sup>4</sup> KARLA PLEVOVA,<sup>5</sup> DAVID OSCIER,<sup>6</sup> FLORENCE NGUYEN-KHAC,<sup>7</sup> GIAN MATTEO RIGOLIN,<sup>8</sup> ANASTASIA ATHANASIADOU,<sup>9</sup> FANNY BARAN-MARSZAK,<sup>10</sup> ALBERTO VALIENTE,<sup>11</sup> MARIA JOSÉ TEROL,<sup>12</sup> PAU ABRISQUETA,<sup>13</sup> BLANCA ESPINET,<sup>14</sup> ANNA PUIGGROS,<sup>14</sup> ANNALISA MARTINES,<sup>3</sup> VALERIA RUOCCO,<sup>15</sup> STEFANO PRAVATO,<sup>15</sup> ROBIN FOA,<sup>16</sup> FRANCESCA ROMANA MAURO,<sup>16</sup> KOSTAS STOMATOPULOS,<sup>17</sup> PAOLO GHIA,<sup>18</sup> ANTONIO CUNEO,<sup>8</sup> LIVIO TRENTIN,<sup>15</sup>

**XIX International Workshop on CLL**

16 – 20 September 2021, Virtual

[www.iwcll2021.org](http://www.iwcll2021.org) • 1-888-476-9129



- <sup>1</sup> Hematology and clinical immunology unit, Department of Medicine, University of Padova, Padova, Italy
- <sup>2</sup> Department of Immunology, Genetics and Pathology, Science for Life Laboratory, Uppsala University, Uppsala, Sweden
- <sup>3</sup> Immunology and Molecular Oncology Unit, Veneto Institute of Oncology IOV-IRCSS, Padova, Italy
- <sup>4</sup> MLL Munich Leukemia Laboratory, Munich, Germany, Munich, Germany
- <sup>5</sup> Central European Institute of Technology (CEITEC), Masaryk University; Department of Internal Medicine – Hematology and Oncology, University Hospital Brno and Faculty of Medicine, Masaryk University, Brno, Czech Republic
- <sup>6</sup> Department of Haematology, Royal Bournemouth Hospital, Bournemouth, United Kingdom
- <sup>7</sup> Service d'Hématologie Biologique, Hôpital Pitié-Salpêtrière, Paris, France, Paris, France
- <sup>8</sup> Hematology Section, Department of Medical Sciences, Azienda Ospedaliera-Universitaria, Arcispedale S. Anna, University of Ferrara, Ferrara, Italy
- <sup>9</sup> Hematology Department and HCT Unit, G. Papanicolaou Hospital, Thessaloniki, Greece
- <sup>10</sup> Laboratoire d'hématologie, Hopital Avicenne, Assistance Publique-Hôpitaux de Paris, Paris, France
- <sup>11</sup> Servicio de Genética. Complejo Hospitalario de Navarra, Pamplona, Spain, Pamplona, Spain
- <sup>12</sup> Hospital Clínico de Valencia, Valencia, Spain
- <sup>13</sup> Hospital Universitari Vall d'Hebron, Barcelona, Spain
- <sup>14</sup> Servei de Patologia, Hospital del Mar, Barcelona, Spain; Grup de Recerca Translacional en Neoplàsies Hematològiques, Programa de Recerca en Càncer, Institut Hospital del Mar d'Investigacions Mèdiques (IMIM), Barcelona, Spain, Barcelona, Spain
- <sup>15</sup> Hematology and Clinical Immunology Unit, Department of Medicine, University of Padova, Padova, Italy
- <sup>16</sup> Department of Translational and Precision Medicine, Hematology unit, 'Sapienza' University, Rome, Italy
- <sup>17</sup> Institute of Applied Biosciences, Center for Research and Technology Hellas, Thessaloniki, Greece
- <sup>18</sup> Strategic Research program on CLL, Università Vita-Salute San Raffaele and IRCCS Ospedale San Raffaele, Milan, Italy

**1083634**

**TG-1701, a Selective Bruton Tyrosine Kinase (BTK) Inhibitor, as Monotherapy and in Combination with Ublituximab and Umbralisib (U2) in Patients with Chronic Lymphocytic Leukemia**

CHAN Y. CHEAH,<sup>1</sup>WOJCIECH JURCZAK,<sup>2</sup>MASA LASICA,<sup>3</sup>STANLEY CHEUNG,<sup>4</sup>TOMASZ WRÓBEL,<sup>5</sup>JAN WALEWSKI,<sup>6</sup>COSTAS YANNAKOU,<sup>7</sup>KATHARINE L. LEWIS,<sup>8</sup>

**XIX International Workshop on CLL**

16 – 20 September 2021, Virtual

[www.iwcll2021.org](http://www.iwcll2021.org) • 1-888-476-9129



MONIKA DŁUGOSZ-DANECKA,<sup>9</sup>KRZYSZTOF GIANNOPOULOS,<sup>10</sup>HARI P. MISKIN,<sup>11</sup>EMMANUEL NORMANT,<sup>12</sup>OWEN A. O'CONNOR,<sup>12</sup>ALEJANDRO D. RICART,<sup>12</sup>CONSTANTINE S. TAM,<sup>13</sup>

<sup>1</sup> Linear Clinical Research, and Department of Haematology, Sir Charles Gairdner Hospital, Nedlands, Western Australia, Medical School, University of Western Australia, Crawley, Australia

<sup>2</sup> Maria Skłodowska-Curie National Research Institute of Oncology, Krakow, Poland

<sup>3</sup> St. Vincent's Hospital and University of Melbourne, Melbourne, Australia

<sup>4</sup> Ashford Cancer Centre Research, Austria

<sup>5</sup> Department of Hematology, Wroclaw Medical University, Poland

<sup>6</sup> Maria Skłodowska-Curie National Research Institute of Oncology, Poland

<sup>7</sup> Epworth Healthcare, Freemasons Hospital and University of Melbourne, East Melbourne, Australia

<sup>8</sup> Linear Clinical Research, and Department of Haematology, Sir Charles Gairdner Hospital, Australia

<sup>9</sup> Maria Skłodowska-Curie National Research Institute of Oncology, Cracow, Poland

<sup>10</sup> Hematology Department, St John's Cancer Centre, Poland

<sup>11</sup> TG Therapeutics Inc., New York, New York, United States

<sup>12</sup> TG Therapeutics, Inc., United States

<sup>13</sup> St. Vincent Hospital and University of Melbourne, Australia

## 1083667

### **Umbralisib Plus Ublituximab (U2) Is Superior to Obinutuzumab Plus Chlorambucil (O+Chl) in Patients with Treatment-Naïve (TN) and Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia (CLL): Results from the Phase 3 Unity-CLL Study**

WOJCIECH JURCZAK,<sup>1</sup>JOHN G. GRIBBEN,<sup>2</sup>RYAN JACOBS,<sup>3</sup>SEBASTIAN GROSICKI,<sup>4</sup>KRZYSZTOF GIANNOPOULOS,<sup>5</sup>TOMASZ WRÓBEL,<sup>6</sup>SYED F. ZAFAR,<sup>7</sup>JENNIFER L. CULTRERA,<sup>8</sup>SUMAN KAMBHAMPATI,<sup>9</sup>ALEXEY DANILOV,<sup>10</sup>JOHN M. BURKE,<sup>11</sup>JEROME GOLDSCHMIDT,<sup>12</sup>DOUGLAS F. BEACH,<sup>13</sup>SCOTT F. HUNTINGTON,<sup>14</sup>JAVIER PINILLA-IBARZ,<sup>15</sup>JEFF SHARMAN,<sup>16</sup>TANYA SIDDIQI,<sup>17</sup>DANIELLE BRANDER,<sup>18</sup>MAZYAR SHADMAN,<sup>19</sup>JOHN M. PAGEL,<sup>20</sup>MONIKA DŁUGOSZ-DANECKA,<sup>21</sup>NILANJAN GHOSH,<sup>22</sup>KATHRYN S. KOLIBABA,<sup>23</sup>PETER SPORTELLI,<sup>24</sup>HARI P. MISKIN,<sup>24</sup>OWEN A. O'CONNOR,<sup>23</sup>MICHAEL S. WEISS,<sup>24</sup>IAN W. FLINN,<sup>25</sup>

<sup>1</sup> Maria Skłodowska-Curie National Research Institute of Oncology, Krakow, Poland

**XIX International Workshop on CLL**

16 – 20 September 2021, Virtual

[www.iwcll2021.org](http://www.iwcll2021.org) • 1-888-476-9129



- <sup>2</sup> Barts Cancer Institute, London, United Kingdom
- <sup>3</sup> Department of Hematology, Lymphoma Division, Assistant Professor of Medicine, Levine Cancer Institute/Atrium Health, Charlotte, North Carolina, United States
- <sup>4</sup> Department of Hematology and Cancer Prevention, School of Public Health, Silesian Medical University, Poland
- <sup>5</sup> Hematology Department, St John's Cancer Centre, Poland
- <sup>6</sup> Department of Hematology, Wroclaw Medical University, Poland
- <sup>7</sup> Florida Cancer Specialists South / Sarah Cannon Research Institute, United States
- <sup>8</sup> Florida Cancer Specialists North / Sarah Cannon Research Institute, United States
- <sup>9</sup> Sarah Cannon Research Institute At Research Medical Ctr, United States
- <sup>10</sup> City of Hope National Medical Center, Duarte, California, United States
- <sup>11</sup> Knight Cancer Institute, Oregon Health & Science University, United States
- <sup>12</sup> Blue Ridge Cancer Care / US Oncology Research, United States
- <sup>13</sup> Pennsylvania Hospital, University of Pennsylvania, United States
- <sup>14</sup> Yale Cancer Center, United States
- <sup>15</sup> Department of Immunology, H. Lee Moffitt Cancer Center & Research Institute, Tampa, Florida, United States
- <sup>16</sup> Willamette Valley Cancer Institute, Eugene, Oregon, United States
- <sup>17</sup> City of Hope National Medical Center, United States
- <sup>18</sup> Duke Cancer Institute, Duke University Medical Center, Durham, North Carolina, United States
- <sup>19</sup> Fred Hutchinson Cancer Research Center, University of Washington, Clinical Research Division, Seattle, WA, USA, Seattle, Washington, United States
- <sup>20</sup> Center for Blood Disorders and Stem Cell Transplantation, Swedish Cancer Institute, United States
- <sup>21</sup> Maria Sklodowska-Curie National Research Institute of Oncology, United States
- <sup>22</sup> Department of Hematology, Lymphoma Division, Levine Cancer Institute, Charlotte, North Carolina, United States
- <sup>23</sup> TG Therapeutics, Inc., United States
- <sup>24</sup> TG Therapeutics Inc., New York, New York, United States
- <sup>25</sup> Sarah Cannon Research Institute/Tennessee Oncology, United States





**1083755**

**A Quality-adjusted Survival (Q-TWiST) Analysis of Acalabrutinib with or Without Obinutuzumab in Patients with Treatment-naïve Chronic Lymphocytic Leukemia (CLL)**

JEFF SHARMAN,<sup>1</sup>UGOCHI EMERIBE,<sup>2</sup>LING CAI,<sup>3</sup>PRIYANKA GAITONDE,<sup>2</sup>

<sup>1</sup> Willamette Valley Cancer Institute, Eugene, Oregon, United States

<sup>2</sup> AstraZeneca, Gaithersburg, Maryland, United States

<sup>3</sup> AstraZeneca, South San Francisco, California, United States

**1083790**

**Outcomes of Patients with Chronic Lymphocytic Leukemia (CLL) Sequentially Resistant to Both BCL2 and BTK Inhibition**

VICTOR LIN,<sup>1</sup>THOMAS LEW,<sup>2</sup>EDWARD CLIFF,<sup>3</sup>PIERS BLOMBERY,<sup>2</sup>ELLA THOMPSON,<sup>2</sup>SASANKA HANDUNNETTI,<sup>2</sup>DAVID WESTERMAN,<sup>2</sup>BRYONE KUSS,<sup>4</sup>CONSTANTINE TAM,<sup>2</sup>DAVID HUANG,<sup>5</sup>JOHN SEYMOUR,<sup>6</sup>ANDREW ROBERTS,<sup>2</sup>MARY ANN ANDERSON,<sup>3</sup>

<sup>1</sup> Royal Melbourne Hospital, Parkville, Australia

<sup>2</sup> Peter MacCallum Cancer Centre, Australia

<sup>3</sup> Royal Melbourne Hospital, Australia

<sup>4</sup> Flinders University and Medical Centre, Bedford Park, Australia

<sup>5</sup> Walter and Eliza Hall Institute of Medical Research, Australia

<sup>6</sup> Peter MacCallum Cancer Centre and Royal Melbourne Hospital, Melbourne, Australia

**1083793**

**Lynx (lymphoid Next-generation Sequencing): Ngs Panel and Bioinformatic Tool for Integrative Analysis of Prognostic and Predictive Markers in B-cell Malignancies**

VERONIKA NAVRKALOVA,<sup>1</sup>TOMAS REIGL,<sup>2</sup>KARLA PLEVOVA,<sup>3</sup>JAKUB HYNST,<sup>2</sup>KAROL PAL,<sup>2</sup>JAKUB PORC,<sup>2</sup>ANDREA MARECKOVA,<sup>1</sup>HANA JELINKOVA,<sup>1</sup>MICHAEL DOUBEK,<sup>1</sup>ŠÁRKA POSPÍŠILOVÁ,<sup>4</sup>

<sup>1</sup> Department of Internal Medicine – Hematology and Oncology, Masaryk University and University Hospital Brno, Brno, Czech Republic, Brno, Czech Republic

**XIX International Workshop on CLL**

16 – 20 September 2021, Virtual

[www.iwcll2021.org](http://www.iwcll2021.org) • 1-888-476-9129



<sup>2</sup> Center of Molecular Medicine, Central European Institute of Technology, Masaryk University, Brno, Czech Republic, Brno, Czech Republic

<sup>3</sup> Central European Institute of Technology (CEITEC), Masaryk University; Department of Internal Medicine – Hematology and Oncology, University Hospital Brno and Faculty of Medicine, Masaryk University, Brno, Czech Republic

<sup>4</sup> Center of Molecular Medicine, Central European Institute of Technology, Masaryk University Brno & Department of Internal Medicine-Hematology and Oncology, University Hospital Brno and Faculty of Medicine, Masaryk University Brno, Czech Republic, Brno, Czech Republic

**1083796**

**Retrospective Observational Study of the Treatment of Chronic Lymphocytic Leukaemia (CLL) with Ibrutinib Monotherapy Focused on the Management of Hypertension**

RAFAEL PARRA GABILONDO,<sup>1</sup>PAU ABRISQUETA,<sup>2</sup>JAVIER LOSCERTALES,<sup>3</sup>MARIA JOSE TEROL,<sup>4</sup>ÁNGEL RAMÍREZ,<sup>5</sup>MACARENA ORTIZ,<sup>6</sup>INMACULADA PÉREZ,<sup>7</sup>CAROLINA CUÉLLAR-GARCÍA,<sup>8</sup>MARGARITA FERNÁNDEZ,<sup>9</sup>ALICIA RODRÍGUEZ,<sup>10</sup>ANA LARIO,<sup>11</sup>JULIO DELGADO,<sup>12</sup>ANA GODOY,<sup>13</sup>JOSE MARÍA ARGUIÑANO,<sup>14</sup>MARÍA JOSÉ BERRUEZO,<sup>15</sup>ANA OLIVEIRA,<sup>16</sup>JOSÉ ÁNGEL HERNÁNDEZ,<sup>17</sup>LOLA GARCÍA,<sup>18</sup>ÁNGELES MEDINA,<sup>19</sup>PALOMA GARCÍA,<sup>20</sup>SANTIAGO OSORIO,<sup>21</sup>PATRICIA BALTASAR,<sup>22</sup>MIGUEL FERNÁNDEZ,<sup>23</sup>FERNANDO MARCO,<sup>24</sup>MARÍA JESÚS VIDAL,<sup>25</sup>ALICIA SMUCLER,<sup>26</sup>MONTSERRAT LÓPEZ,<sup>27</sup>ISIDRO JARQUE,<sup>28</sup>ALEXIA SUÁREZ,<sup>29</sup>RUBÉN FERNÁNDEZ,<sup>30</sup>AIMA LANCHARRO,<sup>31</sup>EDUARDO RÍOS,<sup>32</sup>MARÍA DEL CARMEN LOSADA,<sup>33</sup>ERNESTO PÉREZ,<sup>34</sup>RICARDO GARCÍA,<sup>35</sup>RAFAEL RAMOS,<sup>36</sup>LUCRECIA YÁÑEZ,<sup>37</sup>JOSÉ LUIS BELLO,<sup>38</sup>CRISTINA LORIENTE,<sup>1</sup>MIGUEL VILLANUEVA,<sup>1</sup>ALBERTO ARRIBAS,<sup>1</sup>

<sup>1</sup> Janssen-Cilag, Madrid, Spain

<sup>2</sup> Vall d'Hebron Institute of Oncology (VHIO), Hospital Universitari Vall d'Hebron, Barcelona, Spain

<sup>3</sup> H. U. de La Princesa, Madrid, Madrid, Spain

<sup>4</sup> H.U. Clínico de Valencia, Valencia, Valencia, Spain

<sup>5</sup> Hospital Universitario Central de Asturias, Oviedo, Spain

<sup>6</sup> H. U. Carlos Haya, Málaga, Malaga, Spain

<sup>7</sup> Hospital Virgen de la Victoria, Málaga, Spain

<sup>8</sup> Hospital de la Santa Creu i Sant Pau, Barcelona, Spain

**XIX International Workshop on CLL**

16 – 20 September 2021, Virtual

[www.iwcll2021.org](http://www.iwcll2021.org) • 1-888-476-9129



- <sup>9</sup> Hospital Universitario Reina Sofia, Córdoba, Spain
- <sup>10</sup> Hospital Universitario Virgen de la Macarena, Sevilla, Spain
- <sup>11</sup> Hospital Universitario Ramón y Cajal, Madrid, Spain
- <sup>12</sup> Hospital Clinic I Provincial, Barcelona, Spain
- <sup>13</sup> Hospital Universitario Miguel Servet, Zaragoza, Spain
- <sup>14</sup> Hospital de Navarra, Pamplona, Spain
- <sup>15</sup> Hospital de Jerez, Jerez, Spain
- <sup>16</sup> ICO Hospitalet, L'Hospitalet De Llobregat, Spain
- <sup>17</sup> Hospital Universitario Infanta Leonor, Madrid, Spain
- <sup>18</sup> Hospital Morales Meseguer, Murcia, Spain
- <sup>19</sup> Hospital Costa del Sol, Marbella, Spain
- <sup>20</sup> Hospital Universitario San Cecilio, Granada, Spain
- <sup>21</sup> Hospital Universitario Gregorio Marañón, Madrid, Spain
- <sup>22</sup> H. U. La Paz, Madrid, madrid, Spain
- <sup>23</sup> Hospital Universitario Doctor Peset, Valencia, Spain
- <sup>24</sup> Hospital Universitario de Basurto, Bilbao, Spain
- <sup>25</sup> Hospital de León, León, Spain
- <sup>26</sup> Hospital del Bierzo, Ponferrada, Spain
- <sup>27</sup> Hospital Universitario Príncipe de Asturias, Alcala De Henares, Spain
- <sup>28</sup> Hospital Universitario La Fe, Valencia, Spain
- <sup>29</sup> Hospital Doctor Negrín, Las Palmas, Spain
- <sup>30</sup> Hospital Cabueñes, Gijón, Spain
- <sup>31</sup> Hospital Arnau de Vilanova, Valencia, Spain
- <sup>32</sup> Hospital Virgen de Valme, Sevilla, Spain
- <sup>33</sup> Hospital Universitario Insular de Gran Canaria, Las Palmas, Spain
- <sup>34</sup> Hospital Txagorritxu, Vitoria, Spain
- <sup>35</sup> Hospital San Pedro, Logroño, Spain
- <sup>36</sup> Hospital Universitario de Badajoz, Badajoz, Spain



<sup>37</sup> Hospital Marqués de Valdecilla, Santander, Spain

<sup>38</sup> HOSP. CLINICO UNIVERSITARIO SANTIAGO DE COMPOSTELA, Santiago de Compostela, Spain

**1083804**

**Role of Ahr and Hif1a in the Suppressive Ability of Tregs During CLL Development**

GIULIA MARIA PAGANO,<sup>1</sup>JEROME PAGGETTI,<sup>1</sup>ETIENNE MOUSSAY,<sup>1</sup>

<sup>1</sup> Luxembourg Institute of Health, Luxembourg, Luxembourg

**1083807**

**Cessation of Ibrutinib Results in Reduced Infections and Durable Remissions – First Analysis of an On-off-repeat Study in Patients with Chronic Lymphocytic Leukemia**

JEANETTE LUNDIN,<sup>1</sup>TOM A. MULDER,<sup>2</sup>MAGDALENA KÄTTSTRÖM,<sup>3</sup>ANDERS UDDEVIK,<sup>4</sup>HÅKAN MELLSTEDT,<sup>2</sup>KIA HEIMERSSON,<sup>2</sup>LOTTA HANSSON,<sup>5</sup>MARZIA PALMA,<sup>5</sup>ANDERS ÖSTERBORG,<sup>5</sup>

<sup>1</sup> Karolinska University Hospital Solna/Karolinska Institutet, Stockholm, Sweden

<sup>2</sup> Department of Oncology-Pathology, Karolinska Institutet, Stockholm, Sweden

<sup>3</sup> Department of Medicine, Section of Hematology, Örebro University Hospital, Örebro, Sweden

<sup>4</sup> Department of Medicine, Section of Hematology, Gävle Hospital, Gävle, Sweden

<sup>5</sup> Department of Oncology-Pathology, Karolinska Institutet, Stockholm, Sweden, Department of Hematology, Lymphoma Unit, Karolinska University Hospital Solna, Stockholm, Sweden, Solna, Sweden

**1083808**

**Applying a Molecular Approach for Everyday Clinical Practice in Chronic Lymphocytic Leukemia**

MARIAM IBAÑEZ,<sup>1</sup>RAFAEL ANDREU,<sup>2</sup>M JOSE MACIÁN,<sup>3</sup>ESPERANZA SUCH,<sup>3</sup>ANA VICENTE,<sup>3</sup>GAYANE AVETISYAN,<sup>3</sup>M CARMEN MELENDEZ,<sup>3</sup>ALESSANDRO LIQUORI,<sup>3</sup>PEDRO ASENSI,<sup>3</sup>PILAR LLORET,<sup>3</sup>ISIDRO JARQUE,<sup>2</sup>ALEJANDRO PACIOS,<sup>4</sup>ISABEL PICON,<sup>4</sup>EVA DONATO,<sup>5</sup>M CARMEN MAS,<sup>6</sup>CARMEN ALONSO,<sup>6</sup>CAROLINA CAÑIGRAL,<sup>7</sup>AMPARO SEMPERE,<sup>3</sup>SAMUEL ROMERO,<sup>3</sup>MARTA SANTIAGO,<sup>3</sup>GUILLERMO SANZ,<sup>3</sup>JAVIER DE LA RUBIA,<sup>3</sup>LEONOR SENENT,<sup>3</sup>IRENE LUNA,<sup>3</sup>

**XIX International Workshop on CLL**

16 – 20 September 2021, Virtual

[www.iwcll2021.org](http://www.iwcll2021.org) • 1-888-476-9129



<sup>1</sup> Instituto de Investigación Sanitaria La Fe, VALENCIA, Spain

<sup>2</sup> Hospital Universitario La Fe, Valencia, Spain

<sup>3</sup> Hosp. Universitario y Politécnico La Fe, VALENCIA, Spain

<sup>4</sup> HOSPITAL DE MANISES, VALENCIA, Spain

<sup>5</sup> HOSPITAL DR PESET, VALENCIA, Spain

<sup>6</sup> Hospital Arnau de Vilanova, VALENCIA, Spain

<sup>7</sup> HOSPITAL GENERAL DE CASTELLON, CASTELLON, Spain

### **1083815**

#### **Ibrutinib Related Expression Patterns in Chronic Lymphocytic Leukaemia Patients**

CHARLOTTE MCDONALD,<sup>1</sup> CHARALAMPOS XANTHOPOULOS,<sup>1</sup> VLADIMIR TEIF,<sup>2</sup> KEN MILLS,<sup>3</sup> EFTERPI KOSTARELI,<sup>4</sup>

<sup>1</sup> Wellcome-Wolfson Institute for Experimental Medicine, Queen's University Belfast, Belfast, United Kingdom, Belfast, United Kingdom

<sup>2</sup> School of Life Sciences, University of Essex, UK, Essex, United Kingdom

<sup>3</sup> Patrick G. Johnston Centre for Cancer Research, Queen's University Belfast, Belfast, United Kingdom, Belfast, United Kingdom

<sup>4</sup> WWIEM, Queens University Belfast, Belfast, United Kingdom

### **1083838**

#### **Efficacy and Safety of Acalabrutinib versus Ibrutinib in Previously Treated Chronic Lymphocytic Leukemia: Results of a Phase 3 Clinical Trial**

PETER HILLMEN,<sup>1</sup> JOHN BYRD,<sup>2</sup> PAOLO GHIA,<sup>3</sup> ARNON KATER,<sup>4</sup> ASHER CHANAN-KHAN,<sup>5</sup> RICHARD FURMAN,<sup>6</sup> SUSAN O'BRIEN,<sup>7</sup> MUSTAFA NURI YENEREL,<sup>8</sup> ARPAD ILLES,<sup>9</sup> NEIL KAY,<sup>10</sup> JOSE GARCÍA MARCO,<sup>11</sup> ANTHONY MATO,<sup>12</sup> JAVIER PINILLA-IBARZ,<sup>13</sup> JOHN SEYMOUR,<sup>14</sup> STEPHANE LEPRETRE,<sup>15</sup> STEPHAN STILGENBAUER,<sup>16</sup> TADEUSZ ROBAK,<sup>17</sup> PRITI PATEL,<sup>18</sup> KARA HIGGINS,<sup>18</sup> TING YU,<sup>18</sup> WOJCIECH JURCZAK,<sup>19</sup>

<sup>1</sup> Leeds Institute of Medical Research at St James's, Leeds, United Kingdom

<sup>2</sup> The Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States

**XIX International Workshop on CLL**

16 – 20 September 2021, Virtual

[www.iwcll2021.org](http://www.iwcll2021.org) • 1-888-476-9129





- <sup>3</sup> Strategic Research program on CLL, Università Vita-Salute San Raffaele and IRCCS Ospedale San Raffaele, Milan, Italy
- <sup>4</sup> Amsterdam University Medical Centers, Amsterdam, on behalf of Hovon, Amsterdam, Netherlands
- <sup>5</sup> Mayo Clinic Jacksonville, Jacksonville, Florida, United States
- <sup>6</sup> Weill Cornell Medicine, New York Presbyterian Hospital, New York, New York, United States
- <sup>7</sup> Chao Family Comprehensive Cancer Center, University of California-Irvine, Orange, California, United States
- <sup>8</sup> Istanbul University, Istanbul Faculty of Medicine, Istanbul, Turkey
- <sup>9</sup> University of Debrecen, Debrecen, Hungary
- <sup>10</sup> Mayo Clinic Rochester, Rochester, Minnesota, United States
- <sup>11</sup> Hospital Universitario Puerta de Hierro-Majadahonda, Majadahonda, Spain
- <sup>12</sup> Memorial Sloan Kettering Cancer Center, New York, New York, United States
- <sup>13</sup> Department of Immunology, H. Lee Moffitt Cancer Center & Research Institute, Tampa, Florida, United States
- <sup>14</sup> Peter MacCallum Cancer Centre and Royal Melbourne Hospital, Melbourne, Australia
- <sup>15</sup> Centre Henri Becquerel and Normandie University UNIROUEN, Rouen, France
- <sup>16</sup> Department of Internal Medicine III, Ulm University, Ulm, Germany, Ulm, Germany
- <sup>17</sup> Medical University of Lodz, Lodz, Poland
- <sup>18</sup> AstraZeneca, South San Francisco, California, United States
- <sup>19</sup> Maria Sklodowska-Curie National Research Institute of Oncology, Krakow, Poland

**1083841**

**Analysis of BTK-independent Calcium Signalling Downstream of the B-cell Receptor Signalling in Human Malignant B Cells**

RACHAEL ARTHUR,<sup>1</sup>ALEX WATHEN,<sup>1</sup>ADAM LINLEY,<sup>2</sup>FREDA STEVENSON,<sup>1</sup>FRANCESCO FORCONI,<sup>1</sup>ANDREW STEELE,<sup>3</sup>PACKHAM GRAHAM,<sup>1</sup>BEATRIZ VALLE-ARGOS,<sup>1</sup>

<sup>1</sup> University of Southampton, Southampton, United Kingdom

<sup>2</sup> Liverpool University, Liverpool, United Kingdom

<sup>3</sup> Janssen Pharmaceutical Companies of Johnson and Johnson, Southampton, Pennsylvania, United States

**XIX International Workshop on CLL**

16 – 20 September 2021, Virtual

[www.iwcll2021.org](http://www.iwcll2021.org) • 1-888-476-9129



**1083852**

**Leukemic Cell-derived Interleukin-9 Impairs the Ability of Cytotoxic T Lymphocytes to Form Functional Lytic Synapses in Chronic Lymphocytic Leukemia**

LAURA PATRUSSI,<sup>1</sup>GIOIA BONCOMPAGNI,<sup>1</sup>VANESSA TATANGELO,<sup>1</sup>NAGAJA  
CAPITANI,<sup>1</sup>FEDERICA FREZZATO,<sup>2</sup>ANDREA VISENTIN,<sup>3</sup>LIVIO TRENTIN,<sup>2</sup>COSIMA BALDARI,<sup>1</sup>

<sup>1</sup> University of Siena, Siena, Italy

<sup>2</sup> Hematology and Clinical Immunology Unit, Department of Medicine, University of Padova, Padova, Italy

<sup>3</sup> University of Padova, Padova, Italy

**1083855**

**Active DNA Demethylation Pathway Intermediates as a New Biomarkers of CLL Development and Progression**

JAROSLAW CZYZ,<sup>1</sup>DANIEL GACKOWSKI,<sup>2</sup>KINGA KOSZUCKA,<sup>3</sup>MARTA STARCZAK,<sup>2</sup>MACIEJ  
GAWROŃSKI,<sup>2</sup>JUSTYNA SZPOTAN,<sup>2</sup>ALEKSANDRA SKALSKA,<sup>2</sup>ANNA ŁABEJSZO,<sup>2</sup>ANNA  
JACHALSKA,<sup>4</sup>MARCIN KRUSZEWSKI,<sup>4</sup>CZYŻEWSKA JOANNA,<sup>5</sup>ŁUKASZ SZUKALSKI,<sup>6</sup>ADRIANA  
CZYŻ,<sup>5</sup>KAROLINA KACZOROWSKA,<sup>4</sup>OLIŃSKI RYSZARD,<sup>2</sup>

<sup>1</sup> Department of Hematology Faculty of Medicine Collegium Medicum in Bydgoszcz Nicolaus Copernicus University in Toruń, Bydgoszcz, Poland

<sup>2</sup> Department of Clinical Biochemistry, Faculty of Pharmacy; Collegium Medicum in Bydgoszcz, Nicolaus Copernicus University in Toruń, 85-092 Bydgoszcz, Bydgoszcz, Poland

<sup>3</sup> Department of Clinical Biochemistry, Faculty of Pharmacy; Collegium Medicum in Bydgoszcz, Nicolaus Copernicus University in Toruń, 85-092 Bydgoszcz, Poland, Bydgoszcz, Poland

<sup>4</sup> Department of Hematology ; Collegium Medicum in Bydgoszcz, Nicolaus Copernicus University in Toruń, Bydgoszcz, Poland

<sup>5</sup> University Hospital No2 - Jan Biziel Memorial Hospital, Bydgoszcz, Poland

<sup>6</sup> Department of Hematology, Collegium Medicum in Bydgoszcz, Nicolaus Copernicus University in Torun, Poland, Bydgoszcz, Poland



**1083872**

**CLL Cell Counts and CD20 Levels Rapidly Decreased in Relapsed/refractory CLL Patients Treated with Ublituximab and Umbralisib**

JENNIFER BRUNO,<sup>1</sup>CHRISTINE HERNE,<sup>1</sup>ANDREA BARAN,<sup>1</sup>KARL VANDERMEID,<sup>1</sup>PAUL BARR,<sup>1</sup>SALLY QUATAERT,<sup>1</sup>CLIVE ZENT,<sup>1</sup>CHARLES CHU,<sup>1</sup>

<sup>1</sup> University of Rochester Medical Center, Rochester, New York, United States

**1083882**

**Establishment and Molecular Characterization of a 3D Bioprinted Chronic Lymphocytic Leukemia (CLL) in Vitro Model**

RICCARDO PINOS,<sup>1</sup>FRANCESCA VITTORIA SBRANA,<sup>2</sup>FEDERICA BARBAGLIO,<sup>2</sup>ANNA SOFIA TASCINI,<sup>1</sup>LYDIA SCARFO,<sup>3</sup>PAOLO GHIA,<sup>4</sup>CRISTINA SCIELZO,<sup>2</sup>

<sup>1</sup> San Raffaele Scientific Institute, Milan, Italy

<sup>2</sup> IRCCS Ospedale San Raffaele, Milano, Italy

<sup>3</sup> Strategic Research Program on CLL and Laboratory of B-cell Neoplasia, Università Vita-Salute San Raffaele and IRCCS Ospedale San Raffaele, MILANO, Italy

<sup>4</sup> Strategic Research program on CLL, Università Vita-Salute San Raffaele and IRCCS Ospedale San Raffaele, Milan, Italy

**1083893**

**GURU-LLC: A New National Translational Research Group in CLL in Uruguay**

PABLO OPPEZZO,<sup>1</sup>ANA INÉS LANDONI,<sup>2</sup>GIMENA DOS SANTOS,<sup>3</sup>RAFAEL ALONSO,<sup>4</sup>LILIAN DIAZ,<sup>5</sup>VIRGINIA COSTA ILLANES,<sup>6</sup>VIRGINIA LEMA,<sup>7</sup>GABRIELA DE GALVEZ,<sup>8</sup>VICTORIA IRIGOIN,<sup>8</sup>PABLO MUXI,<sup>9</sup>CAROLINA OLIVER,<sup>10</sup>JORGE SCLAVI,<sup>11</sup>MARTIN FERRANDO,<sup>12</sup>PATRICIA KOLLAR,<sup>13</sup>MARIANA STEVENAZZI,<sup>14</sup>ALBERTO VAZQUEZ,<sup>15</sup>RITA URIA,<sup>16</sup>MARÍA ELENA MARQUEZ,<sup>16</sup>FLORENCIA PALACIOS,<sup>16</sup>GUILLERMO DIGHIERO,<sup>16</sup>MERCEDES LASSUS,<sup>17</sup>CECILIA GUILLERMO,<sup>18</sup>RAÚL GABUS,<sup>19</sup>

<sup>1</sup> Institut Pasteur de Montevideo, Montevideo, Uruguay

<sup>2</sup> Unit of Hematology and Transplant of hematopoietic precursors, Hospital Maciel, Montevideo, Uruguay

**XIX International Workshop on CLL**

16 – 20 September 2021, Virtual

[www.iwcll2021.org](http://www.iwcll2021.org) • 1-888-476-9129



- <sup>3</sup> Institut Pasteur de Montevideo and Dept of Hematology of the University Hospital, Montevideo, Uruguay
- <sup>4</sup> Faculty of Medicine, University of the Republic, Montevideo, Uruguay
- <sup>5</sup> Servicio Medico Integral, Montevideo, Montevideo, Uruguay
- <sup>6</sup> Hospital of the Armed Forces, Montevideo, Uruguay
- <sup>7</sup> Department of Transplant and Hematology / Servicio de medicina Integral, United States
- <sup>8</sup> CASMU IAMPP, Montevideo, Uruguay
- <sup>9</sup> Hospital Britànico, Montevideo, Uruguay
- <sup>10</sup> CASMU IAMPP & British Hospital, Montevideo, Uruguay
- <sup>11</sup> Mutualista CAMS, Mercedes, Dept de Soriano, Uruguay
- <sup>12</sup> Sanatorio Casa de Galicia, Montevideo, Uruguay
- <sup>13</sup> Sanatorio de la Medica uruguaya, Montevideo, Uruguay
- <sup>14</sup> Sanatorio SEMM Mautone, Maldonado, Uruguay
- <sup>15</sup> Sanatorio del Circulo Catolico, Montevideo, United States
- <sup>16</sup> Institut Pasteur de Montevideo, Montevideo, Uruguay
- <sup>17</sup> Independent Consultant, Milano, Italy
- <sup>18</sup> University Hospital, Montevideo, Montevideo, Uruguay
- <sup>19</sup> Hospital Maciel, Montevideo and Hospital de la Asociación Médica, San José, Montevideo, Uruguay

### **1083895**

#### **The CD180 Toll-like Receptor Is Heterogeneously Expressed in Lymph Nodes of Chronic Lymphocytic Leukaemia Patients and May Hold Prognostic Value**

KURTIS EDWARDS,<sup>1</sup>KRISTINA ZAITSEVA,<sup>1</sup>UZMA SAYED,<sup>1</sup>EMANUELA VOLPI,<sup>1</sup>AMIT NATHWANI,<sup>2</sup>JOHN G. GRIBBEN,<sup>3</sup>PETER LYDYARD,<sup>1</sup>SERGEY SERGEY KRYSOV,<sup>3</sup>NINO PORAKISHVILI,<sup>1</sup>

<sup>1</sup> University of Westminster, LONDON, United Kingdom

<sup>2</sup> University College London, London, United Kingdom

<sup>3</sup> Barts Cancer Institute, London, United Kingdom

**XIX International Workshop on CLL**

16 – 20 September 2021, Virtual

[www.iwcll2021.org](http://www.iwcll2021.org) • 1-888-476-9129



**1083914**

**The Role of Inflammation in CLL Progression. Linking Anomalous AID Expression to Pro-inflammatory Signalling**

MARÍA ELENA MARQUEZ,<sup>1</sup> FRANCINE BITTENCOURT POTRICH,<sup>1</sup> ANGIMAR URIEPERO,<sup>1</sup> CLAUDIA ORTEGA,<sup>1</sup> AGUSTÍN CORREA,<sup>1</sup> FLORENCIA PALACIOS,<sup>1</sup> CAROLINA OLIVER,<sup>2</sup> ANA INÉS LANDONI,<sup>3</sup> GIMENA DOS SANTOS,<sup>4</sup> CECILIA GUILLERMO,<sup>5</sup> RAÚL GABUS,<sup>6</sup> PABLO OPPEZZO,<sup>7</sup>

<sup>1</sup> Institut Pasteur de Montevideo, Montevideo, Uruguay

<sup>2</sup> CASMU IAMPP & British Hospital, Montevideo, Uruguay

<sup>3</sup> Unit of Hematology and Transplant of hematopoietic precursors, Hospital Maciel, Montevideo, Uruguay

<sup>4</sup> Institut Pasteur de Montevideo and Dept of Hematology of the University Hospital, Montevideo, Uruguay

<sup>5</sup> Hospital de Clínicas, Montevideo, Uruguay

<sup>6</sup> Hospital Maciel, Montevideo and Hospital de la Asociación Médica, San José, Montevideo, Uruguay

<sup>7</sup> Institut Pasteur de Montevideo, Montevideo, Uruguay

**1083933**

**XPO1 Inhibitor Selinexor Elicits Antitumor Activity in Chronic Lymphocytic Leukemia via Nuclear Retention of IκB and Is Synergistic with the p53 Reactivating Drug PRIMA-1Met in p53 Deficient/Mutant CLLs**

ZHANGDI XU,<sup>1</sup> BIHUI PAN,<sup>2</sup> YI MIAO,<sup>3</sup> KAIXIN DU,<sup>2</sup> JIAZHU WU,<sup>1</sup> WEI XU,<sup>2</sup>

<sup>1</sup> Jiangsu Province Hospital, Nanjing, China (People's Republic)

<sup>2</sup> Jiangsu Province Hospital, China (People's Republic)

<sup>3</sup> Jiangsu Province Hospital, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China (People's Republic)





**1083938**

**Impact of Adherence to Ibrutinib on Clinical Outcomes in Real-World Patients with Chronic Lymphocytic Leukemia**

JAMES COLLINS,<sup>1</sup>SARAH STUMP,<sup>2</sup>HILLARY HEILING,<sup>3</sup>ALLISON DEAL,<sup>4</sup>DARRIAN PROCO,<sup>5</sup>CATHARINE NGUYEN,<sup>5</sup>MONICA COZAD,<sup>6</sup>ANTHONY MATO,<sup>7</sup>CATHERINE COOMBS,<sup>3</sup>BENYAM MULUNEH,<sup>6</sup>

<sup>1</sup> University of North Carolina Eshelman School of Pharmacy, Raleigh, North Carolina, United States

<sup>2</sup> Memorial Sloan Kettering Cancer Center, Manhattan, New York, United States

<sup>3</sup> UNC Lineberger Cancer Center, United States

<sup>4</sup> UNC Lineberger Cancer Center, Chapel Hill, North Carolina, United States

<sup>5</sup> University of North Carolina Eshelman School of Pharmacy, United States

<sup>6</sup> University of North Carolina Eshelman School of Pharmacy, Chapel Hill, North Carolina, United States

<sup>7</sup> Memorial Sloan Kettering Cancer Center, New York, New York, United States

**1083940**

**Development of a Quantitative Assay to Measure the Bcl-2 Family Proteins and Their Relationships to Drug Response**

RONG CHEN,<sup>1</sup>CHAOMEI LIU,<sup>1</sup>PING XIONG,<sup>1</sup>YULING CHEN,<sup>1</sup>DANIELLA ZHELEVA,<sup>2</sup>DAVID BLAKE,<sup>2</sup>WILLIAM WIERDA,<sup>3</sup>WILLIAM PLUNKETT,<sup>3</sup>

<sup>1</sup> The University of Texas MD Anderson Cancer Center, Houston, Texas, United States

<sup>2</sup> Cyclacel Ltd., United States

<sup>3</sup> The University of Texas MD Anderson Cancer Center, United States



**1083945**

**Patterns of BTK Mutation and Clonal Evolution Induced by the Selective BTK Inhibitor (BTKi), Tirabrutinib in Chronic Lymphocytic Leukaemia (CLL)**

ROSS JACKSON,<sup>1</sup>CHRISTOPHER TRETHERWEY,<sup>1</sup>HARRIET WALTER,<sup>1</sup>SANDRINE JAYNE,<sup>1</sup>CHRISTOPHER FEGAN,<sup>2</sup>MARTIN DYER,<sup>1</sup>

<sup>1</sup> University of Leicester, Leicester, United Kingdom

<sup>2</sup> Cardiff University, Cardiff, United Kingdom

**1083950**

**Accelerated Phase Chronic Lymphocytic Leukemia: Clinical, Cytogenetical and Molecular Characterization of 12 Patients**

LEOPOLDINE LAPIERRE,<sup>1</sup>LAETITIA LARGEAUD,<sup>1</sup>CHARLOTTE SYRYKH,<sup>1</sup>SALIM KANOUN,<sup>1</sup>LUCIE COSTER,<sup>1</sup>CAMILLE LAURENT,<sup>1</sup>BASTIEN CABARROU,<sup>2</sup>CHRISTIAN RECHER,<sup>1</sup>BENOIT BRANCO,<sup>1</sup>NOEMIE GADAUD,<sup>1</sup>DELPHINE BRECHEMIER,<sup>3</sup>LOIC YSEBAERT,<sup>1</sup>MARTIN GAUTHIER,<sup>1</sup>

<sup>1</sup> IUCT-Oncopole, Toulouse, France

<sup>2</sup> IUCT-Oncopole, France

<sup>3</sup> CHU de Toulouse, Toulouse, France

**1083961**

**Successful Retreatment of CLL with Venetoclax Following Clonal Evolution During 37 Months of Tirabrutinib and Idelalisib**

ROSS JACKSON,<sup>1</sup>VICTORIA SMITH,<sup>1</sup>HARRIET WALTER,<sup>1</sup>SANDRINE JAYNE,<sup>1</sup>MARTIN DYER,<sup>1</sup>

<sup>1</sup> University of Leicester, Leicester, United Kingdom



**1083985**

**Dual Variable Domain Antibodies Against FcγR for Potential Treatment of Chronic Lymphocytic Leukemia**

AMRO FULFULAN,<sup>1</sup> DOBEEN HWANG,<sup>2</sup> SHI SHU,<sup>3</sup> XIULING LI,<sup>4</sup> CHRISTOPH RADER,<sup>4</sup> ADRIAN WIESTNER,<sup>3</sup> SIVASUBRAMANIAN BASKAR,<sup>3</sup>

<sup>1</sup> Catholic University of America, Bethesda, Maryland, United States

<sup>2</sup> Scripps Research Institute, United States

<sup>3</sup> National Institute of Health, Bethesda, Maryland, United States

<sup>4</sup> Scripps Research, United States

**1083987**

**A Phase 1/2 Study of Umbralisib, Ublituximab, and Venetoclax in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL)**

PAUL M. BARR,<sup>1</sup> BRIAN T. HILL,<sup>2</sup> CLIVE ZENT,<sup>3</sup> ANDREA M. BARAN,<sup>1</sup> MIJAMIN FRIEND,<sup>1</sup> DIKSHA BISWA,<sup>1</sup> ANJALI ADVANI,<sup>4</sup> ALLISON WINTER,<sup>4</sup> KELSEY HOLKOVIC,<sup>4</sup> JANE L. LIESVELD,<sup>1</sup> DEBORAH A. MULFORD,<sup>1</sup> ANDREW BUI,<sup>5</sup> PETER SPORTELLI,<sup>6</sup> HARI P. MISKIN,<sup>6</sup> MICHAEL S. WEISS,<sup>6</sup> JONATHAN W. FRIEDBERG,<sup>1</sup> SHUO MA,<sup>7</sup>

<sup>1</sup> Wilmot Cancer Institute, University of Rochester Medical Center, Rochester, New York, United States

<sup>2</sup> Cleveland Clinic, Cleveland, Ohio, United States

<sup>3</sup> University of Rochester Medical Center, Rochester, New York, United States

<sup>4</sup> Taussig Cancer Institute, Cleveland Clinic, Cleveland, Ohio, United States

<sup>5</sup> TG Therapeutics, Inc., New York, New York, United States

<sup>6</sup> TG Therapeutics Inc., New York, New York, United States

<sup>7</sup> Division of Hematology and Oncology, Northwestern University Feinberg School of Medicine; Robert H. Lurie Comprehensive Cancer Center, Chicago, Illinois, United States



**1084059**

**A Cross-Sectional Study Examining How Knowledge of Genetic and Biomarkers Affects the Information and Communication Experiences of Patients with CLL**

NATALIE DREN,<sup>1</sup>LORNA WARWICK,<sup>1</sup>OLUFUNMILAYO BAMIGBOLA,<sup>1</sup>

<sup>1</sup> Lymphoma Coalition, United States

**1084060**

**Inhibition of the Pentose-phosphate-pathway (PPP) Mediates Macrophage Reprogramming and Induces Increased Antibody-dependent Lymphoma Cell Clearance by Macrophages While Supportive Bystander Function Is Diminished**

ELENA IZQUIERDO-ALVAREZ,<sup>1</sup>NADINE NICKEL,<sup>2</sup>STUART BLAKEMORE,<sup>2</sup>DANIELA VORHOLT,<sup>2</sup>SAMRUDDHI CHAWAN,<sup>2</sup>JANICA WIEDERSTEIN,<sup>2</sup>REBECCA LINKE,<sup>2</sup>MARCUS KRÜGER,<sup>2</sup>CORAL BARABAS,<sup>3</sup>ALMA VILLASENOR,<sup>3</sup>CAROLINA COSTA PICOSI,<sup>4</sup>MICHAEL HALLEK,<sup>2</sup>CHRISTIAN PALLASCH,<sup>2</sup>ANNA BEIELSTEIN,<sup>5</sup>

<sup>1</sup> Universidad CEU San Pablo, Spain

<sup>2</sup> CECAD, Germany

<sup>3</sup> San Pablo-CEU University, Spain

<sup>4</sup> San Pablo-CEU University, United States

<sup>5</sup> University Hospital Cologne, Germany

**1084061**

**Evaluation of Venetoclax Initiation Process at University of North Carolina Medical Center**

MONICA COZAD,<sup>1</sup>SARAH STUMP,<sup>2</sup>KAITLYN BUHLINGER,<sup>3</sup>JAMES COLLINS,<sup>4</sup>CATHERINE COOMBS,<sup>5</sup>BENYAM MULUNEH,<sup>4</sup>

<sup>1</sup> University of North Carolina Eshelman School of Pharmacy, Chapel Hill, North Carolina, United States

<sup>2</sup> Memorial Sloan Kettering Cancer Center, United States

<sup>3</sup> University of North Carolina Medical Center, United States

<sup>4</sup> University of North Carolina Eshelman School of Pharmacy, United States

<sup>5</sup> The University of North Carolina Cancer Center, United States

**XIX International Workshop on CLL**

16 – 20 September 2021, Virtual

[www.iwcll2021.org](http://www.iwcll2021.org) • 1-888-476-9129



**1084062**

**CD200 Baseline Serum Levels Predict Prognosis of Chronic Lymphocytic Leukemia**

CANDIDA VITALE,<sup>1</sup>MARTA COSCIA,<sup>1</sup>DANIELA LAMORTE,<sup>2</sup>GIUSEPPE PIETRANTUONO,<sup>2</sup>PERUTELLI FRANCESCA,<sup>3</sup>IORELLA D'AURIA,<sup>2</sup>TEODORA STATUTO,<sup>2</sup>LUCIANA VALVANO,<sup>2</sup>ANNAMARIA TOMASSO,<sup>4</sup>VALENTINA GRIGGIO,<sup>5</sup>REBECCA JONES,<sup>5</sup>GIOVANNA MANSUETO,<sup>2</sup>ORESTE VILLANI,<sup>2</sup>SIMONA D'AGOSTINO,<sup>2</sup>DIMITAR EFREMOV,<sup>6</sup>LUCA LAURENTI,<sup>7</sup>GIOVANNI D'ARENA,<sup>8</sup>

<sup>1</sup> Division of Hematology, A.O.U. Città della Salute e della Scienza di Torino and Department of Molecular Biotechnology and Health Sciences, University of Turin, Italy, Italy

<sup>2</sup> Referral cancer Center of Basilicata, Italy

<sup>3</sup> A.O.U. Città della Salute e della Scienza, University of Torino, Italy

<sup>4</sup> Hematology Unit, Fondazione Policlinico Gemelli, Italy

<sup>5</sup> A.O.U. Città della Salute e della Scienza, University of Torino, Italy

<sup>6</sup> Molecular Hematology , International Center for Genetic Engineering and Biotechnology, Italy

<sup>7</sup> Institute of Haematology, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy, Italy

<sup>8</sup> Hematology, ASL Salerno, Italy, Italy

**1084063**

**What Drives Treatment Preferences in CLL? Listening to the Patient Voice**

CLAIRE ERVIN,<sup>1</sup>ARLIENE MANGALINDAN,<sup>2</sup>SHEILA SHAPOURI,<sup>2</sup>JESSIE SUTPHIN,<sup>1</sup>CAROL MANSFIELD,<sup>1</sup>BEENISH S. MANZOOR,<sup>3</sup>KAVITA SAIL,<sup>4</sup>JENNIFER DINE,<sup>1</sup>

<sup>1</sup> RTI Health Solutions, United States

<sup>2</sup> Genentech, United States

<sup>3</sup> AbbVie Inc., United States

<sup>4</sup> AbbVie, United States





**1084064**

**Overcoming Drug-Resistance in Chronic Lymphocytic Leukemia: The Development of a Cell Line Resistant to Ibrutinib**

FEDERICA FREZZATO,<sup>1</sup>LIVIA ZORNETTA,<sup>2</sup>ANDREA VISENTIN,<sup>2</sup>FILIPPO SEVERIN,<sup>2</sup>SERENA PIZZO,<sup>2</sup>EDOARDO RUGGERI,<sup>2</sup>NAYLA MOUAWAD,<sup>2</sup>LEONARDO MARTINELLO,<sup>2</sup>ELISA PAGNIN,<sup>2</sup>FRANCESCO PIAZZA,<sup>2</sup>MONICA FACCO,<sup>2</sup>LIVIO TRENTIN,<sup>2</sup>

<sup>1</sup> Department of Medicine - DIMED, Italy

<sup>2</sup> University of Padova, Italy

**1084065**

**Small Extracellular Vesicles Derived from CLL Microenvironment Sustain Disease Progression in Vivo by Hampering Anti-tumor Immunity**

ETIENNE MOUSSAY,<sup>1</sup>JERMONE PAGGETTI,<sup>1</sup>ELODIE VIRY,<sup>1</sup>PABLO ELÍAS MORANDE,<sup>1</sup>ERNESTO GARGIULO,<sup>1</sup>

<sup>1</sup> Luxembourg Institute of Health, Luxembourg

**1084066**

**Single-cell RNA Sequencing Suggests Novel Drivers of Chronic Lymphocytic Leukemia in Patients with Ibrutinib Resistance**

HUI JIN,<sup>1</sup>ZIJUAN WU,<sup>2</sup>HUAYUAN ZHU,<sup>2</sup>LUQIAO WANG,<sup>2</sup>DANLING GU,<sup>2</sup>WEI XU,<sup>2</sup>JIANYONG LI,<sup>3</sup>

<sup>1</sup> Department of Hematology, The First Affiliated Hospital of Nanjing Medical University, China (People's Republic)

<sup>2</sup> Department of Hematology, The First Affiliated Hospital of Nanjing Medical University, China (People's Republic)

<sup>3</sup> Jiangsu Province Hospital, China (People's Republic)



**1084067**

**Pirtobrutinib (LOXO-305), a Next Generation, Highly Selective, Non-covalent BTK Inhibitor in Previously Treated CLL/SLL: Results from the Phase 1/2 BRUIN Study**

JOHN PAGEL,<sup>1</sup>CATHERINE COOMBS,<sup>2</sup>NIRAV SHAH,<sup>3</sup>NICOLE LAMANNA,<sup>4</sup>EWA LECH-MARANDA,<sup>5</sup>TOBY A EYRE,<sup>6</sup>JENNIFER WOYACH,<sup>7</sup>WILLIAM WIERDA,<sup>8</sup>CHAN Y CHEAH,<sup>9</sup>LINDSEY ROEKER,<sup>10</sup>MANISH PATEL,<sup>11</sup>BITA FAKHRI,<sup>12</sup>MINAL A BARVE,<sup>13</sup>CONSTANTINE S TAM,<sup>14</sup>DAVID J LEWIS,<sup>15</sup>JAMES N GERSON,<sup>16</sup>ALVARO ALENCAR,<sup>17</sup>JUSTIN TAYLOR,<sup>17</sup>OMAR ABDEL-WAHAB,<sup>10</sup>PAOLO GHIA,<sup>18</sup>STEPHEN J SCHUSTER,<sup>16</sup>JESSICA CHEN,<sup>19</sup>BINOJ C NAIR,<sup>20</sup>DONALD E TSAI,<sup>20</sup>NORA C KU,<sup>20</sup>MATTHEW DAVIDS,<sup>21</sup>JENNIFER BROWN,<sup>21</sup>ANTHONY MATO,<sup>10</sup>WOJCIECH JURCZAK,<sup>22</sup>

<sup>1</sup> Swedish Cancer Center, United States

<sup>2</sup> The University of North Carolina Cancer Center, United States

<sup>3</sup> Medical College of Wisconsin, United States

<sup>4</sup> Herbert Irving Comprehensive Cancer Center, Columbia University, United States

<sup>5</sup> Institute of Hematology and Transfusion Medicine, United States

<sup>6</sup> Oxford University Hospitals NHS Foundation Trust, Churchill Cancer Center, United Kingdom

<sup>7</sup> The Ohio State University, United States

<sup>8</sup> MD Anderson Cancer Center, United States

<sup>9</sup> Linear Clinical Research and Sir Charles Gairdner Hospital, Australia

<sup>10</sup> Memorial Sloan Kettering Cancer Center, United States

<sup>11</sup> Florida Cancer Specialists/Sarah Cannon Research Institute, United States

<sup>12</sup> University of California San Francisco, United States

<sup>13</sup> Mary Crowley Cancer Research, United States

<sup>14</sup> Peter MacCallum Cancer Center, Royal Melbourne Hospital, and University of Melbourne, Australia

<sup>15</sup> Plymouth Hospitals NHS Trust - Derriford Hospital, United Kingdom

<sup>16</sup> Lymphoma Program, Abramson Cancer Center, University of Pennsylvania, United States

<sup>17</sup> University of Miami Miller School of Medicine, United States

<sup>18</sup> Università Vita-Salute San Raffaele and IRCCS Ospedale San Raffaele, Italy

<sup>19</sup> Eli Lilly and Company, United States

**XIX International Workshop on CLL**

16 – 20 September 2021, Virtual

[www.iwcll2021.org](http://www.iwcll2021.org) • 1-888-476-9129



<sup>20</sup> Loxo Oncology at Lilly, United States

<sup>21</sup> Dana-Farber Cancer Institute, United States

<sup>22</sup> Maria Skłodowska-Curie National Research Institute of Oncology, Poland

**1084068**

**Utilizing Clinical Features of Progression to Predict Richter's Syndrome in Patients with CLL Progressing After Ibrutinib**

ADAM KITTAI,<sup>1</sup>YING HUANG,<sup>2</sup>ASHLEIGH KEITER,<sup>2</sup>KYLE BECKWITH,<sup>2</sup>DAN GOLDSTEIN,<sup>2</sup>SEEMA BHAT,<sup>2</sup>DAVID BOND,<sup>2</sup>JOHN BYRD,<sup>2</sup>MICHAEL GREVER,<sup>2</sup>KERRY ROGERS,<sup>2</sup>JENNIFER WOYACH,<sup>2</sup>

<sup>1</sup> Ohio State University, Columbus, Ohio, United States

<sup>2</sup> The Ohio State University, United States

**1084069**

**A Survey of European Chronic Lymphocytic Leukemia (CLL) Patients' and Caregivers' Awareness, Preferences, and Understanding Related to Finite (Limited) Duration Therapy and Minimal Residual Disease (MRD)**

CHRIS STEWART,<sup>1</sup>JOHN BYRD,<sup>2</sup>ALEXEY V. DANILOV,<sup>3</sup>ALAN SKARBNIK,<sup>4</sup>MICHAEL RYNNE,<sup>5</sup>ROBYN BRUMBLE,<sup>6</sup>LIZA AVRUCH,<sup>6</sup>JOHN PAGEL,<sup>7</sup>BRIAN KOFFMAN,<sup>6</sup>NEIL BAILEY,<sup>8</sup>

<sup>1</sup> Gallup, Inc., United States

<sup>2</sup> University of Cincinnati College of Medicine, United States

<sup>3</sup> City of Hope National Medical Center, United States

<sup>4</sup> Novant Health, United States

<sup>5</sup> CLL Ireland, Ireland

<sup>6</sup> CLL SOCIETY, United States

<sup>7</sup> Swedish Cancer Center, United States

<sup>8</sup> Swedish Cancer Institute, Seattle, Washington, United States



**1084070**

**Targeting Translation by Disrupting the Newly Identified Prohibitin-eIF4F Complex as a Novel Therapeutic Strategy in CLL**

ETIENNE MOUSSAY,<sup>1</sup>JERMONE PAGGETTI,<sup>1</sup>VANESSA KLAPP,<sup>1</sup>ANNE LARGEOT,<sup>1</sup>

<sup>1</sup> Luxembourg Institute of Health, Luxembourg

**1084071**

**The Intellectual History of CLL: 1999 to 2019**

GERALD MARTI,<sup>1</sup>

<sup>1</sup> NIH, Potomac, United States

**1084072**

**Preliminary Results of the FILO Phase 2 Trial for Untreated Fit Patients with Intermediate Risk Chronic Lymphocytic Leukemia Comparing Ibrutinib Plus Venetoclax (IV) versus FCR**

ANNE QUINQUENEL,<sup>1</sup>REMI LETESTU,<sup>2</sup>MAGALI LEGARFF,<sup>2</sup>FABIEN SUBTIL,<sup>3</sup>MAD HELENIE ELSEN SOHN,<sup>3</sup>THERESE AURRANT,<sup>4</sup>KAMEL LARIBI,<sup>5</sup>FLORENCE CYMBALISTA,<sup>6</sup>VINCENT LEVY,<sup>2</sup>LAURENCE SIMON,<sup>7</sup>DAMIEN ROOS-WEIL,<sup>2</sup>VERONIQUE LEBLOND,<sup>8</sup>MARIE-SARAH DILHUYDY,<sup>9</sup>CECILE TOMOWIAK,<sup>10</sup>CAROLINE DARTIGEAS,<sup>11</sup>ROMAIN GUIEZE,<sup>12</sup>OLIVIER TOURNILHAC,<sup>13</sup>EMMANUELLE FERRANT,<sup>14</sup>SOPHIE DE GUIBERT,<sup>15</sup>PIERRE FEUGIER,<sup>16</sup>FATIHA MERABET,<sup>17</sup>STEPHANE LEPRETRE,<sup>18</sup>PHILIPPE CARASSOU,<sup>19</sup>JULIE GAY,<sup>20</sup>BENEDICTE HIVERT,<sup>21</sup>LUC MATTHIEU FORNECKER,<sup>22</sup>JEHAN DUPUIS,<sup>2</sup>LYSIANE MOLINA,<sup>23</sup>BRUNO VILLEMAGNE,<sup>24</sup>GUILLAUME CARTRON,<sup>25</sup>ANNE-SOPHIE MICHALLET,<sup>26</sup>BERNARD DRENOU,<sup>27</sup>BEATRICE MAHE,<sup>28</sup>OMAR BENBRAHI,<sup>29</sup>XAVIER CAHU,<sup>30</sup>CHRISTELLE PORTOIS,<sup>31</sup>LOIC YSEBAERT,<sup>32</sup>FLORENCE NGUYEN-KHAC,<sup>33</sup>VALERIE ROUILLE,<sup>25</sup>ALAIN DELMER,<sup>34</sup>

<sup>1</sup> CHU Reims, France

<sup>2</sup> APHP, France

<sup>3</sup> HCL, France

<sup>4</sup> IPC, France

**XIX International Workshop on CLL**

16 – 20 September 2021, Virtual

[www.iwcll2021.org](http://www.iwcll2021.org) • 1-888-476-9129



- <sup>5</sup> Service Hématologie, CH Le Mans, Le Mans, France, France
- <sup>6</sup> Laboratoire d'Hématologie, Hôpital Avicenne, APHP, Bobigny, France, France
- <sup>7</sup> Centre hospitalier sud francilien, France
- <sup>8</sup> Service Hématologie, Hôpital de la Pitié-Salpêtrière, APHP, Paris, France, France
- <sup>9</sup> CHU Bordeaux, France
- <sup>10</sup> Service Hématologie, CHU Poitiers, Poitiers, France, France
- <sup>11</sup> Service Hématologie et thérapie cellulaire, CHU Tours, Tours, France, France
- <sup>12</sup> Service Hématologie, CHU Clermont Ferrand, Clermont Ferrand, France, France
- <sup>13</sup> CHU, France
- <sup>14</sup> CHLS, France
- <sup>15</sup> CHU Rennes, France
- <sup>16</sup> CHRU Nancy, France
- <sup>17</sup> Service Hématologie, CH de Versailles, Versailles, France, France
- <sup>18</sup> Centre Henri Becquerel, France
- <sup>19</sup> CHR Metz, France
- <sup>20</sup> CH Cote Basque, France
- <sup>21</sup> groupement des hôpitaux catholiques, France
- <sup>22</sup> CHU Strasbourg, France
- <sup>23</sup> CHU Grenoble, France
- <sup>24</sup> CH La roche sur yon, France
- <sup>25</sup> CHU Montpellier, France
- <sup>26</sup> Service Hématologie, Centre Léon Bérard, Lyon, France, France
- <sup>27</sup> Service Hématologie, CH de Mulhouse, Mulhouse, France, France
- <sup>28</sup> Chu Nantes, France
- <sup>29</sup> Chr Orleans, France
- <sup>30</sup> Centre Privé cesson sevigne, France
- <sup>31</sup> SLST Sud Loire, France
- <sup>32</sup> IUCT Oncopole, France





<sup>33</sup> Service d'Hématologie Biologique, Hôpital Pitié-Salpêtrière, Paris, France, Paris, France

<sup>34</sup> Service Hématologie, CHU de Reims, Reims, France, France

### 1084073

#### **Prediction of Outcomes in CLL Patients Treated with Ibrutinib: Validation of 4 Prognostic Scores and Development of a Simplified Three-factor Model**

STEFANO MOLICA,<sup>1</sup>DIANA GIANNARELLI,<sup>2</sup>ANDREA VISENTIN,<sup>3</sup>GIANLUIGI REDA,<sup>4</sup>PAOLO SPOROLETTI,<sup>5</sup>ANNA MARIA FRUSTACI,<sup>6</sup>ANNALISA CHIARENZA,<sup>7</sup>STEFANIA CIOLLI,<sup>8</sup>CANDIDA VITALE,<sup>9</sup>LUCA LAURENTI,<sup>10</sup>LORENZO DE PAOLI,<sup>11</sup>ROBERTA MURRU,<sup>12</sup>MASSIMO GENTILE,<sup>13</sup>RICCARDO MOIA,<sup>14</sup>LUCIANO LEVATO,<sup>15</sup>GIAN MATTEO RIGOLIN,<sup>16</sup>ANNA MARIA GIORDANO,<sup>17</sup>GIOVANNI DEL POETA,<sup>18</sup>CATERINA STELITANO,<sup>19</sup>MARINA DEODATO,<sup>20</sup>CAUDIA IELO,<sup>21</sup>ALESSANDRO NOTO,<sup>4</sup>VALERIO GUARENTE,<sup>4</sup>ALESSANDRA TEDESCHI,<sup>22</sup>MARTA COSCIA,<sup>9</sup>GIANLUCA GAIDANO,<sup>14</sup>ANTONIO CUNEO,<sup>16</sup>ROBIN FOÀ,<sup>21</sup>LIVIO TRENTIN,<sup>3</sup>FRANCESCA ROMANA MAURO,<sup>21</sup>

<sup>1</sup> Dipartimento Onco-Ematologico, Azienda Ospedaliera Pugliese - Ciaccio, CATANZARO, Italy

<sup>2</sup> Biostatistic Unit, Istituto Regina Elena, IRCCS, Roma, Italy, Italy

<sup>3</sup> University of Padova, Italy

<sup>4</sup> Fondazione IRCCS Cà Granda Ospedale Maggiore Policlinico, Milan, Italy

<sup>5</sup> 5 Institute of Hematology-Centro di Ricerca Emato-Oncologica (CREO), Department of Medicine, University of Perugia, Italy, Italy

<sup>6</sup> Dept of Hematology, Niguarda Cancer Center, ASST Grande Ospedale Metropolitano Niguarda Milano, Italy, Italy

<sup>7</sup> Division of Hematology, Ferrarotto Hospital, Catania, Italy, Italy

<sup>8</sup> Hematology Unit, Careggi Hospital, Firenze, Italy, Italy

<sup>9</sup> Division of Hematology, A.O.U. Città della Salute e della Scienza di Torino and Department of Molecular Biotechnology and Health Sciences, University of Turin, Italy, Italy

<sup>10</sup> Institute of Haematology, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy, Italy

<sup>11</sup> Division of Hematology, Department of Translational Medicine, University of Eastern Piedmont, Novara, Italy, Italy

<sup>12</sup> Haematology and Stem Cell Transplantation Unit, Ospedale Oncologico A. Businco, AO Brotzu, Cagliari, Italy, Italy

**XIX International Workshop on CLL**

16 – 20 September 2021, Virtual

[www.iwcll2021.org](http://www.iwcll2021.org) • 1-888-476-9129



- <sup>13</sup> Hematology Unit, Hematology and Oncology Department, Cosenza, Italy, Italy
- <sup>14</sup> 11 Division of Hematology, Department of Translational Medicine, University of Eastern Piedmont, Novara, Italy, Italy
- <sup>15</sup> Department Hematology-Oncology, Azienda Ospedaliera Pugliese-Ciaccio, Catanzaro, Italy, Italy
- <sup>16</sup> Hematology, Department of Medical Sciences, St. Anna University Hospital, Ferrara, Italy, Italy
- <sup>17</sup> Department of Emergency and Organ Transplantation (D.E.T.O.), Hematology Section, University of Bari, Italy
- <sup>18</sup> 16 Hematology, Department of Biomedicine and Prevention, University Tor Vergata, Rome, Italy
- <sup>19</sup> Department Hematology, Grande Ospedale Metropolitano, Reggio Calabria, Italy, Italy
- <sup>20</sup> Dept of Hematology, Niguarda Cancer Center, ASST Grande Ospedale Metropolitano Niguarda Milano, Italy, Italy
- <sup>21</sup> Hematology, Department of Translational and Precision Medicine, 'Sapienza' University, Rome, Italy, Italy
- <sup>22</sup> ASST Grande Ospedale Metropolitano Niguarda, Italy

#### 1084074

#### Detection of Rare Germline Variants in the Genomes of Patients with B-Cell Neoplasms

MIGUEL CID LÓPEZ,<sup>1</sup> ANDRÉS PELETEIRO RAÍNO,<sup>1</sup> JOSÉ ÁNGEL DÍAZ ARIAS,<sup>1</sup> BEATRIZ ANTELO RODRÍGUEZ,<sup>1</sup> LAURA BAO PÉREZ,<sup>1</sup> NATALIA ALONSO VENCE,<sup>1</sup> ÁNGELES BENDAÑA LÓPEZ,<sup>1</sup> AITOR ABUÍN BLANCO,<sup>1</sup> PAULA MELERO VALENTÍN,<sup>1</sup> ROI FERREIRO FERRO,<sup>1</sup> CARLOS ALISTE SANTOS,<sup>1</sup> MÁXIMO FRANCISCO FRAGA RODRÍGUEZ,<sup>1</sup> MARTA SONIA GONZÁLEZ PÉREZ,<sup>1</sup> MANUEL MATEO PÉREZ ENCINAS,<sup>1</sup> JOSÉ LUIS BELLO LÓPEZ,<sup>1</sup> ADRIÁN MOSQUERA ORGUEIRA,<sup>2</sup>

<sup>1</sup> University Hospital of Santiago de Compostela, Spain

<sup>2</sup> NA, Spain



**1084075**

**Single-cell Dynamics of Mitochondrial DNA Mutations and Chromatin Accessibility in Chronic Lymphocytic Leukemia Following Therapeutic Bottlenecks**

LIVIUS PENTER,<sup>1</sup>SATYEN H. GOHIL,<sup>2</sup>CALEB LAREAU,<sup>3</sup>LEIF S. LUDWIG,<sup>4</sup>ERIN M. PARRY,<sup>1</sup>SHUQIANG LI,<sup>1</sup>JENNIFER BROWN,<sup>1</sup>MATTHEW DAVIDS,<sup>1</sup>DONNA S. NEUBERG,<sup>1</sup>KENNETH J. LIVAK,<sup>1</sup>VIJAY G. SANKARAN,<sup>1</sup>CATHERINE WU,<sup>1</sup>

<sup>1</sup> Dana-Farber Cancer Institute, United States

<sup>2</sup> Department of Haematology, University College London Hospitals NHS Foundation Trust, London, United Kingdom, United Kingdom

<sup>3</sup> Department of Pathology, Stanford University, United States

<sup>4</sup> Berlin Institute for Medical Systems Biology, Max Delbrück Center for Molecular Medicine in the Helmholtz Association (MDC), Germany

**1084076**

**Ubiquitin-like Post-translational Modifications in Chronic Lymphocytic Leukemia: A New Stage in the Quest of Its Etiology**

LUCRECIA YAÑEZ,<sup>1</sup>VÍCTOR ARENAS,<sup>2</sup>JOSE LUIS CASTAÑO,<sup>2</sup>JUAN JOSÉ DOMÍNGUEZ,<sup>1</sup>SARA BRAVO,<sup>3</sup>ÍÑIGO ROMÓN,<sup>1</sup>CARLOS PIPAÓN,<sup>4</sup>

<sup>1</sup> Hospital Universitario Marqués de Valdecilla, Spain

<sup>2</sup> Instituto de Investigación Marqués de Valdecilla, Spain

<sup>3</sup> Hospital Clínico Universitario de Valladolid, Spain

<sup>4</sup> Instituto de Investigación Marqués de Valdecilla, Santander, Spain

**1084077**

**The inhibition of Focal Adhesion Kinase (FAK) leads to apoptosis in CLL cells, besides downmodulating the pro-survival cytoskeletal interactors, HS1 and Cortactin.**

FEDERICA FREZZATO,<sup>1</sup>NAYLA MOUAWAD,<sup>1</sup>EDOARDO RUGGERI,<sup>1</sup>LEONARDO MARTINELLO,<sup>1</sup>LIVIA ZORNETTA,<sup>1</sup>FILIPPO SEVERIN,<sup>1</sup>ELISA PAGNIN,<sup>1</sup>ANDREA VISENTIN,<sup>1</sup>MONICA FACCO,<sup>1</sup>LIVIO TRENTIN,<sup>1</sup>SERENA PIZZO,<sup>1</sup>

<sup>1</sup> University of Padova, Italy

**XIX International Workshop on CLL**

16 – 20 September 2021, Virtual

[www.iwcll2021.org](http://www.iwcll2021.org) • 1-888-476-9129



**1084078**

**Ibrutinib Treatment for Patients with Chronic Lymphocytic Leukemia in the First-line Setting: Up to 7 Years of Follow-up in the RESONATE-2 Study**

TADEUSZ ROBAK,<sup>1</sup> PAOLO GHIA,<sup>2</sup> CAROLYN OWEN,<sup>3</sup> ALESSANDRA TEDESCHI,<sup>4</sup> OSNAT BAIREY,<sup>5</sup> JAN BURGER,<sup>6</sup> PETER HILLMEN,<sup>7</sup> STEVE COUTRE,<sup>8</sup> STEPHEN DEVEREUX,<sup>9</sup> SEBASTIAN GROSICKI,<sup>10</sup> HELEN MCCARTHY,<sup>11</sup> JIANYONG LI,<sup>12</sup> FRITZ OFFNER,<sup>13</sup> CAROL MORENO,<sup>14</sup> SANDRA DAI,<sup>15</sup> ANITA SZOKE,<sup>15</sup> JAMES DEAN,<sup>15</sup> THOMAS KIPPS,<sup>16</sup> PAUL BARR,<sup>17</sup>

<sup>1</sup> Medical University of Lodz, Lodz, Poland

<sup>2</sup> Università Vita-Salute San Raffaele and IRCCS Ospedale San Raffaele, Italy

<sup>3</sup> Tom Baker Cancer Centre, University of Calgary, Canada

<sup>4</sup> ASST Grande Ospedale Metropolitano Niguarda, Italy

<sup>5</sup> Rabin Medical Center, Israel

<sup>6</sup> Department of Leukemia, University of Texas MD Anderson Cancer Center, United States

<sup>7</sup> The Leeds Teaching Hospitals, St. James Institute of Oncology, United Kingdom

<sup>8</sup> Stanford Cancer Center, Stanford University School of Medicine, United States

<sup>9</sup> Kings College Hospital, NHS Foundation Trust, United Kingdom

<sup>10</sup> School of Public Health, Silesian Medical University, Poland

<sup>11</sup> Royal Bournemouth General Hospital, United Kingdom

<sup>12</sup> Jiangsu Province Hospital, China (People's Republic)

<sup>13</sup> Universitair Ziekenhuis Gent, Belgium

<sup>14</sup> Hospital de la Santa Creu i Sant Pau, Autonomous University of Barcelona, Spain

<sup>15</sup> Pharmacyclics LLC, an AbbVie Company, United States

<sup>16</sup> UCSD Moores Cancer, United States

<sup>17</sup> Wilmot Cancer Institute, University of Rochester Medical Center, United States



**1084079**

**Economic Impact of Treatment Sequences for Chronic Lymphocytic Leukemia (CLL): A Cost of Care Model of First-Line Treatment Sequences**

NISHA C. HAZRA,<sup>1</sup>HONGHAO FANG,<sup>1</sup>BEENISH S. MANZOOR,<sup>2</sup>XAVIER TROUSSARD,<sup>3</sup>VINCENT LEVY,<sup>4</sup>LOIC YSEBAERT,<sup>5</sup>NATHANAEL KABORE,<sup>2</sup>KAVITA SAIL,<sup>2</sup>

<sup>1</sup> Analysis Group, Inc., United States

<sup>2</sup> AbbVie Inc., United States

<sup>3</sup> Centre Hospitalier Universitaire Caen Normandie, France

<sup>4</sup> APHP, United States

<sup>5</sup> IUCT Oncopole, France

**1084080**

**IL4-STAT6 Signaling Induces CD20 in Chronic Lymphocytic Leukemia and This Axis Is Repressed by PI3K $\delta$  Inhibitor Idelalisib**

VERONIKA SANDOVA,<sup>1</sup>GABRIELA MLADONICKA PAVLASOVA,<sup>2</sup>VACLAV SEDA,<sup>2</sup>SONALI SHARMA,<sup>2</sup>VERONIKA PALUSOVA,<sup>2</sup>YVONA BRYCHTOVA,<sup>3</sup>SARKA POSPISILOVA,<sup>4</sup>STACEY M.FERNANDES,<sup>5</sup>ANNA PANOVSKA,<sup>6</sup>MICHAEL DOUBEK,<sup>7</sup>MATTHEW DAVIDS,<sup>8</sup>JENNIFER BROWN,<sup>8</sup>JIRI MAYER,<sup>4</sup>MAREK MRAZ,<sup>1</sup>

<sup>1</sup> CEITEC MU and University Hospital Brno, Czech Republic

<sup>2</sup> Central European Institute of Technology, Masaryk University, Brno, Czech Republic, Czech Republic

<sup>3</sup> Department of Internal Medicine, Hematology and Oncology, University Hospital Brno and Faculty of Medicine, Masaryk University, Brno, Czech Republic, Czech Republic

<sup>4</sup> Department of Internal Medicine, Hematology and Oncology, University Hospital Brno, Brno, Czech Republic., Czech Republic

<sup>5</sup> Dana-Farber Cancer Institute, Boston, MA, United States

<sup>6</sup> University Hospital Brno, Czech Republic

<sup>7</sup> University Hospital Brno & Masaryk University, Czech Republic

<sup>8</sup> Dana-Farber Cancer Institute, United States

**XIX International Workshop on CLL**

16 – 20 September 2021, Virtual

[www.iwcll2021.org](http://www.iwcll2021.org) • 1-888-476-9129





**1084081**

**GAB1 – Novel Regulator of Migration Capacity and Tonic AKT Activity in CLL: Implications for Combinatorial Therapy with BCR Inhibitors**

VACLAV SEDA,<sup>1</sup>EVA VOJACKOVA,<sup>2</sup>LAURA ONDRISOVA,<sup>2</sup>LENKA KOSTALOVA,<sup>2</sup>SONALI SHARMA,<sup>2</sup>TOMAS LOJA,<sup>3</sup>DANIEL ZICHA,<sup>4</sup>JAN VERNER,<sup>5</sup>SARKA POSPISILOVA,<sup>6</sup>YVONA BRYCHTOVA,<sup>7</sup>ANNA PANOVSKA,<sup>6</sup>MICHAEL DOUBEK,<sup>8</sup>JIRI MAYER,<sup>9</sup>MAREK MRAZ,<sup>1</sup>

<sup>1</sup> CEITEC MUNI and University Hospital Brno, Czech Republic

<sup>2</sup> Central European Institute of Technology, Masaryk University, Brno, Czech Republic, Czech Republic

<sup>3</sup> CEITEC Masaryk University, Czech Republic

<sup>4</sup> CEITEC University of Technology, Czech Republic

<sup>5</sup> University Hospital Brno and Faculty of Medicine, Masaryk University, Czech Republic

<sup>6</sup> University Hospital Brno, Czech Republic

<sup>7</sup> Department of Internal Medicine, Hematology and Oncology, University Hospital Brno and Faculty of Medicine, Masaryk University, Brno, Czech Republic, Czech Republic

<sup>8</sup> University Hospital Brno & Masaryk University, Czech Republic

<sup>9</sup> Department of Internal Medicine, Hematology and Oncology, University Hospital Brno, Brno, Czech Republic., Czech Republic

**1084082**

**Ibrutinib Blocks CD40 Signalling in CLL in Vivo by Reducing TRAF4 Levels**

SONALI SHARMA,<sup>1</sup>GABRIELA MLADONICKA PAVLASOVA,<sup>2</sup>VACLAV SEDA,<sup>3</sup>KATERINA AMRUZ CERNA,<sup>2</sup>EVA VOJACKOVA,<sup>2</sup>DANIEL FILIP,<sup>2</sup>LAURA ONDRISOVA,<sup>2</sup>VERONIKA SANDOVA,<sup>2</sup>LENKA KOSTALOVA,<sup>2</sup>PEDRO F. ZENI,<sup>2</sup>MAREK BORSKY,<sup>4</sup>JAN OPPELT,<sup>2</sup>KVETOSLAVA LISKOVA,<sup>5</sup>LEOS KREN,<sup>6</sup>ANDREA JANIKOVA,<sup>7</sup>SARKA POSPISILOVA,<sup>4</sup>STACEY M.FERNANDES,<sup>8</sup>MEDHAT SHEHATA,<sup>9</sup>LAURA Z. RASSENTI,<sup>10</sup>ULRICH JAEGER,<sup>11</sup>MICHAEL DOUBEK,<sup>12</sup>MATTHEW DAVIDS,<sup>13</sup>JENNIFER BROWN,<sup>13</sup>JIRI MAYER,<sup>14</sup>THOMAS KIPPS,<sup>15</sup>MAREK MRAZ,<sup>16</sup>

<sup>1</sup> CEITEC MU, Czech Republic

<sup>2</sup> Central European Institute of Technology, Masaryk University, Czech Republic

<sup>3</sup> Central European Institute of Technology, Masaryk University, Brno, Czech Republic, Czech Republic

**XIX International Workshop on CLL**

16 – 20 September 2021, Virtual

[www.iwcll2021.org](http://www.iwcll2021.org) • 1-888-476-9129



- <sup>4</sup> Department of Internal Medicine, Hematology and Oncology, University Hospital Brno, Czech Republic
- <sup>5</sup> Department of Pathology, University Hospital Brno and Faculty of Medicine, Masaryk University, Czech Republic
- <sup>6</sup> Department of Pathology, University Hospital Brno and Faculty of Medicine, Masaryk University,, Czech Republic
- <sup>7</sup> Department of Internal Medicine, Hematology and Oncology, University Hospital Brno,, Czech Republic
- <sup>8</sup> Dana-Farber Cancer Institute, Czech Republic
- <sup>9</sup> Medical University of Vienna, Vienna, Austria., Czech Republic
- <sup>10</sup> University of California San Diego, La Jolla, CA, United States
- <sup>11</sup> Medical University of Vienna, Vienna, Austria., Austria
- <sup>12</sup> University Hospital Brno & Masaryk University, Czech Republic
- <sup>13</sup> Dana-Farber Cancer Institute, United States
- <sup>14</sup> Department of Internal Medicine, Hematology and Oncology, University Hospital Brno,Brno, Czech Republic., Czech Republic
- <sup>15</sup> UCSD Moores Cancer, United States
- <sup>16</sup> CEITEC MUNI and UNiversity Hospital Brno, Czech Republic

**1084083**

**Cardiac Toxicity in a Pilot Study of Duvelisib and Ibrutinib Combination Therapy for Chronic Lymphocytic Leukemia**

CLARE SUN,<sup>1</sup> DOUGLAS R. ROSING,<sup>2</sup> MARK C. HAIGNEY,<sup>3</sup> CODY J. PEER,<sup>4</sup> WILLIAM D. FIGG,<sup>4</sup> ADRIAN WIESTNER,<sup>2</sup>

<sup>1</sup> Hematology Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD, United States

<sup>2</sup> Hematology Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, United States

<sup>3</sup> Division of Cardiology, Department of Medicine, Uniformed Services University of the Health Sciences, United States

<sup>4</sup> Clinical Pharmacology Program, Center for Cancer Research, National Cancer Institute, National Institutes of Health, United States

**XIX International Workshop on CLL**

16 – 20 September 2021, Virtual

[www.iwcll2021.org](http://www.iwcll2021.org) • 1-888-476-9129



**1084084**

**Adaptation of Chronic Lymphocytic Leukemia to Ibrutinib Is Mediated by Epigenetic Plasticity of Residual Disease and By-pass Signaling via MAPK Pathway**

GABRIELA FORESTIERI,<sup>1</sup>JUI WAN LOH,<sup>2</sup>AMARTYA SINGH,<sup>2</sup>VALERIA SPINA,<sup>1</sup>ANTONELLA ZUCCHETTO,<sup>3</sup>ADALGISA CONDOLUCI,<sup>4</sup>MARTIN FADERL,<sup>1</sup>RICARDO KOCH,<sup>1</sup>ALESSIO BRUSCAGGIN,<sup>1</sup>KATIA PINI,<sup>1</sup>DEBORAH PIFFARETTI,<sup>1</sup>WEI WU,<sup>1</sup>TAMARA BITTOLO,<sup>3</sup>ERIKA TISSINO,<sup>3</sup>LORENZO DE PAOLI,<sup>5</sup>CLARA DEAMBROGI,<sup>6</sup>ANNA MARIA FRUSTACI,<sup>7</sup>FRANCESCO AUTORE,<sup>8</sup>MICHELE MERLI,<sup>9</sup>LYDIA SCARFÒ,<sup>10</sup>SILVIA RASI,<sup>6</sup>JAKOB PASSWEG,<sup>11</sup>RICCARDO MOIA,<sup>6</sup>CLAUDIO MARTINES,<sup>12</sup>PAOLO GHIA,<sup>13</sup>FRANCO CAVALLI,<sup>1</sup>EMANUELE ZUCCA,<sup>4</sup>BERNHARD GERBER,<sup>4</sup>SILKE GILLESSEN,<sup>4</sup>GEORG STÜSSI,<sup>4</sup>LODOVICO TERZI DI BERGAMO,<sup>1</sup>MARCO MONTILLO,<sup>9</sup>MICHAEL GREGOR,<sup>14</sup>LUCA LAURENTI,<sup>15</sup>ALESSANDRA TEDESCHI,<sup>16</sup>GIANLUCA GAIDANO,<sup>17</sup>DIMITAR EFREMOV,<sup>12</sup>VALTER GATTEI,<sup>3</sup>HOSSEIN KHIABANIAN,<sup>2</sup>DAVIDE ROSSI,<sup>1</sup>

<sup>1</sup> Institute of Oncology Research, Switzerland

<sup>2</sup> Rutgers Cancer Institute of New Jersey, United States

<sup>3</sup> Centro di Riferimento Oncologico di Aviano, Italy

<sup>4</sup> Oncology Institute of Southern Switzerland, Switzerland

<sup>5</sup> Division of Hematology, Department of Translational Medicine, University of Eastern Piedmont, Novara, Italy; Italy

<sup>6</sup> University of Eastern Piedmont, Italy

<sup>7</sup> Dept of Hematology, Niguarda Cancer Center, ASST Grande Ospedale Metropolitano Niguarda Milano, Italy; Italy

<sup>8</sup> Catholic University of the Sacred Heart, Italy

<sup>9</sup> Ospedale di Circolo e Fondazione Macchi, Italy

<sup>10</sup> IRCCS San Raffaele Scientific Institute, Italy

<sup>11</sup> University Hospital Basel, Switzerland

<sup>12</sup> International Centre for Genetic Engineering and Biotechnology, Italy

<sup>13</sup> Università Vita-Salute San Raffaele and IRCCS Ospedale San Raffaele, Italy

<sup>14</sup> Department of Hematology, Cantonal Hospital Lucerne, Switzerland, Switzerland

<sup>15</sup> Institute of Haematology, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy, Italy

**XIX International Workshop on CLL**

16 – 20 September 2021, Virtual

[www.iwcll2021.org](http://www.iwcll2021.org) • 1-888-476-9129



<sup>16</sup> Niguarda Cancer Center, Italy

<sup>17</sup> 11 Division of Hematology, Department of Translational Medicine, University of Eastern Piedmont, Novara, Italy, Italy

#### **1084085**

#### **Pirtobrutinib (LOXO-305), a Next Generation, Highly Selective, Non-covalent BTK Inhibitor in Previously Treated Richter Transformation: Results from the Phase 1/2 BRUIN Study**

MEGHAN THOMPSON,<sup>1</sup> NIRAV SHAH,<sup>2</sup> NICOLE LAMANNA,<sup>3</sup> TOBY A EYRE,<sup>4</sup> WOJCIECH JURCZAK,<sup>5</sup> JENNIFER WOYACH,<sup>6</sup> EWA LECH-MARANDA,<sup>7</sup> WILLIAM WIERDA,<sup>8</sup> DAVID J LEWIS,<sup>9</sup> DENISE WANG,<sup>10</sup> MING YIN,<sup>10</sup> MINNA BALBAS,<sup>10</sup> BINOJ C NAIR,<sup>10</sup> EDWARD Y ZHU,<sup>10</sup> DONALD E TSAI,<sup>10</sup> NORA C KU,<sup>10</sup> CATHERINE COOMBS,<sup>11</sup> ANTHONY MATO,<sup>1</sup>

<sup>1</sup> Memorial Sloan Kettering Cancer Center, United States

<sup>2</sup> Medical College of Wisconsin, United States

<sup>3</sup> Herbert Irving Comprehensive Cancer Center, Columbia University, United States

<sup>4</sup> Oxford University Hospitals NHS Foundation Trust, Churchill Cancer Center, United Kingdom

<sup>5</sup> Maria Sklodowska-Curie National Research Institute of Oncology, Poland

<sup>6</sup> The Ohio State University, United States

<sup>7</sup> Institute of Hematology and Transfusion Medicine, Poland

<sup>8</sup> MD Anderson Cancer Center, United States

<sup>9</sup> Plymouth Hospitals NHS Trust - Derriford Hospital, United Kingdom

<sup>10</sup> Loxo Oncology at Lilly, United States

<sup>11</sup> The University of North Carolina Cancer Center, United States

#### **1084086**

#### **The Impact of COVID-19 on UK CLL Patients**

NICK YORK,<sup>1</sup> BRIAN GARDOM,<sup>2</sup> MARC AUCLAND,<sup>2</sup> NICOLE SCULLY,<sup>1</sup> GREG FEGAN,<sup>3</sup> CHRISTOPHER FEGAN,<sup>4</sup> RENATA WALEWSKA,<sup>5</sup>

<sup>1</sup> Leukaemia Care, United Kingdom

**XIX International Workshop on CLL**

16 – 20 September 2021, Virtual

[www.iwcll2021.org](http://www.iwcll2021.org) • 1-888-476-9129



<sup>2</sup> CLL Support Association, United Kingdom

<sup>3</sup> Swansea University, United Kingdom

<sup>4</sup> Cardiff University, United Kingdom

<sup>5</sup> University Hospitals Dorset, United Kingdom

### **1084087**

#### **Central Nervous System Involvement of Richter Transformation: A Single Center Experience**

YUCAI WANG,<sup>1</sup> SAMEER PARIKH,<sup>2</sup> TIMOTHY CALL,<sup>2</sup> NEIL KAY,<sup>2</sup> SAAD KENDERIAN,<sup>2</sup> PATRICK JOHNSTON,<sup>2</sup> LUIS PORRATA,<sup>2</sup> GRZEGORZ NOWAKOWSKI,<sup>2</sup> STEPHEN ANSELL,<sup>2</sup> RONG HE,<sup>2</sup> JOSE LEIS,<sup>2</sup> WEI DING,<sup>2</sup>

<sup>1</sup> Mayo Clinic, Rochester, Minnesota, United States

<sup>2</sup> Mayo Clinic, United States

### **1084088**

#### **TRANSCEND CLL 004: Phase 1 Cohort of Lisocabtagene Maraleucel (Liso-cel) Combined with Ibrutinib for Patients with Relapsed/Refractory CLL/SLL**

KATHLEEN DORRITIE,<sup>1</sup> JAVIER MUNOZ,<sup>2</sup> DEBORAH STEPHENS,<sup>3</sup> SCOTT SOLOMON,<sup>4</sup> HEIDI GILLENWATER,<sup>5</sup> LUCY GONG,<sup>5</sup> YEONHEE KIM,<sup>5</sup> KEN OGASAWARA,<sup>5</sup> JERILL THORPE,<sup>5</sup> TANYA SIDDIQI,<sup>6</sup> WILLIAM WIERDA,<sup>7</sup>

<sup>1</sup> UPMC Hillman Cancer Center, United States

<sup>2</sup> Banner MD Anderson Cancer Center, United States

<sup>3</sup> Huntsman Cancer Institute, University of Utah, United States

<sup>4</sup> Northside Hospital Cancer Institute, United States

<sup>5</sup> Bristol Myers Squibb, United States

<sup>6</sup> City of Hope National Medical Center, Duarte, California, United States

<sup>7</sup> The University of Texas - MD Anderson Cancer Center - Leukemia Center, United States





**1084089**

**Multi-Year Longitudinal Analysis: Curriculum Targeting BTK in B-Cell Malignancies Significantly Impacts Knowledge and Skills of the Entire Care Team**

LAUREN WILLIS,<sup>1</sup>TRISTIN ABAIR,<sup>2</sup>RICH CARACIO,<sup>2</sup>DEBORAH STEPHENS,<sup>3</sup>JAN BURGER,<sup>4</sup>ANTHONY MATO,<sup>5</sup>JEFF P. SHARMAN,<sup>6</sup>DANIELLE BRANDER,<sup>7</sup>JOHN PAGEL,<sup>8</sup>

<sup>1</sup> Medscape Education, New York, New York, United States

<sup>2</sup> Medscape Education, New York City, New York, United States

<sup>3</sup> Huntsman Cancer Institute, University of Utah, Salt Lake City, Utah, United States

<sup>4</sup> The University of Texas MD Anderson Cancer Center, Houston, Texas, United States

<sup>5</sup> Memorial Sloan Kettering Cancer Center, New York City, New York, United States

<sup>6</sup> Willamette Valley Cancer Institute and Research Center, Eugene, Oregon, United States

<sup>7</sup> Duke Cancer Institute, Durham, North Carolina, United States

<sup>8</sup> Swedish Cancer Institute, Seattle, Washington, United States

**1084090**

**Zanubrutinib Monotherapy in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia: 34-month Follow-up Results**

WEI XU,<sup>1</sup>SHENMIAO YANG,<sup>2</sup>KESHU ZHOU,<sup>3</sup>LING PAN,<sup>4</sup>ZENGJUN LI,<sup>5</sup>JIANFENG ZHOU,<sup>6</sup>SUJUN GAO,<sup>7</sup>DAOBIN ZHOU,<sup>8</sup>JIANDA HU,<sup>9</sup>RU FENG,<sup>10</sup>HAIWEN HUANG,<sup>11</sup>TINGYU WANG,<sup>12</sup>MENG JI,<sup>13</sup>HAIYI GUO,<sup>14</sup>JANE HUANG,<sup>15</sup>WILLIAM NOVOTNY,<sup>15</sup>SHIBAO FENG,<sup>14</sup>JIANYONG LI,<sup>16</sup>

<sup>1</sup> The First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital, Nanjing, China, Nanjing Shi, China (People's Republic)

<sup>2</sup> Peking University Peoples Hospital, Peking University Institute of Hematology, Beijing, China, China (People's Republic)

<sup>3</sup> Affiliated Cancer Hospital of Zhengzhou University, Henan Cancer Hospital, Zhengzhou, China, China (People's Republic)

<sup>4</sup> West China Hospital of Sichuan University, Chengdu, China, China (People's Republic)

<sup>5</sup> Blood Disease Hospital, Chinese Academy of Medical Science, Tianjin, China, China (People's Republic)

<sup>6</sup> Tongji Hospital, Tongji Medical College, Wuhan, China, China (People's Republic)

**XIX International Workshop on CLL**

16 – 20 September 2021, Virtual

[www.iwcll2021.org](http://www.iwcll2021.org) • 1-888-476-9129



- <sup>7</sup> The First Hospital of Jilin University, Changchun, China, China (People's Republic)
- <sup>8</sup> Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China, China (People's Republic)
- <sup>9</sup> Fujian Institute of Hematology, Fujian Provincial Key Laboratory on Hematology, Fujian Medical University Union Hospital, Fuzhou, China, China (People's Republic)
- <sup>10</sup> Nanfang Hospital of Southern Medical University, Guangzhou, China, China (People's Republic)
- <sup>11</sup> The 1st Hospital of Soochow University, Suzhou, China, China (People's Republic)
- <sup>12</sup> Blood Disease Hospital, Chinese Academy of Medical Science, Tianjin, China, Tianjin, China (People's Republic)
- <sup>13</sup> BeiGene (Beijing) Co., Ltd., Beijing, China and BeiGene USA, Inc., San Mateo, CA, USA, United States
- <sup>14</sup> BeiGene (Beijing) Co., Ltd., Beijing, China, BeiGene (Shanghai) Co., Ltd., Shanghai, China, and BeiGene USA, Inc., San Mateo, CA, USA, China (People's Republic)
- <sup>15</sup> BeiGene (Beijing) Co., Ltd., Beijing, China and BeiGene USA, Inc., San Mateo, CA, USA, China (People's Republic)
- <sup>16</sup> The First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital, Nanjing, China, China (People's Republic)

**1084091**

**Long Non-coding RNA LINC00525 Promotes Proliferation and Inhibits Apoptosis of Chronic Lymphocytic Leukemia Cells by Targeting miR-338-3p/WWP1 Axis**

LEI CAO,<sup>1</sup>HAILING LIU,<sup>1</sup>XIAO SHI,<sup>1</sup>WEI XU,<sup>1</sup>JIANYONG LI,<sup>2</sup>LEI FAN,<sup>1</sup>CHANGQING YANG,<sup>3</sup>

<sup>1</sup> The First Affiliated Hospital of Nanjing Medical University, China (People's Republic)

<sup>2</sup> Jiangsu Province Hospital, China (People's Republic)

<sup>3</sup> N/A, China (People's Republic)



**1084092**

**Detailed Analysis of Treatment-related Clonal Evolution in CLL Through the Identification of Abnormal Molecular Pathways**

PETR TAUS,<sup>1</sup>KAROL PAL,<sup>2</sup>KAMILA STRANSKA,<sup>3</sup>SARKA PAVLOVA,<sup>4</sup>JITKA MALCIKOVA,<sup>3</sup>ANNA PANOVSKA,<sup>5</sup>MICHAEL DOUBEK,<sup>3</sup>SARKA POSPISILOVA,<sup>3</sup>KARLA PLEVOVA,<sup>3</sup>KRISTYNA ZAVACKA,<sup>3</sup>

<sup>1</sup> Central European Institute of Technology (CEITEC), Masaryk University, Czech Republic

<sup>2</sup> Masaryk University, Czech Republic

<sup>3</sup> University Hospital Brno & Masaryk University, Czech Republic

<sup>4</sup> Central European Institute of Technology (CEITEC), Masaryk University; Department of Internal Medicine – Hematology and Oncology, University Hospital Brno and Faculty of Medicine, Masaryk University, Czech Republic

<sup>5</sup> University Hospital Brno, Czech Republic

**1084093**

**Zanubrutinib in Patients with B-cell Malignancies Intolerant to Ibrutinib And/or Acalabrutinib**

MAZYAR SHADMAN,<sup>1</sup>JEFF SHARMAN,<sup>2</sup>MOSHE LEVY,<sup>3</sup>RYAN PORTER,<sup>4</sup>SYED F. ZAFAR,<sup>5</sup>JOHN M. BURKE,<sup>6</sup>ARVIND CHAUDHRY,<sup>7</sup>BENJAMIN FREEMAN,<sup>8</sup>JAMAL MISLEH,<sup>9</sup>HABTE YIMER,<sup>10</sup>JENNIFER L. CULTRERA,<sup>11</sup>TROY H. GUTHRIE,<sup>12</sup>EDWIN KINGSLEY,<sup>13</sup>SUBRAMANYA S. RAO,<sup>14</sup>DIH-YIH CHEN,<sup>15</sup>XIAOPING ZHANG,<sup>15</sup>ADAM IDOINE,<sup>15</sup>AILEEN COHEN,<sup>15</sup>KUNTHEL BY,<sup>15</sup>LINLIN XU,<sup>15</sup>JANE HUANG,<sup>15</sup>IAN FLINN,<sup>16</sup>

<sup>1</sup> Fred Hutchinson Cancer Research Center, University of Washington, Clinical Research Division, Seattle, WA, USA, Seattle, Washington, United States

<sup>2</sup> Willamette Valley Cancer Institute and Research Center, Eugene, OR, USA, Eugene, Oregon, United States

<sup>3</sup> Texas Oncology-Baylor Charles A. Sammons Cancer Center, Dallas, TX, USA, Dallas, Texas, United States

<sup>4</sup> SSM Health Dean Medical Group, Madison, WI, USA, United States

<sup>5</sup> Florida Cancer Specialists & Research Institute, Fort Myers, FL, USA, Fort Myers, Florida, United States

<sup>6</sup> Rocky Mountain Cancer Centers, Aurora, CO, USA, United States

<sup>7</sup> Summit Cancer Centers, Spokane, WA, USA, United States

<sup>8</sup> Summit Medical Group, Florham Park, NJ, USA, United States

**XIX International Workshop on CLL**

16 – 20 September 2021, Virtual

[www.iwcll2021.org](http://www.iwcll2021.org) • 1-888-476-9129



- <sup>9</sup> Medical Oncology Hematology Consultants PA, Newark, DE, USA, United States  
<sup>10</sup> Texas Oncology-Tyler, Tyler, TX, USA, United States  
<sup>11</sup> Florida Cancer Specialists & Research Institute, Leesburg, FL, USA, United States  
<sup>12</sup> GenesisCare, Jacksonville, FL, USA, United States  
<sup>13</sup> Comprehensive Cancer Centers of Nevada, Las Vegas, NV, USA, United States  
<sup>14</sup> Alpha Med Physicians Group, Tinley Park, IL, USA, United States  
<sup>15</sup> BeiGene (Beijing) Co., Ltd., Beijing, China and BeiGene USA, Inc., San Mateo, CA, USA, United States  
<sup>16</sup> Sarah Cannon Research Institute/Tennessee Oncology, Nashville, TN, USA, United States

**1084094**

**Re-designing anti-CD20 Monoclonal Antibody Therapy of CLL Using Novel Insights into Limitations of Innate Immune Cytotoxicity**

CHRISTINE HERNE,<sup>1</sup>CHARLES CHU,<sup>1</sup>JENNIFER BRUNO,<sup>1</sup>ANDREA M. BARAN,<sup>2</sup>KARL VANDERMEID,<sup>3</sup>SALLY QUATAERT,<sup>3</sup>PAUL BARR,<sup>4</sup>CLIVE ZENT,<sup>3</sup>

- <sup>1</sup> University of Rochester Medical Center, United States  
<sup>2</sup> Wilmot Cancer Institute, University of Rochester Medical Center, Rochester, New York, United States  
<sup>3</sup> University of Rochester Medical Center, Rochester, New York, United States  
<sup>4</sup> Wilmot Cancer Institute, University of Rochester Medical Center, United States

**1084095**

**Evaluation of Immunoglobulin Gene Somatic Hypermutation Status by Next Generation Sequencing Is Superior to Using Sanger Sequencing**

MENGGE GAO,<sup>1</sup>YANG LIU,<sup>2</sup>KE WANG,<sup>2</sup>JIN LU,<sup>2</sup>XIAOJUN HUANG,<sup>2</sup>SHENMIAO YANG,<sup>2</sup>XIAOSU ZHAO,<sup>2</sup>

- <sup>1</sup> Peking university people's hospital, China (People's Republic)  
<sup>2</sup> Peking University Institute of Hematology, China (People's Republic)



**1084107**

**The Inflammasome Complex as a Novel Therapeutic Target in Chronic Lymphocytic Leukemia**

GIMENA DOS SANTOS,<sup>1</sup>FLORENCIA RAMMAURO,<sup>2</sup>ANGIMAR URIEPERO,<sup>2</sup>FRANCINE BITTENCOURT POTRICH,<sup>2</sup>MARÍA ELENA MARQUEZ,<sup>2</sup>DANIEL PRIETO,<sup>2</sup>SOFIA RUSSO,<sup>2</sup>MERCEDES SEGOVIA,<sup>2</sup>RAÚL GABUS,<sup>3</sup>CECILIA GUILLERMO,<sup>4</sup>MARCELO HILL,<sup>5</sup>PABLO OPPEZZO,<sup>6</sup>

<sup>1</sup> Institut Pasteur de Montevideo and Dept of Hematology of the University Hospital, Montevideo, Uruguay

<sup>2</sup> Institut Pasteur de Montevideo, Montevideo, Uruguay

<sup>3</sup> Hospital Maciel, Montevideo and Hospital de la Asociación Médica, San José, Montevideo, Uruguay

<sup>4</sup> Hospital de Clínicas, Montevideo, Uruguay

<sup>5</sup> Institut Pasteur de Montevideo, Uruguay

<sup>6</sup> Institut Pasteur de Montevideo, Montevideo, Uruguay

**1084109**

**Venetoclax and Ibrutinib Decrease Mitochondrial Metabolism in Chronic Lymphocytic Leukemia via the AMPK/SIRT1/PGC-1 $\alpha$  Signalling Pathway**

SUBIR ROY CHOWDHURY,<sup>1</sup>CHERYL PELTIER,<sup>1</sup>EILEEN MCMILLAN-WARD,<sup>1</sup>RYAN SALEH,<sup>1</sup>TRICIA CHOQUETTE,<sup>1</sup>MAXIM SKORODINSKY,<sup>1</sup>KIRA PETERS,<sup>1</sup>EDWIN NGUYEN,<sup>1</sup>AMANDEEP SINGH,<sup>2</sup>ERIC BOUCHARD,<sup>1</sup>JAMES JOHNSTON,<sup>3</sup>AARON J MARSHALL,<sup>4</sup>SPENCER B GIBSON,<sup>5</sup>VERSHA BANERJI,<sup>6</sup>

<sup>1</sup> CancerCare Manitoba Research Institute, Canada

<sup>2</sup> CancerCare Manitoba Research Institute, United States

<sup>3</sup> Research Institute in Oncology and Hematology, Department of Internal Medicine, Max Rady College of Medicine, University of Manitoba, Canada

<sup>4</sup> Department of Immunology, Research Institute in Oncology and Hematology, Max Rady College of Medicine, University of Manitoba, Canada

<sup>5</sup> Research Institute in Oncology and Hematology, Department of Immunology, Max Rady College of Medicine, University of Manitoba, Canada

<sup>6</sup> CancerCare Manitoba Research Institute/ University of Manitoba, Winnipeg, Canada

**XIX International Workshop on CLL**

16 – 20 September 2021, Virtual

[www.iwcll2021.org](http://www.iwcll2021.org) • 1-888-476-9129





**1084121**

**Impaired Antibody Response After mRNA COVID-19 Vaccination in Patients with Chronic Lymphocytic Leukemia**

MARIA STEFANIA INFANTE,<sup>1</sup> ISABEL GONZÁLEZ-GASCÓN Y MARÍN,<sup>1</sup> CAROLINA MUÑOZ,<sup>1</sup> MARIA ANGELES FONCILLAS,<sup>1</sup> ELENA LANDETE,<sup>1</sup> JUAN CHURRUCA,<sup>1</sup> KAREN MARÍN,<sup>1</sup> VICTORIA RAMOS ASCANIO,<sup>2</sup> ELENA VALDIVIELSO,<sup>3</sup> TAMAR TALAVÁN,<sup>1</sup> JOSÉ ÁNGEL HERNÁNDEZ,<sup>4</sup>

<sup>1</sup> Universitary Hospital Infanta Leonor, Madrid, Spain, Spain

<sup>2</sup> Universitary Hospital Infanta Leonor, Madrid, Spain

<sup>3</sup> Complutense University, Madrid, Spain, Spain

<sup>4</sup> Hospital Universitario Infanta Leonor, Madrid, Spain

**1084126**

**A Pilot Study of Gut Microbiome in Patients with Chronic Lymphocytic Leukemia or Monoclonal B-cell Lymphocytosis**

YUCAI WANG,<sup>1</sup> SAMEER PARIKH,<sup>2</sup> STEPHEN JOHNSON,<sup>2</sup> JUN CHEN,<sup>2</sup> NEIL KAY,<sup>2</sup> THOMAS WITZIG,<sup>2</sup> SUSAN SLAGER,<sup>2</sup> MATTHEW HOLETS,<sup>2</sup> TIMOTHY CALL,<sup>2</sup> SAAD KENDERIAN,<sup>2</sup> ELI MUGHTAR,<sup>2</sup> AMBER KOEHLER,<sup>2</sup> JOSE LEIS,<sup>2</sup> WEI DING,<sup>2</sup>

<sup>1</sup> Mayo Clinic, Rochester, Minnesota, United States

<sup>2</sup> Mayo Clinic, United States

**1084129**

**Cell-free DNA (cfDNA)-based Serial Minimal Residual Disease Assessment in Patients with Chronic Lymphocytic Leukemia Treated with Time-limited Obinutuzumab, Acalabrutinib and Venetoclax**

MORITZ FÜRSTENAU,<sup>1</sup> JONATHAN WEISS,<sup>1</sup> ADAM GIZA,<sup>1</sup> FABIAN FRANZEN,<sup>1</sup> SANDRA ROBRECHT,<sup>1</sup> ANNA-MARIA FINK,<sup>2</sup> KIRSTEN FISCHER,<sup>1</sup> EUGEN TAUSCH,<sup>3</sup> STEPHAN STILGENBAUER,<sup>4</sup> MATTHIAS RITGEN,<sup>5</sup> ANKE SCHILHABEL,<sup>5</sup> MONIKA BRÜGGEMANN,<sup>5</sup> BARBARA EICHHORST,<sup>6</sup> MICHAEL HALLEK,<sup>1</sup> PAULA CRAMER,<sup>1</sup>



<sup>1</sup> Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf (CIO ABCD), German CLL Study Group, University Hospital Cologne, University of Cologne, Cologne, Germany, Germany

<sup>2</sup> University of Cologne, Germany

<sup>3</sup> Department of Internal Medicine III, University of Ulm, Ulm, Germany, Germany

<sup>4</sup> Department of Internal Medicine III, Ulm University, Ulm, Germany, Ulm, Germany

<sup>5</sup> 2nd Department of Internal Medicine, University of Schleswig-Holstein, Campus Kiel, Kiel, Germany, Germany

<sup>6</sup> Department of Internal Medicine, University of Cologne, Cologne, Germany, Germany

### **1084132**

#### **Fixed-duration (FD) first-line treatment with ibrutinib plus venetoclax for chronic lymphocytic leukemia/small lymphocytic lymphoma: primary analysis of the FD Cohort of the Phase 2 CAPTIVATE Study**

WILLIAM G. WIERDA,<sup>1</sup> JOHN N. ALLAN,<sup>2</sup> TANYA SIDDIQI,<sup>3</sup> THOMAS J. KIPPS,<sup>4</sup> RYAN JACOBS,<sup>5</sup> STEPHEN OPAT,<sup>6</sup> PAUL M. BARR,<sup>7</sup> ALESSANDRA TEDESCHI,<sup>8</sup> LIVIO TRENTIN,<sup>9</sup> RAJAT BANNERJI,<sup>10</sup> SHARON JACKSON,<sup>11</sup> BRYONE KUSS,<sup>12</sup> CAROL MORENO,<sup>13</sup> EDITH SZA FER-GLUSMAN,<sup>14</sup> KRISTIN RUSSELL,<sup>14</sup> CATHY ZHOU,<sup>14</sup> JOI NINOMOTO,<sup>14</sup> JAMES P. DEAN,<sup>14</sup> CONSTANTINE TAM,<sup>15</sup> PAOLO GHIA,<sup>16</sup>

<sup>1</sup> University of Texas MD Anderson Cancer Center, Texas, United States

<sup>2</sup> Weill Cornell Medicine, New York, New York, United States

<sup>3</sup> City of Hope National Medical Center, Duarte, California, United States

<sup>4</sup> UCSD Moores Cancer Center, San Diego, California, United States

<sup>5</sup> Department of Hematology, Lymphoma Division, Assistant Professor of Medicine, Levine Cancer Institute/Atrium Health, Charlotte, North Carolina, United States

<sup>6</sup> Monash University, Clayton, Australia

<sup>7</sup> Wilmot Cancer Institute, University of Rochester Medical Center, Rochester, New York, United States

<sup>8</sup> ASST Grande Ospedale Metropolitano Niguarda, Milano, Italy

<sup>9</sup> University of Padova, Padova, Italy

<sup>10</sup> Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey, United States

**XIX International Workshop on CLL**

16 – 20 September 2021, Virtual

[www.iwcll2021.org](http://www.iwcll2021.org) • 1-888-476-9129



<sup>11</sup> Middlemore Hospital, Auckland, New Zealand

<sup>12</sup> Flinders University and Medical Centre, Bedford Park, Australia

<sup>13</sup> Hospital de la Santa Creu i Sant Pau, Autonomous University of Barcelona, Barcelona, Spain

<sup>14</sup> Pharmacyclics LLC, an AbbVie Company, Sunnyvale, California, United States

<sup>15</sup> Peter MacCallum Cancer Center & St. Vincent's Hospital and the University of Melbourne, Melbourne, Australia

<sup>16</sup> Università Vita-Salute San Raffaele and IRCCS Ospedale San Raffaele, Milano, Italy

### 1084141

#### **First Interim Analysis of ALPINE Study: Results of a Phase 3 Randomized Study of Zanubrutinib vs Ibrutinib in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma**

PETER HILLMEN,<sup>1</sup> BARBARA EICHHORST,<sup>2</sup> JENNIFER BROWN,<sup>3</sup> NICOLE LAMANNA,<sup>4</sup> SUSAN O'BRIEN,<sup>5</sup> CONSTANTINE TAM,<sup>6</sup> LUGUI QIU,<sup>7</sup> MACIEJ KAZMIERCZAK,<sup>8</sup> KESHU ZHOU,<sup>9</sup> MARTIN ŠIMKOVIČ,<sup>10</sup> JIRI MAYER,<sup>11</sup> AMANDA GILLESPIE-TWARDY,<sup>12</sup> MAZYAR SHADMAN,<sup>13</sup> ALESSANDRA FERRAJOLI,<sup>14</sup> PETER GANLY,<sup>15</sup> ROBERT WEINKOVE,<sup>16</sup> TOMMI SALMI,<sup>17</sup> MENG JI,<sup>18</sup> JESSICA YECIES,<sup>18</sup> KENNETH WU,<sup>18</sup> WILLIAM NOVOTNY,<sup>17</sup> JANE HUANG,<sup>17</sup> WOJCIECH JURCZAK,<sup>19</sup>

<sup>1</sup> St James's University Hospital, Leeds, United Kingdom, Leeds, United Kingdom

<sup>2</sup> Department of Internal Medicine, University of Cologne, Cologne, Germany, Germany

<sup>3</sup> Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA, United States

<sup>4</sup> Herbert Irving Comprehensive Cancer Center, Columbia University, New York, NY, USA, United States

<sup>5</sup> Chao Family Comprehensive Cancer Center, University of California, Irvine, CA, USA, United States

<sup>6</sup> Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia; University of Melbourne, Parkville, Victoria, Australia; St Vincent's Hospital, Fitzroy, Victoria, Australia; Royal Melbourne Hospital, Parkville, Victoria, Australia, Australia

<sup>7</sup> Chinese Academy of Medical Sciences, Peking Union Medical College, Tianjin, China, China (People's Republic)

<sup>8</sup> Department of Hematology and Bone Marrow Transplantation, Poznan University of Medical Sciences, Poznan, Poland, Poland

**XIX International Workshop on CLL**

16 – 20 September 2021, Virtual

[www.iwcll2021.org](http://www.iwcll2021.org) • 1-888-476-9129



- <sup>9</sup> Affiliated Cancer Hospital of Zhengzhou University, Henan Cancer Hospital, Zhengzhou, China, China (People's Republic)
- <sup>10</sup> 4th Department of Internal Medicine - Hematology, University Hospital, Hradec Kralove, Czech Republic; Faculty of Medicine, Charles University, Prague, Czech Republic, Czech Republic
- <sup>11</sup> Department of Internal Medicine-Hematology and Oncology, Masaryk University and University Hospital, Brno, Czech Republic, Czech Republic
- <sup>12</sup> Blue Ridge Cancer Care, Roanoke, VA, USA, United States
- <sup>13</sup> Fred Hutchinson Cancer Research Center, University of Washington, Clinical Research Division, Seattle, WA, USA, Seattle, Washington, United States
- <sup>14</sup> Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA, United States
- <sup>15</sup> Department of Haematology, Christchurch Hospital, Christchurch, New Zealand; Department of Pathology and Biomedical Science, University of Otago, Christchurch, New Zealand, New Zealand
- <sup>16</sup> Wellington Blood and Cancer Centre, Capital and Coast District Health Board, Wellington, New Zealand; Malaghan Institute of Medical Research, Wellington, New Zealand, New Zealand
- <sup>17</sup> BeiGene (Beijing) Co., Ltd., Beijing, China and BeiGene USA, Inc., San Mateo, CA, USA, China (People's Republic)
- <sup>18</sup> BeiGene (Beijing) Co., Ltd., Beijing, China and BeiGene USA, Inc., San Mateo, CA, USA, United States
- <sup>19</sup> Maria Sklodowska-Curie National Institute of Oncology, Krakow, Poland, United States

## **1084142**

### **Altered T Follicular Helper Cell Subsets and Function in Chronic Lymphocytic Leukemia**

XUN WU,<sup>1</sup>J ERNESTO F. DESPAIGNE,<sup>2</sup>CHRISTINE ZHANG,<sup>3</sup>VISHALA NEPPALLI,<sup>4</sup>VERSHA BANERJI,<sup>5</sup>JAMES JOHNSTON,<sup>6</sup>SPENCER B GIBSON,<sup>7</sup>AARON J MARSHALL,<sup>8</sup>

- <sup>1</sup> Department of Immunology, Max Rady College of Medicine ,University of Manitoba, Winnipeg, Canada
- <sup>2</sup> Department of Immunology, Max Rady College of Medicine ,University of Manitoba, Canada
- <sup>3</sup> Department of Immunology, Max Rady College of Medicine, University of Manitoba, Canada
- <sup>4</sup> Health Sciences Centre, Max Rady College of Medicine, University of Manitoba, Canada
- <sup>5</sup> CancerCare Manitoba Research Institute/ University of Manitoba, Winnipeg, Canada
- <sup>6</sup> Research Institute in Oncology and Hematology, Department of Internal Medicine, Max Rady College of Medicine, University of Manitoba, Canada

**XIX International Workshop on CLL**

16 – 20 September 2021, Virtual

[www.iwcll2021.org](http://www.iwcll2021.org) • 1-888-476-9129



<sup>7</sup> Research Institute in Oncology and Hematology, Department of Immunology, Max Rady College of Medicine University of Manitoba, Canada

<sup>8</sup> Department of Immunology, Research Institute in Oncology and Hematology, Max Rady College of Medicine, University of Manitoba, Canada

**1084145**

**Can Whole Genome Sequencing Detect a Complex Karyotype in Chronic Lymphocytic Leukaemia?**

MARTIN HARRIS,<sup>1</sup>PETER HILLMEN,<sup>2</sup>ULF KLEIN,<sup>3</sup>

<sup>1</sup> Leeds Teaching Hospital Trust - Genomics Laboratory, Leeds, United Kingdom

<sup>2</sup> Leeds Teaching Hospital Trust, United Kingdom

<sup>3</sup> University of Leeds, United Kingdom

**1084159**

**Functional Antibody Testing for Streptococcus Pneumoniae and Haemophilus Influenza Type B in Patients with CLL/low Grade NHL and Response to Vaccination in a UK Tertiary Centre**

MUHAMMAD ANAS MEMON,<sup>1</sup>DEAN SMITH,<sup>2</sup>CHRISTOPHER FOX,<sup>3</sup>NICOLAS MARTINEZ-CALLE,<sup>2</sup>

<sup>1</sup> Department of Clinical Haematology, Nottingham University Hospitals NHS Trust, Nottingham, United Kingdom

<sup>2</sup> Department of Clinical Haematology, Nottingham University Hospitals NHS Trust, United Kingdom

<sup>3</sup> Department of Clinical Haematology, Nottingham University Hospitals NHS Trust and School of Medicine, University of Nottingham, United Kingdom

**1084161**

**Combination Therapy with Ibrutinib (ibr) and Venetoclax (ven) Leads to Deep Responses in Relapsed/refractory (rel/ref) Chronic Lymphocytic Leukemia (CLL): Results of a Phase 2 Study**

TANYA SIDDIQI,<sup>1</sup>PAMELA CLAY,<sup>2</sup>KATE MURRAY,<sup>2</sup>NAVSHINA SHEKH,<sup>1</sup>ALEXANDRA MUIR,<sup>3</sup>STEVEN ROSEN,<sup>1</sup>STEVEN COUTRE,<sup>2</sup>

<sup>1</sup> City of Hope National Medical Center, United States





<sup>2</sup> Stanford Cancer Institute, United States

<sup>3</sup> City of Hope National Medical Center, Duarte, California, United States

### **1084168**

#### **Expression of the IL12 and IL23 Receptors and Cytokines in Chronic Lymphocytic Leukemia and Normal B Cells**

MARTINA CARDILLO,<sup>1</sup>SERENA MATIS,<sup>2</sup>DANIELE REVERBERI,<sup>2</sup>ROSANNA MASSARA,<sup>2</sup>MONICA COLOMBO,<sup>2</sup>NADIA BERTOLA,<sup>3</sup>SILVIA RAVERA,<sup>3</sup>NICHOLAS CHIORAZZI,<sup>4</sup>MANLIO FERRARINI,<sup>3</sup>FRANCO FAIS,<sup>3</sup>GIOVANNA CUTRONA,<sup>2</sup>

<sup>1</sup> The Feinstein Institute for Medical Research, Manhasset, New York, United States

<sup>2</sup> Ospedale Policlinico San Martino, Italy

<sup>3</sup> Università degli studi di Genova, Italy

<sup>4</sup> Karches Center for Oncology Research, The Feinstein Institutes for Medical Research, Northwell Health, Manhasset, NY, USA, New York, New York, United States

### **1084197**

#### **BTK inhibitors, irrespective of ITK inhibition, downregulate an immunosuppressive program in chronic lymphocytic leukemia and enhance CD19/CD3-mediated cytotoxicity of T cells**

MAISSA MHIBIK,<sup>1</sup>ERIKA GAGLIONE,<sup>2</sup>DAVID EIK,<sup>3</sup>ELLEN KENDALL,<sup>3</sup>AMY BLACKBURN,<sup>3</sup>KEYVAN KEYVANFAR,<sup>3</sup>MARIA JOAO BAPTISTA,<sup>4</sup>INHYE AHN,<sup>5</sup>CLARE SUN,<sup>6</sup>JUNPENG QI,<sup>7</sup>CHRISTOPH RADER,<sup>7</sup>ADRIAN WIESTNER,<sup>5</sup>

<sup>1</sup> Laboratory of Lymphoid Malignancies, Hematology Branch, NHLBI, NIH, Bethesda, Maryland, United States

<sup>2</sup> Laboratory of Lymphoid Malignancies, Hematology Branch, NHLBI, NIH,, Bethesda, Maryland, United States

<sup>3</sup> Laboratory of Lymphoid Malignancies, Hematology Branch, NHLBI, NIH,, United States

<sup>4</sup> Lymphoid Neoplasms, Josep Carreras Leukaemia Research Institute, United States

<sup>5</sup> Laboratory of Lymphoid Malignancies, Hematology Branch, NHLBI, NIH, United States

<sup>6</sup> Hematology Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD, United States

**XIX International Workshop on CLL**

16 – 20 September 2021, Virtual

[www.iwcll2021.org](http://www.iwcll2021.org) • 1-888-476-9129



<sup>7</sup> The Scripps Research Institute, Jupiter, Florida, United States

**1084202**

**Targeting PAK1 Overcomes Resistance to Ibrutinib in Chronic Lymphocytic Leukemia**

ZIJUAN WU,<sup>1</sup>DANLING GU,<sup>1</sup>LUQIAO WANG,<sup>1</sup>XUEYING LU,<sup>1</sup>HUI JIN,<sup>2</sup>JIANYONG LI,<sup>1</sup>

<sup>1</sup> Department of Hematology, The First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital, Nanjing, 210029, China, China (People's Republic)

<sup>2</sup> Department of Hematology, The First Affiliated Hospital of Nanjing Medical University, China (People's Republic)

**1084243**

**Population-level Impact of Ibrutinib for Chronic Lymphocytic Leukemia (CLL) and Small Lymphocytic Lymphoma (SLL) in British Columbia, Canada**

RANIA KHELIFI,<sup>1</sup>STEVEN HUANG,<sup>2</sup>KERRY SAVAGE,<sup>3</sup>DIEGO VILLA,<sup>3</sup>DAVID SCOTT,<sup>3</sup>KHALED RAMADAN,<sup>4</sup>JOSEPH CONNORS,<sup>3</sup>LAURIE SEHN,<sup>3</sup>CYNTHIA TOZE,<sup>5</sup>ALINA GERIE,<sup>3</sup>

<sup>1</sup> Department of Experimental Medicine, University of British Columbia, Canada

<sup>2</sup> Leukemia/BMT Program of BC, BC Cancer, Division of Hematology, University of British Columbia, Canada

<sup>3</sup> Centre for Lymphoid Cancer, BC Cancer, Division of Medical Oncology, University of British Columbia, Canada

<sup>4</sup> St. Paul's Hospital, Division of Hematology, University of British Columbia, Canada

<sup>5</sup> Leukemia/BMT Program of BC, BC Cancer, Division of Hematology, University of British Columbia, Canada

**1084244**

**Covid-19 in patients with chronic lymphocytic leukemia: Clinical outcome and B- and T-cell immunity during 13 months in consecutive patients**

LISA BLIXT,<sup>1</sup>GORDANA BOGDANOVIC,<sup>2</sup>MARCUS BUGGERT,<sup>3</sup>YU GAO,<sup>4</sup>SOPHIA HOBER,<sup>5</sup>KATIE HEALY,<sup>6</sup>HEMMING JOHANSSON,<sup>7</sup>CHRISTIAN KJELLANDER,<sup>8</sup>SARA MRAVINACOVA,<sup>5</sup>

**XIX International Workshop on CLL**

16 – 20 September 2021, Virtual

[www.iwcll2021.org](http://www.iwcll2021.org) • 1-888-476-9129



SANDRA MUSCHIOI,<sup>9</sup>PETER NILSSON,<sup>10</sup>MARZIA PALMA,<sup>11</sup>ELISA PIN,<sup>10</sup>EDVARD C.I. SMITH,<sup>12</sup>OLGA STROMBERG,<sup>13</sup>MARGARET SÄLLBERG CHEN,<sup>14</sup>RULA ZAIN,<sup>15</sup>LOTTA HANSSON,<sup>11</sup>ANDERS ÖSTERBORG,<sup>11</sup>

<sup>1</sup> Dept of Hematology, Karolinska University Hospital Solna and Dept of Oncology-Pathology, Karolinska Institutet, Stockholm, Sweden

<sup>2</sup> Dept of Microbiology, Karolinska University Hospital, Stockholm, Sweden

<sup>3</sup> Center for Infectious Medicine, Dept of Medicine Huddinge, Karolinska Institutet, Stockholm, Sweden

<sup>4</sup> Center for Infectious Medicine, Dept of Medicine Huddinge, Karolinska Institutet, Sweden

<sup>5</sup> Dept of Protein Science, SciLifeLab and KTH Royal Institute of Technology, Stockholm, Sweden, Sweden

<sup>6</sup> Dept of Dental Medicine, Karolinska Institutet, Huddinge, Stockholm, Sweden

<sup>7</sup> Dept of Oncology-Pathology, Karolinska Institutet, Sweden

<sup>8</sup> Dept of Internal Medicine, Capio St Göran Hospital, Stockholm, Sweden, Sweden

<sup>9</sup> Dept of Microbiology, Karolinska University Hospital, Stockholm, Sweden, Sweden

<sup>10</sup> Dept of Protein Science, SciLifeLab and KTH Royal Institute of Technology, Stockholm, Sweden

<sup>11</sup> Department of Oncology-Pathology, Karolinska Institutet, Stockholm, Sweden, Department of Hematology, Lymphoma Unit, Karolinska University Hospital Solna, Stockholm, Sweden, Solna, Sweden

<sup>12</sup> Dept of Laboratory Medicine, Karolinska Institutet, Stockholm, Sweden

<sup>13</sup> Dept of Internal Medicine, Södersjukhuset, Stockholm, Sweden, Sweden

<sup>14</sup> Dept of Dental Medicine, Karolinska Institutet, Stockholm, Sweden

<sup>15</sup> Dept of Laboratory Medicine, Karolinska Institutet and Centre for Rare Diseases, Department of Clinical Genetics, Karolinska University Hospital, Stockholm, Sweden

**1084248**

**GEUS-CLL: a comprehensive assay that integrates (epi)genetic information with clinical impact in CLL**

ESTER CUENCA-LEON,<sup>1</sup>PAU CARRIÓ,<sup>2</sup>SHEILA SANTIN,<sup>2</sup>NÚRIA SEGUÍ,<sup>2</sup>JÚLIA MATAS,<sup>3</sup>ANA POU,<sup>2</sup>DAVID MARTIN,<sup>2</sup>MARTA FORN,<sup>2</sup>ÍÑAKI MARTIN-SUBERO,<sup>4</sup>TORSTEN HAFERLACH,<sup>5</sup>LLORENÇ COLL,<sup>2</sup>MIGUEL A. PEINADO,<sup>2</sup>ELIAS CAMPO,<sup>6</sup>

<sup>1</sup> ANILING, Barcelona, Spain

**XIX International Workshop on CLL**

16 – 20 September 2021, Virtual

[www.iwcll2021.org](http://www.iwcll2021.org) • 1-888-476-9129



<sup>2</sup> ANILING, Spain

<sup>3</sup> IGTP, Spain

<sup>4</sup> Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Hospital Clínic de Barcelona, Barcelona, Spain, Spain

<sup>5</sup> MLL Münchner Leukämielabor GmbH, Germany

<sup>6</sup> Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain; Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Madrid, Spain; Hospital Clinic de Barcelona, Universitat de Barcelona, Barcelona, Spain, Spain

### 1084256

#### **Integration of pre-, on- and post-treatment risk factors, including CLL-IPI and MRD, improves outcome prediction after fixed-duration therapy of CLL: Introduction of the refined Continuous Individualized Risk Index (CIRI2-CLL)**

OTHMAN AL-SAWAF,<sup>1</sup> MOHAMMAD ESFAHANI,<sup>2</sup> CAN ZHANG,<sup>3</sup> EUGEN TAUSCH,<sup>4</sup> ANKE SCHILHABEL,<sup>5</sup> BARBARA EICHHORST,<sup>6</sup> STEPHAN STILGENBAUER,<sup>7</sup> MICHAEL HALLEK,<sup>3</sup> ASH ALIZADEH,<sup>8</sup> DAVID KURTZ,<sup>8</sup> KIRSTEN FISCHER,<sup>9</sup>

<sup>1</sup> University Hospital, Cologne, Germany

<sup>2</sup> Stanford University, United States

<sup>3</sup> University Hospital of Cologne, Germany

<sup>4</sup> Department of Internal Medicine III, University of Ulm, Ulm, Germany, Germany

<sup>5</sup> 2nd Department of Internal Medicine, University of Schleswig-Holstein, Campus Kiel, Kiel, Germany, Germany

<sup>6</sup> Department of Internal Medicine, University of Cologne, Cologne, Germany, Germany

<sup>7</sup> Department of Internal Medicine III, Ulm University, Ulm, Germany, Ulm, Germany

<sup>8</sup> Stanford Cancer, United States

<sup>9</sup> Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf (CIO ABCD), German CLL Study Group, University Hospital Cologne, University of Cologne, Cologne, Germany, Germany



**1084257**

**Patients with CLL treated by Ibrutinib in a real-life setting: a retrospective observational study, using the SNDS database (OSIRIS)**

SYLVAIN CHOQUET,<sup>1</sup> CLARISSE MARCHAL,<sup>2</sup> MANON BELHASSEN,<sup>2</sup> FLORE JACOUD,<sup>2</sup> CAROLINE GUILMET,<sup>3</sup> SANDRINE DUPUIS,<sup>3</sup> MARIE PIERRÈS,<sup>3</sup> GÉRARD DE POUVOURVILLE,<sup>4</sup> VINCENT LEVY,<sup>5</sup>

<sup>1</sup> Hôpital Pitié salpêtrière AP-HP, Paris, France

<sup>2</sup> PELyon, Lyon, France

<sup>3</sup> Janssen-cilag France, Issy-les-Moulineaux, France

<sup>4</sup> ESSEC, Cergy-Pontoise, France

<sup>5</sup> Département de Recherche Clinique, Hôpital Avicenne, APHP, Bobigny, France, Bobigny, France

**1084263**

**Outcomes of CLL patients treated with ibrutinib versus R-idelalisib: real-world data from the CLLEAR registry**

MARTIN ŠPAČEK,<sup>1</sup> LUKÁŠ SMOLEJ,<sup>2</sup> LUCIE NEKVINDOVÁ,<sup>3</sup> ZLATUŠE KŘISTKOVÁ,<sup>3</sup> MARTIN ŠIMKOVIČ,<sup>4</sup> YVONA BRYCHTOVA,<sup>5</sup> ANNA PANOVSKA,<sup>5</sup> STANISLAVA MAŠLEJOVÁ,<sup>5</sup> LUCIE BEZDĚKOVÁ,<sup>5</sup> JANA ZUCHNICKÁ,<sup>6</sup> RENATA URBANOVÁ,<sup>7</sup> DAN LYSÁK,<sup>8</sup> JAN NOVÁK,<sup>9</sup> MARTIN BREJCHA,<sup>10</sup> MICHAEL DOUBEK,<sup>5</sup>

<sup>1</sup> First Department of Internal Medicine - Hematology, General University Hospital, Prague, Czech Republic, Praha 2, Czech Republic

<sup>2</sup> 4th Department of Internal Medicine - Hematology, University Hospital and Charles University Faculty of Medicine, Hradec Králové, Czech Republic, Hradec Králové, Czech Republic

<sup>3</sup> Institute of Biostatistics and Analyses, Ltd., Brno, Czech Republic

<sup>4</sup> 4th Department of Internal Medicine - Hematology, University Hospital, Hradec Kralove, Czech Republic; Faculty of Medicine, Charles University, Prague, Czech Republic, Czech Republic

<sup>5</sup> University Hospital, Brno, Czech Republic

<sup>6</sup> Department of Hematooncology, University Hospital, Ostrava, Czech Republic, Czech Republic

<sup>7</sup> Department of Hematooncology, University Hospital, Olomouc, Czech Republic, Czech Republic

<sup>8</sup> Department of Hematooncology, University Hospital, Pilsen, Czech Republic, Czech Republic

<sup>9</sup> University Hospital Královské Vinohrady, Praha, Czech Republic

**XIX International Workshop on CLL**

16 – 20 September 2021, Virtual

[www.iwcll2021.org](http://www.iwcll2021.org) • 1-888-476-9129





<sup>10</sup> Department of Hematology, Hospital Agel, Nový Jičín, Czech Republic, Czech Republic

### 1084265

#### **Chronic Lymphocytic Leukemia with 3'IGH Deletion Is Associated with a Biallelic Traf3 Inactivation that Results in an Adverse Clinical Outcome**

CLAUDIA PÉREZ-CARRETERO,<sup>1</sup>MARÍA HERNÁNDEZ-SÁNCHEZ,<sup>2</sup>MIGUEL QUIJADA-ÁLAMO,<sup>2</sup>TERESA GONZÁLEZ,<sup>2</sup>ALBERTO RODRÍGUEZ-SÁNCHEZ,<sup>2</sup>MARTA MARTÍN-IZQUIERDO,<sup>2</sup>SANDRA SANTOS-MÍNGUEZ,<sup>2</sup>CRISTINA MIGUEL-GARCÍA,<sup>2</sup>EVA LUMBRERAS,<sup>2</sup>BEATRIZ ALBARRÁN,<sup>3</sup>JUAN OLAZABAL,<sup>4</sup>ALFONSO GARCÍA DE COCA,<sup>5</sup>ARACELI RUBIO,<sup>6</sup>JULIO DÁVILA,<sup>7</sup>ISABEL GONZÁLEZ-GASCÓN Y MARÍN,<sup>8</sup>JOSÉ ÁNGEL HERNÁNDEZ,<sup>9</sup>ROCÍO BENITO,<sup>2</sup>JESÚS MARÍA HERNÁNDEZ RIVAS,<sup>10</sup>ANA-EUGENIA RODRÍGUEZ-VICENTE,<sup>2</sup>

<sup>1</sup> University of Salamanca, IBSAL, IBMCC, CSIC, Cancer Research Center. Department of Hematology, University Hospital of Salamanca, Spain

<sup>2</sup> University of Salamanca, IBSAL, IBMCC, CSIC, Cancer Research Center. Department of Hematology, University Hospital of Salamanca, Salamanca, Spain

<sup>3</sup> Department of Hematology. Hospital Rio Carrión, Palencia, Spain

<sup>4</sup> Department of Hematology. Hospital Universitario de Burgos, Spain

<sup>5</sup> Department of Hematology. Hospital Clínico, Valladolid, Spain

<sup>6</sup> Department of Hematology, Hospital Miguel Servet, Zaragoza, Spain

<sup>7</sup> Department of Hematology, Hospital Nuestra Señora de Sonsoles, Ávila, Spain

<sup>8</sup> Department of Hematology. Hospital Universitario Infanta Leonor. Universidad Complutense, Madrid, Spain

<sup>9</sup> Hospital Universitario Infanta Leonor, Madrid, Spain

<sup>10</sup> University of Salamanca, Spain

### 1084267

#### **Effect of miR-155 deficiency in CLL cells on the cell cycle dynamics during normoxia vs hypoxia.**

ELENA GOLOVINA,<sup>1</sup>TOMAS HEIZER,<sup>2</sup>LENKA DAUMOVA,<sup>3</sup>KARINA SAVVULIDI VARGOVA,<sup>1</sup>

<sup>1</sup> Institute of Pathological Physiology, First Faculty of Medicine, Charles University, Prague, Czech Republic



<sup>2</sup> The Center for Advanced Preclinical Imaging (CAPI), First Faculty of Medicine, Charles University, Czech Republic

<sup>3</sup> Biocev, First Faculty of Medicine, Charles University, Prague, Czech Republic

**1084271**

### **Identification of Novel Treatment Opportunities for Genetically Defined CLL Subtypes Through Drug Repurposing**

ADRIANA LADUNGOVA,<sup>1</sup> HELENA PESCHELOVA,<sup>2</sup> VERONIKA KOZLOVA,<sup>3</sup> MICHAL SMIDA,<sup>4</sup>

<sup>1</sup> Central European Institute of Technology, Masaryk University; National Centre for Biomolecular Research, Faculty of Science, Masaryk University, Brno, Czech Republic

<sup>2</sup> Central European Institute of Technology, Masaryk University; National Centre for Biomolecular Research, Faculty of Science, Masaryk University, Czech Republic

<sup>3</sup> Central European Institute of Technology (CEITEC), Masaryk University, Czech Republic

<sup>4</sup> Central European Institute of Technology (CEITEC), Masaryk University; Department of Internal Medicine - Hematology and Oncology, Medical Faculty of Masaryk University and University Hospital Brno, Czech Republic

**1084272**

### **Optical Genome Mapping: A New Promising Tool to Assess Genomic Complexity in Chronic Lymphocytic Leukemia (CLL)**

ANNA PUIGGROS,<sup>1</sup> SILVIA RAMOS-CAMPOY,<sup>1</sup> MIREIA DE LA ROSA,<sup>2</sup> TUOMO MANTERE,<sup>3</sup> MARTA SALIDO,<sup>2</sup> CARMEL MELERO,<sup>4</sup> MARÍA RODRÍGUEZ-RIVERA,<sup>2</sup> SANDRINE BOUGEON,<sup>5</sup> ROSA COLLADO,<sup>6</sup> EVA GIMENO,<sup>7</sup> ROCÍO GARCÍA-SERRA,<sup>8</sup> SARA ALONSO,<sup>9</sup> MARCO MORO,<sup>10</sup> LOLA GARCÍA,<sup>11</sup> ALEXANDER HOISCHEN,<sup>12</sup> JACQUELINE SCHOUMANS,<sup>5</sup> BLANCA ESPINET,<sup>1</sup>

<sup>1</sup> Servei de Patologia, Hospital del Mar, Barcelona, Spain; Grup de Recerca Translacional en Neoplàsies Hematològiques, Programa de Recerca en Càncer, Institut Hospital del Mar d'Investigacions Mèdiques (IMIM), Barcelona, Spain, Barcelona, Spain

<sup>2</sup> Molecular Cytogenetics Laboratory, Pathology Department, Hospital del Mar; Translational Research on Hematological Neoplasms Group, Cancer Research Program, Institut Hospital del Mar d'Investigacions Mèdiques (IMIM), Barcelona, Spain, Spain

**XIX International Workshop on CLL**

16 – 20 September 2021, Virtual

[www.iwcll2021.org](http://www.iwcll2021.org) • 1-888-476-9129



<sup>3</sup> Department of Human Genetics, Radboud University Medical Center, Nijmegen, The Netherlands, Netherlands

<sup>4</sup> Molecular Cytogenetics Laboratory, Pathology Department, Hospital del Mar; Translational Research on Hematological Neoplasms Group, Cancer Research Program, Institut Hospital del Mar d'Investigacions Mèdiques (IMIM), Barcelona, Spain, United States

<sup>5</sup> Oncogenomic Laboratory, Hematology Service, Lausanne University Hospital, Lausanne, Switzerland, Switzerland

<sup>6</sup> Servicio de Hematología, Consorcio Hospital General Universitario, Valencia, Spain, Spain

<sup>7</sup> Department of Hematology, Hospital del Mar; Applied Clinical Research in Hematological Malignancies, Cancer Research Program, Institut Hospital del Mar d'Investigacions Mèdiques (IMIM), Barcelona, Spain, Spain

<sup>8</sup> Department of Hematology, Consorcio Hospital General Universitario; Research Foundation from Hospital General Universitario, Valencia, Spain, United States

<sup>9</sup> Department of Hematology, Hospital Universitario Central de Asturias, Oviedo, Spain, Spain

<sup>10</sup> Servicio de Hematología, Hospital Universitario Central de Asturias, Oviedo, Spain, Spain

<sup>11</sup> Hospital Morales Meseguer, Murcia, Spain

<sup>12</sup> Department of Human Genetics, Radboud University Medical Center; Radboud University Medical Center Center for Infectious Diseases (RCI), Department of Internal Medicine and Radboud Institute for Molecular Life Sciences, Radboud University Medical Center, Nijmegen, the Netherlands, Netherlands

**1084273**

### **CD19 Promoter Hypermethylation as Means of Antigen-Negative Escape to CART-19 Therapy**

LENKA DOSTALOVA,<sup>1</sup> ANETA LEDEREROVA,<sup>2</sup> VERONIKA KOZLOVA,<sup>3</sup> HELENA PESCHELOVA,<sup>4</sup> ADRIANA LADUNGOVA,<sup>5</sup> VERONIKA MANCIKOVA,<sup>6</sup> MICHAL SMIDA,<sup>7</sup>

<sup>1</sup> Central European Institute of Technology (CEITEC) Masaryk University; Department of Biology, Faculty of Medicine, Masaryk University, Czech Republic

<sup>2</sup> Central European Institute of Technology (CEITEC) Masaryk University; Department of Internal Medicine - Hematology and Oncology, Medical Faculty of Masaryk University and University Hospital Brno, Czech Republic

<sup>3</sup> Central European Institute of Technology (CEITEC), Masaryk University, Czech Republic

<sup>4</sup> Central European Institute of Technology, Masaryk University; National Centre for Biomolecular Research, Faculty of Science, Masaryk University, Czech Republic

**XIX International Workshop on CLL**

16 – 20 September 2021, Virtual

[www.iwcll2021.org](http://www.iwcll2021.org) • 1-888-476-9129



<sup>5</sup> Central European Institute of Technology, Masaryk University; National Centre for Biomolecular Research, Faculty of Science, Masaryk University, Brno, Czech Republic

<sup>6</sup> Central European Institute of Technology (CEITEC), Masaryk University; Department of Internal Medicine – Hematology and Oncology, University Hospital Brno and Faculty of Medicine, Masaryk University, Czech Republic

<sup>7</sup> Central European Institute of Technology (CEITEC), Masaryk University; Department of Internal Medicine - Hematology and Oncology, Medical Faculty of Masaryk University and University Hospital Brno, Czech Republic

### **1084279**

#### **Identification of Metabolism-Associated circRNA Profiles in Chronic Lymphocytic Leukemia**

HUI JIN,<sup>1</sup>ZIJUAN WU,<sup>1</sup>LUQIAO WANG,<sup>1</sup>HUAYUAN ZHU,<sup>1</sup>LEI FAN,<sup>2</sup>WEI XU,<sup>1</sup>JIANYONG LI,<sup>1</sup>

<sup>1</sup> Department of Hematology, The First Affiliated Hospital of Nanjing Medical University, China (People's Republic)

<sup>2</sup> Jiangsu Province Hospital, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China (People's Republic)

### **1084281**

#### **CRISPR/CAS9 and mRNA-Based Gene Editing and Expression in Chronic Lymphocytic Leukemia Cells**

FEDERICA NARDI,<sup>1</sup>ANTHEA DI RITA,<sup>2</sup>LAURA PEZZELLA,<sup>2</sup>ROBERTA DRAGO,<sup>3</sup>SARA CIOFINI,<sup>4</sup>ALESSANDRO GOZZETTI,<sup>4</sup>MONICA BOCCHIA,<sup>4</sup>ANNA KABANOVA,<sup>5</sup>

<sup>1</sup> Toscana life sciences, University of Siena, Siena, Italy

<sup>2</sup> Toscana life sciences, University of Siena, Italy

<sup>3</sup> Toscana life sciences, University of Parma, Italy

<sup>4</sup> University of Siena, Italy

<sup>5</sup> Toscana life sciences, Italy



**1084284**

**Blinatumomab After R-CHOP Debulking Therapy for Patients with Richter's Syndrome: Results From the Multicenter Phase 2 BLINART Trial From the FILO Group**

ROMAIN GUIEZE,<sup>1</sup> LOIC YSEBAERT,<sup>2</sup> DAMIEN ROOS-WEIL,<sup>3</sup> LYSIANE MOLINA,<sup>4</sup> LUC MATTHIEU FORNECKER,<sup>5</sup> THERESE AURRANT,<sup>6</sup> ANNE-SOPHIE MICHALLET,<sup>7</sup> EMMANUELLE FERRANT,<sup>8</sup> ALINE CLAVERT,<sup>9</sup> ALAIN SAAD,<sup>10</sup> SOPHIE DE GUIBERT,<sup>11</sup> BERNARD DRENOU,<sup>12</sup> PHILIPPE QUITTET,<sup>13</sup> BENEDICTE HIVERT,<sup>14</sup> KAMEL LARIBI,<sup>15</sup> JULIE GAY,<sup>16</sup> JULIEN BROSEUS,<sup>17</sup> VALERIE ROUILLE,<sup>13</sup> DAVID SCHWARTZ,<sup>18</sup> BRUNO PEREIRA,<sup>19</sup> ALAIN DELMER,<sup>20</sup> PIERRE FEUGIER,<sup>17</sup>

<sup>1</sup> Service Hématologie, CHU Clermont Ferrand, Clermont Ferrand, France, France

<sup>2</sup> IUCT Oncopole Toulouse, France

<sup>3</sup> APHP, France

<sup>4</sup> CHU Grenoble, France

<sup>5</sup> CHU Strasbourg, France

<sup>6</sup> IPC, France

<sup>7</sup> Service Hématologie, Centre Léon Bérard, Lyon, France, France

<sup>8</sup> CHLS, France

<sup>9</sup> Service Hématologie, CHU Angers, Angers, France, France

<sup>10</sup> CH Béziers, France

<sup>11</sup> CHU Rennes, France

<sup>12</sup> Service Hématologie, CH de Mulhouse, Mulhouse, France, France

<sup>13</sup> CHU Montpellier, France

<sup>14</sup> groupement des hôpitaux catholiques, France

<sup>15</sup> Service Hématologie, CH Le Mans, Le Mans, France, France

<sup>16</sup> CH Cote Basque, France

<sup>17</sup> CHRU Nancy, France

<sup>18</sup> FILO, France

<sup>19</sup> CHU Clermont-Ferrand, France

<sup>20</sup> Service Hématologie, CHU de Reims, Reims, France, France

**XIX International Workshop on CLL**

16 – 20 September 2021, Virtual

[www.iwcll2021.org](http://www.iwcll2021.org) • 1-888-476-9129





**1084285**

**Phosphorylation Patterns of Tumor Suppressor P53 and Their Impact on the P53 Pathway Activity in Chronic Lymphocytic Leukemia**

MICHAELA PESOVA,<sup>1</sup>VERONIKA MANCIKOVA,<sup>2</sup>SARKA PAVLOVA,<sup>2</sup>ROBERT HELMA,<sup>2</sup>JITKA MALCIKOVA,<sup>2</sup>MARCELA ZENATOVA,<sup>3</sup>VACLAV HEJRET,<sup>4</sup>PETR TAUS,<sup>4</sup>JANA KOTASKOVA,<sup>2</sup>KARLA PLEVOVA,<sup>1</sup>MICHAEL DOUBEK,<sup>2</sup>JIRI MAYER,<sup>2</sup>SARKA POSPISILOVA,<sup>2</sup>

<sup>1</sup> Central European Institute of Technology (CEITEC), Masaryk University; Department of Internal Medicine – Hematology and Oncology, University Hospital Brno and Faculty of Medicine, Masaryk University, Brno, Czech Republic

<sup>2</sup> Central European Institute of Technology (CEITEC), Masaryk University; Department of Internal Medicine – Hematology and Oncology, University Hospital Brno and Faculty of Medicine, Masaryk University, Czech Republic

<sup>3</sup> Department of Internal Medicine – Hematology and Oncology, University Hospital Brno and Faculty of Medicine, Masaryk University, Czech Republic

<sup>4</sup> Central European Institute of Technology (CEITEC), Masaryk University, Czech Republic

**1084286**

**The Economic Burden of CLL in Canada in the Era of Fixed Duration Oral Targeted Therapies**

JEAN LACHAINE,<sup>1</sup>KIMBERLY GUINAN,<sup>1</sup>ANDREW AW,<sup>2</sup>VERSHA BANERJI,<sup>3</sup>ISABELLE FLEURY,<sup>4</sup>CAROLYN OWEN,<sup>5</sup>

<sup>1</sup> PeriPharm, Montreal, Canada

<sup>2</sup> Ottawa Hospital, Canada

<sup>3</sup> CancerCare Manitoba Research Institute/ University of Manitoba, Winnipeg, Canada

<sup>4</sup> Maisonneuve-Rosemont Hospital, University of Montreal, Canada

<sup>5</sup> Foothills Medical Centre, Canada



**1084295**

**Effects of SF3B1 K700E Mutation in Chronic Lymphocytic Leukemia and the Opportunity for Targeted Therapy with SF3B1-Binding Splicing Modulator H3B-8800**

IRENE LOPEZ-OREJA,<sup>1</sup> ANDRE GOHR,<sup>2</sup> HERIBERT PLAYA,<sup>3</sup> ARIADNA GIRO,<sup>4</sup> FABIAN ARENAS,<sup>5</sup> MONICA LOPEZ-GUERRA,<sup>6</sup> ELIAS CAMPO,<sup>7</sup> JUAN VALCÁRCEL,<sup>8</sup> SOPHIE BONNAL,<sup>2</sup> DOLORS COLOMER,<sup>7</sup>

<sup>1</sup> Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain; Centre for Genomic Regulation, Barcelona, Spain; Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Madrid, Spain; Universidad Pompeu Fabra, Barcelona, Spain., Barcelona, Spain

<sup>2</sup> Centre for Genomic Regulation, Barcelona, Spain, Spain

<sup>3</sup> Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain; Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Madrid, Spain; Universitat de Barcelona, Barcelona, Spain, Spain

<sup>4</sup> Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain, Spain

<sup>5</sup> Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain; Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Madrid, Spain, Spain

<sup>6</sup> Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain; Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Madrid, Spain; Hospital Clinic de Barcelona, Spain

<sup>7</sup> Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain; Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Madrid, Spain; Hospital Clinic de Barcelona, Universitat de Barcelona, Barcelona, Spain, Spain

<sup>8</sup> Centre for Genomic Regulation, Barcelona, Spain; Universitat Pompeu Fabra, Barcelona, Spain; Institució Catalana de Recerca i Estudis Avançats (ICREA), Barcelona, Spain., Spain

**1084315**

**Longer Term Follow-Up of a Multicenter, Phase 2 Study of Ibrutinib Plus Fludarabine, Cyclophosphamide, Rituximab (iFCR) as Initial Therapy for Younger Patients with Chronic Lymphocytic Leukemia**

MATTHEW DAVIDS,<sup>1</sup> DANIELLE BRANDER,<sup>2</sup> SVITLANA TYEKUCHEVA,<sup>1</sup> CHINHENG CHEN,<sup>1</sup> JAMES KAMINSKI,<sup>1</sup> JOSIE MONTEGAARD,<sup>1</sup> ALVARO ALENCAR,<sup>3</sup> LEYLA SHUNE,<sup>4</sup> MOHAMMAD OMAIRA,<sup>5</sup> CARON JACOBSON,<sup>1</sup> PHILIPPE ARMAND,<sup>1</sup> SAMUEL NG,<sup>1</sup> JENNIFER CROMBIE,<sup>1</sup> ANN LACASCE,<sup>1</sup> JON ARNASON,<sup>6</sup> EPHRAIM HOCHBERG,<sup>7</sup> RONALD TAKVORAIN,<sup>7</sup> JEREMY ABRAMSON,<sup>7</sup> DAVID FISHER,<sup>1</sup> JENNIFER BROWN,<sup>1</sup>

**XIX International Workshop on CLL**

16 – 20 September 2021, Virtual

[www.iwcll2021.org](http://www.iwcll2021.org) • 1-888-476-9129



- <sup>1</sup> Dana-Farber Cancer Institute, United States  
<sup>2</sup> Duke Cancer Institute, Duke University Medical Center, Durham, North Carolina, United States  
<sup>3</sup> University of Miami Miller School of Medicine, Miami, USA, United States  
<sup>4</sup> University of Kansas Cancer Center, United States  
<sup>5</sup> West Michigan Cancer Center, United States  
<sup>6</sup> Beth Israel Deaconess Medical Center, United States  
<sup>7</sup> Massachusetts General Hospital, United States

**1084321**

**LYN Kinase Programs Stromal Fibroblasts to Support Survival of Chronic Lymphocytic Leukemia Cells**

ALEXANDER VOM STEIN,<sup>1</sup>ROCIO REBOLLIDO-RIOS,<sup>2</sup>MAXIMILIAN KOCH,<sup>2</sup>ANNA LUKAS,<sup>2</sup>VIKTORIA KOHLHAS,<sup>2</sup>JULIA SAGGAU,<sup>2</sup>SEBASTIAN REINARTZ,<sup>2</sup>YUE ZHAO,<sup>3</sup>CHRISTIANE BRUNS,<sup>3</sup>BJÖRN HäUPL,<sup>4</sup>THOMAS OELLERICH,<sup>4</sup>PHUONG-HIEN NGUYEN,<sup>5</sup>MICHAEL HALLEK,<sup>6</sup>

- <sup>1</sup> Department I for Internal Medicine, University Hospital Cologne, Cologne, Germany  
<sup>2</sup> Department I for Internal Medicine, University Hospital Cologne, Germany  
<sup>3</sup> Department of General- Visceral Surgery and Surgical Oncology, University Hospital Cologne, Germany  
<sup>4</sup> Department of Medicine II, Hematology/Oncology, Goethe University Frankfurt, Germany  
<sup>5</sup> Department I for Internal Medicine, University of Cologne, Germany  
<sup>6</sup> Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf (CIO ABCD), German CLL Study Group, University Hospital Cologne, University of Cologne, Cologne, Germany, Germany

**1084329**

**Evaluation of Therapeutic Potential of NRF2 Modulators in Chronic Lymphocytic Leukemia Patients**

RUI GOMES,<sup>1</sup>RAQUEL ALVES,<sup>2</sup>JOANA JORGE,<sup>2</sup>BáRBARA MARQUES,<sup>3</sup>ANA CRISTINA GONÇALVES,<sup>2</sup>JOSé CARDA,<sup>3</sup>ANA BELA SARMENTO-RIBEIRO,<sup>2</sup>

- <sup>1</sup> Faculty of Medicine, University of Coimbra, Coimbra, Portugal

**XIX International Workshop on CLL**

16 – 20 September 2021, Virtual

[www.iwcll2021.org](http://www.iwcll2021.org) • 1-888-476-9129



<sup>2</sup> Laboratory of Oncobiology and Hematology and University Clinic of Hematology, Faculty of Medicine, University of Coimbra, Portugal

<sup>3</sup> Clinical Hematology Department, Centro Hospitalar e Universitário de Coimbra, Portugal

**1084344**

**MRD Dynamics of Patients Receiving Ibrutinib Plus Venetoclax in the Blood Cancer UK TAP CLARITY Study**

TALHA MUNIR,<sup>1</sup> LOUISE-RAE CHERRILL,<sup>2</sup> NICHOLA MCWHIRTER,<sup>3</sup> SURITA DALAL,<sup>3</sup> REBECCA BOUCHER,<sup>2</sup> TINA TANG,<sup>2</sup> FRANCESCA YATES,<sup>2</sup> DONALD MACDONALD,<sup>4</sup> CHRISTOPHER FEGAN,<sup>5</sup> ALISON MCCAIG,<sup>6</sup> ANNA SCHUH,<sup>7</sup> ANDREW PETTITT,<sup>8</sup> JOHN G. GRIBBEN,<sup>9</sup> PIERS PATTEN,<sup>10</sup> STEPHEN DEVEREUX,<sup>10</sup> ADRIAN BLOOR,<sup>11</sup> CHRISTOPHER FOX,<sup>12</sup> FRANCESCO FORCONI,<sup>13</sup> ANDY RAWSTRON,<sup>3</sup> PETER HILLMEN,<sup>1</sup>

<sup>1</sup> Leeds Institute of Medical Research at St James's, Leeds, United Kingdom

<sup>2</sup> University of Birmingham, United Kingdom

<sup>3</sup> St. James's Institute of Oncology, United Kingdom

<sup>4</sup> Hammersmith Hospital, Imperial College Healthcare NHS Trust, United Kingdom

<sup>5</sup> Cardiff University, Cardiff, United Kingdom

<sup>6</sup> Beatson West of Scotland Cancer Centre, United Kingdom

<sup>7</sup> Department of Oncology, University of Oxford, Oxford University Hospitals NHS Foundation Trust, United Kingdom

<sup>8</sup> University of Liverpool and Clatterbridge Cancer Centre NHS Foundation Trust, and Broadgreen University Hospitals NHS Trust, United Kingdom

<sup>9</sup> Barts Cancer Institute, London, United Kingdom

<sup>10</sup> Kings College Hospital NHS Foundation Trust, London, United Kingdom

<sup>11</sup> Christie Hospital NHS Trust, Manchester, United Kingdom

<sup>12</sup> Nottingham University Hospitals NHS Trust, United Kingdom

<sup>13</sup> University of Southampton, Southampton, United Kingdom

**XIX International Workshop on CLL**

16 – 20 September 2021, Virtual

[www.iwcll2021.org](http://www.iwcll2021.org) • 1-888-476-9129



**1084346**

**The Influence of IL4 on the Response of CLL Cells to Combination Treatment with MDM2 and WIP1/PPM1D Phosphatase Inhibitors**

MOHAMMED HOWLADAR,<sup>1</sup> ELAINE WILLMORE,<sup>2</sup> JOHN LUNEC,<sup>3</sup>

<sup>1</sup> Newcastle University Medical Faculty, Newcastle upon Tyne, United Kingdom

<sup>2</sup> Translational and Clinical Research Institute-Newcastle University, Newcastle upon Tyne, United Kingdom

<sup>3</sup> Biosciences Institute, Newcastle upon Tyne, United Kingdom

**1084348**

**Clinical Significance of Prolymphocytes in Chinese Patients with Chronic Lymphocytic Leukemia**

LINGXIAO XING,<sup>1</sup> YAN WANG,<sup>1</sup> YI MIAO,<sup>2</sup> HUAYUAN ZHU,<sup>1</sup> JING ZHANG,<sup>1</sup> LI WANG,<sup>2</sup> LEI FAN,<sup>2</sup> WEI XU,<sup>3</sup> JIANYONG LI,<sup>1</sup>

<sup>1</sup> Jiangsu Province Hospital, The First Affiliated Hospital of Nanjing Medical University, China (People's Republic)

<sup>2</sup> Jiangsu Province Hospital, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China (People's Republic)

<sup>3</sup> Department of Hematology, the First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital, Nanjing, China, 210029, China (People's Republic)

**1084355**

**Mutations in Genes Involved in DNA Damage Response Other than TP53 or ATM are Rare in Patients with Chronic Lymphocytic Leukemia and High-Risk Cytogenetics**

SILVIA RAMOS-CAMPOY,<sup>1</sup> ANNA PUIGGROS,<sup>1</sup> NIEVES GARCÍA-GISBERT,<sup>2</sup> SANDRINE BOUGEON,<sup>3</sup> MARÍA JOSÉ LARRÁYOZ,<sup>4</sup> MARGARITA ORTEGA,<sup>5</sup> MARÍA LAURA BLANCO,<sup>6</sup> ROSA COLLADO,<sup>7</sup> IDOYA ANCÍN,<sup>8</sup> MARCO MORO,<sup>9</sup> EVA GIMENO,<sup>10</sup> ANA FERRER,<sup>11</sup> MARÍA JOSÉ CALASANZ,<sup>4</sup> FLORENCE NGUYEN-KHAC,<sup>12</sup> ANTONIO CUNEO,<sup>13</sup> CLAUDIA HAFERLACH,<sup>14</sup> JACQUELINE SCHOUMANS,<sup>3</sup> BEATRIZ BELLOSILLO,<sup>15</sup> BLANCA ESPINET,<sup>1</sup>

<sup>1</sup> Servei de Patologia, Hospital del Mar, Barcelona, Spain; Grup de Recerca Translacional en Neoplàsies Hematològiques, Programa de Recerca en Càncer, Institut Hospital del Mar d'Investigacions Mèdiques (IMIM), Barcelona, Spain, Barcelona, Spain

**XIX International Workshop on CLL**

16 – 20 September 2021, Virtual

[www.iwcll2021.org](http://www.iwcll2021.org) • 1-888-476-9129





- <sup>2</sup> Grup de Recerca Clínica Aplicada en Neoplàsies Hematològiques, Programa de Recerca en Càncer, Hospital del Mar-IMIM, Barcelona, Spain, Spain
- <sup>3</sup> Oncogenomic Laboratory, Hematology Service, Lausanne University Hospital, Lausanne, Switzerland, Switzerland
- <sup>4</sup> Servicio de Citogenética y Genética Hematológica, Departamento de Genética, Universidad de Navarra, Pamplona, Spain, Spain
- <sup>5</sup> Servei d'Hematologia, Hospital Vall d'Hebron, Barcelona, Spain, Spain
- <sup>6</sup> Servei d'Hematologia, Hospital Universitari de la Santa Creu i Sant Pau, Barcelona, Spain, Spain
- <sup>7</sup> Servicio de Hematología, Consorcio Hospital General Universitario, Valencia, Spain, Spain
- <sup>8</sup> Servicio de Hematología y Hemoterapia, Hospital Universitario Cruces, Bilbao, Spain, Spain
- <sup>9</sup> Servicio de Hematología, Hospital Universitario Central de Asturias, Oviedo, Spain, Spain
- <sup>10</sup> Grup de Recerca Clínica Aplicada en Neoplàsies Hematològiques, Programa de Recerca en Càncer, Hospital del Mar-IMIM, Barcelona, Spain; Servei d'Hematologia, Hospital del Mar, Barcelona, Spain, Spain
- <sup>11</sup> Servei de Patologia, Hospital del Mar, Barcelona, Spain; Grup de Recerca Translacional en Neoplàsies Hematològiques, Programa de Recerca en Càncer, Institut Hospital del Mar d'Investigacions Mèdiques (IMIM), Barcelona, Spain, Spain
- <sup>12</sup> Service d'Hématologie Biologique, Hôpital Pitié-Salpêtrière, Paris, France, Paris, France
- <sup>13</sup> Hematology Section, St. Anna University Hospital, Ferrara, Italy, Italy
- <sup>14</sup> MLL Munich Leukemia Laboratory, Munich, Germany, Munich, Germany
- <sup>15</sup> Servei de Patologia, Hospital del Mar, Barcelona, Spain; Grup de Recerca Clínica Aplicada en Neoplàsies Hematològiques, Programa de Recerca en Càncer, Hospital del Mar-IMIM, Barcelona, Spain, Spain

**1084362**

**The role of  $\alpha 4\beta 1$  in the Pathogenesis of Chronic Lymphocytic Leukemia (CLL); Insights from the Adhesome**

TAHERA ALNASSFAN,<sup>1</sup>KATHLEEN TILL,<sup>1</sup>

<sup>1</sup> The University of Liverpool, Liverpool, United Kingdom

**XIX International Workshop on CLL**

16 – 20 September 2021, Virtual

[www.iwcll2021.org](http://www.iwcll2021.org) • 1-888-476-9129



**1084402**

**Venetoclax Resistance Mechanisms in CLL Identified by Whole Exome and RNA Sequencing on Longitudinal Patient Samples**

ISHWARYA MURALI,<sup>1</sup>JASNEET KHALSA,<sup>1</sup>JUSTIN CHA,<sup>2</sup>FILIPPO UTRO,<sup>3</sup>IGNATY LESHCHINER,<sup>2</sup>YANAN KUANG,<sup>4</sup>KEVIN VASQUEZ,<sup>4</sup>STACEY FERNANDES,<sup>4</sup>KAHN RHRISSORRAKRAI,<sup>3</sup>CHAYA LEVOVITZ,<sup>3</sup>BRIAN DANYSH,<sup>2</sup>KARA SLOWIK,<sup>2</sup>RAQUEL A. JACOBS,<sup>2</sup>CLOUD P. PAWELETZ,<sup>2</sup>LAXMI PARIDA,<sup>5</sup>GAD GETZ,<sup>6</sup>JENNIFER BROWN,<sup>4</sup>

<sup>1</sup> Dana Farber Cancer Institute, United States

<sup>2</sup> Broad Institute, United States

<sup>3</sup> IBM, United States

<sup>4</sup> DFCI, United States

<sup>5</sup> IBM Research, Yorktown Heights, NY, United States

<sup>6</sup> Broad Institute of MIT and Harvard, Cambridge, MA; Center for Cancer Research, Massachusetts General Hospital, Boston, MA; Harvard Medical School, Boston, MA; Department of Pathology, Massachusetts General Hospital, Boston, MA, United States

**1084424**

**Upregulation of miR-26b Impair TGF- $\beta$ /SMAD Pathway Increasing Cell Proliferation in Progressive CLL Patients**

MARÍA ELENA MARQUEZ,<sup>1</sup>SANDRA SERNBO,<sup>1</sup>CATALINA BERCA,<sup>1</sup>ANGIMAR URIEPEPO,<sup>1</sup>CECILIA GUILLERMO,<sup>2</sup>VICTORIA IRIGOIN,<sup>3</sup>GIMENA DOS SANTOS,<sup>4</sup>ANA INÉS LANDONI,<sup>5</sup>RAÚL GABUS,<sup>6</sup>PABLO OPPEZZO,<sup>7</sup>

<sup>1</sup> Institut Pasteur de Montevideo, Montevideo, Uruguay

<sup>2</sup> Hospital de Clínicas, Montevideo, Uruguay

<sup>3</sup> CASMU IAMPP, Montevideo, Uruguay

<sup>4</sup> Institut Pasteur de Montevideo and Dept of Hematology of the University Hospital, Montevideo, Uruguay

<sup>5</sup> Unit of Hematology and Transplant of hematopoietic precursors, Hospital Maciel, Montevideo, Uruguay

<sup>6</sup> Hospital Maciel, Montevideo and Hospital de la Asociación Médica, San José, Montevideo, Uruguay

<sup>7</sup> Institut Pasteur de Montevideo, Montevideo, Uruguay

**XIX International Workshop on CLL**

16 – 20 September 2021, Virtual

[www.iwcll2021.org](http://www.iwcll2021.org) • 1-888-476-9129



**1084425**

**Venetoclax Ramp-Up Strategies for CLL. UK Real World Multicentre Restrospective Study**

ROCÍO FIGUEROA,<sup>1</sup>NICOLAS MARTINEZ-CALLE,<sup>2</sup>GAVIN PRESTON,<sup>3</sup>MOEZ DUNGARWALLA,<sup>4</sup>TINA WORTH,<sup>4</sup>BEN KENNEDY,<sup>5</sup>DANIEL HALPERIN,<sup>5</sup>PIERS PATTEN,<sup>6</sup>JENNIFER VIDLER,<sup>6</sup>NAGAH ELMUSHARAF,<sup>7</sup>PAUL FERGUSON,<sup>8</sup>TOBY EYRE,<sup>9</sup>ANNA SCHUH,<sup>10</sup>ALEXANDROS RAMPOTAS,<sup>9</sup>MICHELLE FURTADO,<sup>11</sup>SATYEN H. GOHIL,<sup>12</sup>DARIO MELOTTI,<sup>12</sup>CHRISTOPHER FOX,<sup>13</sup>TALHA MUNIR,<sup>14</sup>

<sup>1</sup> Nottingham University Hospital NHS Trust. Nottingham, United Kingdom

<sup>2</sup> Department of Clinical Haematology, Nottingham University Hospitals NHS Trust, United Kingdom

<sup>3</sup> Haematology. University of Aberdeen. Scotland. UK, United Kingdom

<sup>4</sup> Haematology. Milton Keynes University Hospital NHS Foundation Trust. Milton Keynes. UK, United Kingdom

<sup>5</sup> Haematology. University Hospitals of Leicester NHS Trust. Leicester. UK, United Kingdom

<sup>6</sup> Haematology. King's College Hospital NHS Foundation Trust. London. UK, United Kingdom

<sup>7</sup> Haematology. Cardiff and Vale University Health Board. Cardiff. UK, United Kingdom

<sup>8</sup> Haematology. University Hospitals of North Midland NHS Trust. Stoke-on-Trent. UK, United Kingdom

<sup>9</sup> Haematology. Oxford University Hospital. Oxford. UK, United Kingdom

<sup>10</sup> Department of Oncology, University of Oxford, Oxford University Hospitals NHS Foundation Trust, United Kingdom

<sup>11</sup> Haematology. Royal Cornwall Hospitals NHS Trust. Cornwall. UK, United Kingdom

<sup>12</sup> Haematology. University College of London Hospital NHS Foundation Trust. London. UK, United Kingdom

<sup>13</sup> Department of Clinical Haematology, Nottingham University Hospitals NHS Trust and School of Medicine, University of Nottingham, United Kingdom

<sup>14</sup> Leeds Institute of Medical Research at St James's, Leeds, United Kingdom

**1084430**

**Molecular Map of Chronic Lymphocytic Leukemia and its Impact on Outcome**

FERRAN NADEU,<sup>1</sup>BINYAMIN A. KNISBACHER,<sup>2</sup>ZIAO LIN,<sup>2</sup>CYNTHIA K. HAHN,<sup>2</sup>MARTÍ DURAN-FERRER,<sup>3</sup>KRISTEN E. STEVENSON,<sup>4</sup>EUGEN TAUSCH,<sup>5</sup>JULIO DELGADO,<sup>6</sup>ALEX BARBERA-MOURELLE,<sup>2</sup>AMARO TAYLOR-WEINER,<sup>2</sup>PABLO BOUSQUETS-MUÑOZ,<sup>7</sup>

**XIX International Workshop on CLL**

16 – 20 September 2021, Virtual

[www.iwcll2021.org](http://www.iwcll2021.org) • 1-888-476-9129



ANDER DIAZ-NAVARRO,<sup>7</sup> ANDREW DUNFORD,<sup>2</sup> SHANKARA ANAND,<sup>2</sup> HELENE KRETZMER,<sup>8</sup> JESUS GUTIERREZ-ABRIL,<sup>9</sup> SARA LÓPEZ-TAMARGO,<sup>7</sup> STACEY M. FERNANDES,<sup>10</sup> CLARE SUN,<sup>11</sup> MARIELA SIVINA,<sup>12</sup> LAURA Z. RASSENTI,<sup>13</sup> CHRISTOF SCHNEIDER,<sup>14</sup> SHUQIANG LI,<sup>2</sup> LAXMI PARIDA,<sup>15</sup> ALEXANDER MEISSNER,<sup>2</sup> FRANÇOIS AGUET,<sup>2</sup> JAN BURGER,<sup>12</sup> ADRIAN WIESTNER,<sup>16</sup> THOMAS J. KIPPS,<sup>13</sup> JENNIFER BROWN,<sup>17</sup> MICHAEL HALLEK,<sup>18</sup> CHIP STEWART,<sup>2</sup> DONNA S. NEUBERG,<sup>4</sup> IÑAKI MARTIN-SUBERO,<sup>19</sup> XOSE S. PUENTE,<sup>20</sup> STEPHAN STILGENBAUER,<sup>21</sup> CATHERINE WU,<sup>22</sup> ELIAS CAMPO,<sup>23</sup> GAD GETZ,<sup>24</sup>

<sup>1</sup> Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain; Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Madrid, Spain, Spain

<sup>2</sup> Broad Institute of MIT and Harvard, Cambridge, MA, United States

<sup>3</sup> Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain, Spain

<sup>4</sup> Department of Data Science, Dana-Farber Cancer Institute, Boston, MA, United States

<sup>5</sup> Department of Internal Medicine III, University of Ulm, Ulm, Germany, Germany

<sup>6</sup> Servicio de Hematología, Hospital Clínic, IDIBAPS, Barcelona, Spain, Barcelona, Spain

<sup>7</sup> Departamento de Bioquímica y Biología Molecular, Instituto Universitario de Oncología, Universidad de Oviedo, Oviedo, Spain, Spain

<sup>8</sup> Department of Genome Regulation, Max Planck Institute for Molecular Genetics, Berlin, Germany, Germany

<sup>9</sup> Computational Oncology Service, Department of Pediatrics, Memorial Sloan Kettering Cancer Center, 1275 York Ave, New York, NY, United States

<sup>10</sup> Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, United States

<sup>11</sup> Hematology Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD, United States

<sup>12</sup> Department of Leukemia, The University of Texas, MD Anderson Cancer Center, Houston, TX, United States

<sup>13</sup> Moores Cancer Center, University of California, San Diego, La Jolla, CA, United States

<sup>14</sup> Department of Internal Medicine III, Ulm University, Ulm, Germany, Germany

<sup>15</sup> IBM Research, Yorktown Heights, NY, United States

<sup>16</sup> Laboratory of Lymphoid Malignancies, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD, United States

<sup>17</sup> Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA., United States

**XIX International Workshop on CLL**

16 – 20 September 2021, Virtual

[www.iwcll2021.org](http://www.iwcll2021.org) • 1-888-476-9129



<sup>18</sup> Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf (CIO ABCD), German CLL Study Group, University Hospital Cologne, University of Cologne, Cologne, Germany, Germany

<sup>19</sup> Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Hospital Clínic de Barcelona, Barcelona, Spain, Spain

<sup>20</sup> Departamento de Bioquímica y Biología Molecular, Instituto Universitario de Oncología, Universidad de Oviedo, Oviedo, Spain., Spain

<sup>21</sup> Department of Internal Medicine III, Ulm University, Ulm, Germany, Ulm, Germany

<sup>22</sup> Broad Institute of MIT and Harvard, Cambridge, MA; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA; Harvard Medical School, Boston, MA; Department of Medicine, Brigham and Women's Hospital, Boston, MA, United States

<sup>23</sup> Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain; Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Madrid, Spain; Hospital Clinic de Barcelona, Universitat de Barcelona, Barcelona, Spain, Spain

<sup>24</sup> Broad Institute of MIT and Harvard, Cambridge, MA; Center for Cancer Research, Massachusetts General Hospital, Boston, MA; Harvard Medical School, Boston, MA; Department of Pathology, Massachusetts General Hospital, Boston, MA, United States

### **1084453**

#### **Outcomes of patients with Chronic Lymphocytic Leukemia (CLL) According to the Reasons for Initiation of First-Line Treatment: A Retrospective Analysis of the Brazilian Registry of CLL**

FERNANDA MARQUES,<sup>1</sup>VERENA PFISTER,<sup>1</sup>FLÁVIA PARRA,<sup>2</sup>MIHOKO YAMAMOTO,<sup>1</sup>LEILA PEROBELLI,<sup>3</sup>RODRIGO SANTUCCI,<sup>4</sup>MARCELO BELLESSO,<sup>5</sup>YANA NOVIS,<sup>6</sup>SERGIO FORTIER,<sup>7</sup>VALERIA BUCCHERI,<sup>8</sup>WELLINGTON SILVA JUNIOR,<sup>9</sup>GLACIANO RIBEIRO,<sup>10</sup>LAURA FOGLIATO,<sup>11</sup>NELSON HAMERSCHLAK,<sup>12</sup>PATRICIA RADTKE,<sup>13</sup>ALITA AZEVEDO,<sup>14</sup>SAMIR NABHAN,<sup>15</sup>RAFAEL GAIOLLA,<sup>16</sup>MATHEUS GONÇALVES,<sup>1</sup>CARLOS CHIATTONE,<sup>7</sup>CELSO ARRAIS-RODRIGUES,<sup>1</sup>

<sup>1</sup> Universidade Federal de Sao Paulo, Sao Paulo, Brazil

<sup>2</sup> Brazilian Registry of CLL – Associação Brasileira de Hematologia e Hemoterapia, Brazil

<sup>3</sup> Hospital Brigadeiro, Sao Paulo, Brazil

<sup>4</sup> Hemomed Instituto de Oncologia e Hematologia, Sao Paulo, Brazil

<sup>5</sup> Hemomed Instituto de Oncologia e Hematologia, Brazil

**XIX International Workshop on CLL**

16 – 20 September 2021, Virtual

[www.iwcll2021.org](http://www.iwcll2021.org) • 1-888-476-9129





- <sup>6</sup> Hospital Sirio Libanes, Sao Paulo, Brazil
- <sup>7</sup> Santa Casa de Misericórdia de São Paulo, Sao Paulo, Brazil
- <sup>8</sup> ICESP - Faculdade de Medicina da USP, Sao Paulo, Brazil
- <sup>9</sup> ICESP - Faculdade de Medicina da USP, Brazil
- <sup>10</sup> Universidade Federal de Minas Gerais, Belo Horizonte, Brazil
- <sup>11</sup> Hospital das Clínicas de Porto Alegre, Brazil
- <sup>12</sup> Hospital Israelita Albert Einstein, Brazil
- <sup>13</sup> Hospital Santa Marcelina, Brazil
- <sup>14</sup> Hemope - Fundação de Hematologia e Hemoterapia de Pernambuco, Recife, Brazil
- <sup>15</sup> Universidade Federal do Paraná, Brazil
- <sup>16</sup> 14. Hospital das Clínicas da Faculdade de Medicina de Botucatu - UNESP, Brazil

**1084475**

**Humoral Response to mRNA Vaccines BNT162b2 and mRNA-1273 COVID-19 in Chronic Lymphocytic Leukemia Patients**

CRISTINA BAGACEAN,<sup>1</sup> R MI LETESTU,<sup>2</sup> CHADI AL NAWAKIL,<sup>3</sup> S GOL NE BRICHLER,<sup>4</sup> VINCENT LEVY,<sup>3</sup> ALAIN DELMER,<sup>5</sup> CAROLINE DARTIGEAS,<sup>6</sup> VERONIQUE LEBLOND,<sup>7</sup> MARIE CHRISTINE B N ,<sup>8</sup> ALINE CLAVERT,<sup>9</sup> DRISS CHAOUI,<sup>10</sup> PHILIPPE GENET,<sup>10</sup> ROMAIN GUIEZE,<sup>11</sup> KAMEL LARIBI,<sup>12</sup> BERNARD DRENOU,<sup>13</sup> LISE WILLEMS,<sup>14</sup> CECILE TOMOWIAK,<sup>15</sup> FATIHA MERABET,<sup>16</sup> CHRISTIAN PUPPINCK,<sup>17</sup> HUGO LEGENDRE,<sup>18</sup> XAVIER TROUSSARD,<sup>19</sup> ST PHANIE MALARTRE,<sup>20</sup> FLORENCE CYMBALISTA,<sup>2</sup> ANNE-SOPHIE MICHALLET,<sup>20</sup>

<sup>1</sup> Service H matologie, CHU de Brest, Institut de Canc ro-H matologie, Brest, France, France

<sup>2</sup> Laboratoire d'H matologie, H pital Avicenne, APHP, Bobigny, France, France

<sup>3</sup> D partement de Recherche Clinique, H pital Avicenne, APHP, Bobigny, France, France

<sup>4</sup> Laboratoire de Virologie, H pital Avicenne, APHP, Bobigny, France, France

<sup>5</sup> Service H matologie, CHU de Reims, Reims, France, France

<sup>6</sup> Service H matologie et th rapie cellulaire, CHU Tours, Tours, France, France

<sup>7</sup> Service H matologie, H pital de la Piti -Salp tri re, APHP, Paris, France, France

<sup>8</sup> Service H matologie Biologique, CHU de Nantes, Nantes, France, France

**XIX International Workshop on CLL**

16 – 20 September 2021, Virtual

[www.iwcll2021.org](http://www.iwcll2021.org) • 1-888-476-9129



- <sup>9</sup> Service Hématologie, CHU Angers, Angers, France, France  
<sup>10</sup> Service Hématologie, CH Argenteuil, Argenteuil, France, France  
<sup>11</sup> Service Hématologie, CHU Clermont Ferrand, Clermont Ferrand, France, France  
<sup>12</sup> Service Hématologie, CH Le Mans, Le Mans, France, France  
<sup>13</sup> Service Hématologie, CH de Mulhouse, Mulhouse, France, France  
<sup>14</sup> Service Hématologie, Hôpital Cochin, APHP, Paris, France, France  
<sup>15</sup> Service Hématologie, CHU Poitiers, Poitiers, France, France  
<sup>16</sup> Service Hématologie, CH de Versailles, Versailles, France, France  
<sup>17</sup> Association de Soutien et d'Information à la Leucémie Lymphoïde Chronique et la maladie de Waldenström (SILLC), France  
<sup>18</sup> Service Hématologie, CHU Sud Réunion, Réunion, France, France  
<sup>19</sup> Laboratoire d'Hématologie, CHU de Caen, Caen, France, France  
<sup>20</sup> Service Hématologie, Centre Léon Bérard, Lyon, France, France

## 1084501

### CLLEAR - Czech National Registry of CLL Patients: Complete Data Analysis 2021

MICHAEL DOUBEK,<sup>1</sup>LUCIE NEKVINDOVÁ,<sup>2</sup>MARTIN SIMKOVIC,<sup>3</sup>RENATA URBANOVÁ,<sup>4</sup>MARTINA ORSULOVA,<sup>1</sup>DAN LYSÁK,<sup>5</sup>MARTIN BREJCHA,<sup>6</sup>JANA ZUCHNICKÁ,<sup>7</sup>ANNA PANOVSKA,<sup>1</sup>PAVEL VODÁREK,<sup>8</sup>PETRA OBRTLÍKOVÁ,<sup>9</sup>LEKAA MOHAMMAD,<sup>10</sup>YVONA BRYCHTOVA,<sup>1</sup>PAVLINA RYZNEROVA,<sup>11</sup>DOMINIKA ECSIOVA,<sup>3</sup>STANISLAVA MAŠLEJOVÁ,<sup>12</sup>LUCIE BEZDEKOVA,<sup>1</sup>HYNEK POUL,<sup>13</sup>JAN NOVAK,<sup>14</sup>ZUZANA KUBOVA,<sup>11</sup>MIROSLAV GENSKY,<sup>15</sup>HANA SKABRAHOVA,<sup>1</sup>MARTINA VEITOVA,<sup>1</sup>KATERINA KLASKOVA,<sup>14</sup>SARKA POSPISILOVA,<sup>1</sup>JAN MOLINSKY,<sup>16</sup>ZLATUŠE KŘSTKOVÁ,<sup>2</sup>MAREK TRNENY,<sup>16</sup>JIRI MAYER,<sup>1</sup>TOMAS PAPAŽIK,<sup>11</sup>MARTIN ŠPAČEK,<sup>17</sup>LUKÁŠ SMOLEJ,<sup>18</sup>

<sup>1</sup> University Hospital, Czech Republic

<sup>2</sup> Institute of Biostatistics and Analyses, Ltd., Brno, Czech Republic

<sup>3</sup> University Hospital Hradec Kralove, Czech Republic

<sup>4</sup> Department of Hematooncology, University Hospital, Olomouc, Czech Republic, Czech Republic

<sup>5</sup> Department of Hematooncology, University Hospital, Pilsen, Czech Republic, Czech Republic

**XIX International Workshop on CLL**

16 – 20 September 2021, Virtual

[www.iwcll2021.org](http://www.iwcll2021.org) • 1-888-476-9129



- <sup>6</sup> Department of Hematology, Hospital Agel, Nový Jičín, Czech Republic, Czech Republic
- <sup>7</sup> Department of Hematooncology, University Hospital, Ostrava, Czech Republic, Czech Republic
- <sup>8</sup> 4th Department of Internal Medicine - Hematology, University Hospital and Faculty of Medicine, Hradec Králové, Czech Republic, Czech Republic
- <sup>9</sup> First Department of Internal Medicine - Hematology, General University Hospital, Prague, Czech Republic, Czech Republic
- <sup>10</sup> University Hospital Plzen, Czech Republic
- <sup>11</sup> University Hospital Olomouc, Czech Republic
- <sup>12</sup> University Hospital, Brno, Czech Republic
- <sup>13</sup> Hospital Pelhrimov, Czech Republic
- <sup>14</sup> University Hospital Kralovske Vinohrady, Czech Republic
- <sup>15</sup> Hospital Liberec, Czech Republic
- <sup>16</sup> General Faculty Hospital, Czech Republic
- <sup>17</sup> First Department of Internal Medicine - Hematology, General University Hospital, Prague, Czech Republic, Praha 2, Czech Republic
- <sup>18</sup> 4th Department of Internal Medicine - Hematology, University Hospital and Charles University Faculty of Medicine, Hradec Králové, Czech Republic, Hradec Králové, Czech Republic

**1084525**

**Efficacy and Safety of Subcutaneous Immunoglobulins in Chronic Lymphatic Leukemia with Secondary Immunodeficiency in COVID-19 Era. A Monocentric Experience**

IDANNA INNOCENTI,<sup>1</sup>FRANCESCO AUTORE,<sup>2</sup>ANNAMARIA TOMASSO,<sup>3</sup>GIULIA BENINTENDE,<sup>3</sup>ALBERTO FRESA,<sup>3</sup>LUCA STIRPARO,<sup>3</sup>FLORENZIA VUONO,<sup>4</sup>EUGENIO GALLI,<sup>4</sup>FEDERICA SORÀ,<sup>5</sup>LUCA LAURENTI,<sup>6</sup>

<sup>1</sup> Sezione di Ematologia, Dipartimento di Diagnostica per Immagini, Radioterapia Oncologica ed Ematologia, Fondazione Policlinico Universitario A. Gemelli IRCCS, Roma, Italy., ROMA, Italy

<sup>2</sup> Sezione di Ematologia, Dipartimento di Diagnostica per Immagini, Radioterapia Oncologica ed Ematologia, Fondazione Policlinico Universitario A. Gemelli IRCCS, Roma, Italy., Rome, Italy

<sup>3</sup> Sezione di Ematologia, Dipartimento di Scienze Radiologiche ed Ematologiche, Università Cattolica del Sacro Cuore, Roma, Italy., Italy

**XIX International Workshop on CLL**

16 – 20 September 2021, Virtual

[www.iwcll2021.org](http://www.iwcll2021.org) • 1-888-476-9129



<sup>4</sup> Sezione di Ematologia, Dipartimento di Diagnostica per Immagini, Radioterapia Oncologica ed Ematologia, Fondazione Policlinico Universitario A. Gemelli IRCCS, Roma, Italy., Italy

<sup>5</sup> Sezione di Ematologia, Dipartimento di Diagnostica per Immagini, Radioterapia Oncologica ed Ematologia, Fondazione Policlinico Universitario A. Gemelli IRCCS, Università Cattolica del Sacro Cuore, Roma, Italy., Italy

<sup>6</sup> 3 Sezione di Ematologia, Dipartimento di Diagnostica per Immagini, Radioterapia Oncologica ed Ematologia, Fondazione Policlinico Universitario A. Gemelli IRCCS, Università Cattolica del Sacro Cuore, Roma, Italy., Italy

### 1084530

#### **Treatment with IL-21/IL-2 and IL-21/IL-15 Enhance Expression of CD107a and Release of Granzyme B and Perforin, Molecules Critical for a CTL Response, in CD8 T cells from CLL Patients**

RUKHSANA ASLAM,<sup>1</sup>PUI YAN CHIU,<sup>2</sup>GERARDO FERRER,<sup>2</sup>BYEONGHO JUNG,<sup>2</sup>FLORENCIA PALACIOS,<sup>3</sup>STEVEN L. ALLEN,<sup>4</sup>JONATHAN E. KOLITZ,<sup>4</sup>JOANNA RHODES,<sup>4</sup>JACQUELINE BARRIENTOS,<sup>5</sup>KANTI R. RAI,<sup>4</sup>BARBARA SHERRY,<sup>2</sup>NICHOLAS CHIORAZZI,<sup>6</sup>

<sup>1</sup> Feinstein Institute For Medical Research, New Hyde Park, New York, United States

<sup>2</sup> Feinstein Institute For Medical Research, United States

<sup>3</sup> Karches Center for Oncology Research, The Feinstein Institutes for Medical Research, Northwell Health, Manhasset, NY, USA / Research Laboratory on Chronic Lymphocytic Leukemia, Institut Pasteur de Montevideo, Uruguay, Uruguay

<sup>4</sup> Karches Center for Oncology Research, The Feinstein Institutes for Medical Research, Northwell Health, Manhasset, NY, USA / Department of Medicine, North Shore University Hospital and Long Island Jewish Medical Center, Northwell Health, Manhasset, NY, USA, United States

<sup>5</sup> Donald & Barbara Zucker School of Medicine at Hofstra/Northwell, Lake Success, New York, United States

<sup>6</sup> Karches Center for Oncology Research, The Feinstein Institutes for Medical Research, Northwell Health, Manhasset, NY, USA, New York, New York, United States

### 1084532

#### **Patterns of Repeat FISH Testing and Clonal Evolution in Patients with Untreated Chronic Lymphocytic Leukemia (CLL)**

AMBER KOEHLER,<sup>1</sup>TIMOTHY CALL,<sup>1</sup>KARI RABE,<sup>1</sup>SARA ACHENBACH,<sup>1</sup>WEI DING,<sup>1</sup>SAAD KENDERIAN,<sup>1</sup>JOSE LEIS,<sup>1</sup>YUCAI WANG,<sup>2</sup>ELI MUCHTAR,<sup>1</sup>HADIYAH AUDIL,<sup>1</sup>

**XIX International Workshop on CLL**

16 – 20 September 2021, Virtual

[www.iwcll2021.org](http://www.iwcll2021.org) • 1-888-476-9129



PAUL HAMPEL,<sup>2</sup>LINDSEY KLUCK,<sup>1</sup>STEPHANIE SMOLEY,<sup>1</sup>CURTIS HANSON,<sup>1</sup>MIN SHI,<sup>1</sup>ESTEBAN BRAGGIO,<sup>1</sup>SUSAN SCHWAGER,<sup>1</sup>SUSAN SLAGER,<sup>1</sup>NEIL KAY,<sup>3</sup>DANIEL VAN DYKE,<sup>1</sup>SAMEER PARIKH,<sup>1</sup>

<sup>1</sup> Mayo Clinic, United States

<sup>2</sup> Mayo Clinic, Rochester, Minnesota, United States

<sup>3</sup> Mayo Clinic Rochester, Rochester, Minnesota, United States

### **1084536**

#### **Prolonged Clinical Course but Similar Outcomes of Hospitalized CLL Patients Due to Acute COVID-19 Infection - Matched Pair Analysis**

MARKO LUCIJANIC,<sup>1</sup>ENA SORIC,<sup>2</sup>MARTINA SEDINIC,<sup>2</sup>ANTICA PASARIC,<sup>2</sup>ANICA SABLJIC,<sup>2</sup>SARA TOMASINEC,<sup>2</sup>MARIJA IVIC,<sup>2</sup>OZREN JAKSIC,<sup>2</sup>

<sup>1</sup> University Hospital Dubrava, Zagreb, Croatia, Croatia

<sup>2</sup> University Hospital Dubrava, Zagreb, Croatia, Zagreb, Croatia

### **1084537**

#### **The Fragility Index in 2010 - 2021 Chronic Lymphocytic Leukemia Randomized Controlled Trials**

CRISTINA BAGACEAN,<sup>1</sup>JEAN CHRISTOPHE IANOTTO,<sup>1</sup>MAROUANE BOUBAYA,<sup>2</sup>FLORENCE CYMBALISTA,<sup>3</sup>CHRISTIAN BERTHOU,<sup>1</sup>VINCENT LEVY,<sup>4</sup>

<sup>1</sup> Service Hématologie, CHU de Brest, Institut de Cancéro-Hématologie, Brest, France, France

<sup>2</sup> Département de Recherche Clinique, Hôpital Avicenne, APHP, Bobigny, France, France

<sup>3</sup> Laboratoire d'Hématologie, Hôpital Avicenne, APHP, Bobigny, France, France

<sup>4</sup> Département de Recherche Clinique, Hôpital Avicenne, APHP, Bobigny, France, Bobigny, France





**1084540**

**Pirtobrutinib (LOXO-305), A Next Generation, Highly Selective, Non-covalent BTK Inhibitor in Previously Treated CLL/SLL: Results from the Phase 1/2 BRUIN Study**

WOJCIECH JURCZAK,<sup>1</sup> JOHN PAGEL,<sup>2</sup> CATHERINE COOMBS,<sup>3</sup> NIRAV SHAH,<sup>4</sup> NICOLE LAMANNA,<sup>5</sup> EWA LECH-MARANDA,<sup>6</sup> TOBY EYRE,<sup>7</sup> JENNIFER WOYACH,<sup>8</sup> WILLIAM WIERDA,<sup>9</sup> CHAN CHEAH,<sup>10</sup> LINDSEY ROEKER,<sup>11</sup> MANISH PATEL,<sup>12</sup> BITA FAKHRI,<sup>13</sup> MINAL BARVE,<sup>14</sup> CONSTANTINE TAM,<sup>15</sup> DAVID LEWIS,<sup>16</sup> JAMES GERSON,<sup>17</sup> ALVARO ALENCAR,<sup>18</sup> JUSTIN TAYLOR,<sup>18</sup> OMAR ABDEL-WAHAB,<sup>11</sup> PAOLO GHIA,<sup>19</sup> STEPHEN SCHUSTER,<sup>17</sup> JESSICA CHEN,<sup>20</sup> BINOJ NAIR,<sup>21</sup> DONALD TSAI,<sup>21</sup> NORA KU,<sup>21</sup> MATTHEW DAVIDS,<sup>22</sup> JENNIFER BROWN,<sup>22</sup> ANTHONY MATO,<sup>11</sup>

<sup>1</sup> Maria Skłodowska-Curie National Research Institute of Oncology, Poland

<sup>2</sup> Swedish Cancer Institute, Seattle, USA, United States

<sup>3</sup> University of North Carolina at Chapel Hill, Chapel Hill, USA, United States

<sup>4</sup> Medical College of Wisconsin, Milwaukee, USA, United States

<sup>5</sup> Herbert Irving Comprehensive Cancer Center, Columbia University, New York, USA, United States

<sup>6</sup> Institute of Hematology and Transfusion Medicine, Warsaw, Poland, Poland

<sup>7</sup> Oxford University Hospitals NHS Foundation Trust, Churchill Cancer Center, Oxford, UK, United Kingdom

<sup>8</sup> The Ohio State University Comprehensive Cancer Center, Columbus, USA, United States

<sup>9</sup> MD Anderson Cancer Center, Houston, USA, United States

<sup>10</sup> Linear Clinical Research and Sir Charles Gairdner Hospital, Perth, Australia, Australia

<sup>11</sup> Memorial Sloan Kettering Cancer Center, New York, USA, United States

<sup>12</sup> Florida Cancer Specialists/Sarah Cannon Research Institute, Sarasota, USA, United States

<sup>13</sup> University of California San Francisco, San Francisco, USA, United States

<sup>14</sup> Mary Crowley Cancer Research, Dallas, USA, United States

<sup>15</sup> St. Vincent's Hospital and University of Melbourne, Melbourne, Australia

<sup>16</sup> Plymouth Hospitals NHS Trust - Derriford Hospital, Plymouth, UK, United Kingdom

<sup>17</sup> Lymphoma Program, Abramson Cancer Center, University of Pennsylvania, Philadelphia, USA, United States

<sup>18</sup> University of Miami Miller School of Medicine, Miami, USA, United States

**XIX International Workshop on CLL**

16 – 20 September 2021, Virtual

[www.iwcll2021.org](http://www.iwcll2021.org) • 1-888-476-9129



<sup>19</sup> Università Vita-Salute San Raffaele and IRCCS Ospedale San Raffaele, Milan, Italy, Italy

<sup>20</sup> Eli Lilly and Company, Indianapolis, IN, USA, United States

<sup>21</sup> Loxo Oncology at Lilly, Stamford, CT, USA, United States

<sup>22</sup> Dana-Farber Cancer Institute and Harvard Medical School, Boston, USA, United States

### **1084571**

#### **Serum Proteomic Analysis Reveals Different Inflammatory Signatures in MBL, IGHV-Mutated CLL, and IGHV-Unmutated CLL**

FLORENCIA PALACIOS,<sup>1</sup>GONZALO BLANCO,<sup>2</sup>KAMALA VANARSA,<sup>3</sup>POOJITHA DUGYALA,<sup>3</sup>STEVEN L. ALLEN,<sup>4</sup>YASMINE KIESO,<sup>5</sup>ANNA PUIGGROS,<sup>6</sup>JACQUELINE BARRIENTOS,<sup>7</sup>XAVIER CALVO,<sup>8</sup>JONATHAN E. KOLITZ,<sup>4</sup>EVA GIMENO,<sup>9</sup>JOANNA RHODES,<sup>4</sup>ANA FERRER,<sup>10</sup>KANTI R. RAI,<sup>4</sup>BLANCA ESPINET,<sup>6</sup>CHANDRA MOHAN,<sup>3</sup>NICHOLAS CHIORAZZI,<sup>11</sup>

<sup>1</sup> Karches Center for Oncology Research, The Feinstein Institutes for Medical Research, Northwell Health, Manhasset, NY, USA / Research Laboratory on Chronic Lymphocytic Leukemia, Institut Pasteur de Montevideo, Uruguay, Uruguay

<sup>2</sup> Karches Center for Oncology Research, The Feinstein Institutes for Medical Research, Northwell Health, Manhasset, NY, USA / Hospital del Mar Medical Research Institute (IMIM), Hospital del Mar, Barcelona, Spain, Spain

<sup>3</sup> Biomedical Engineering & Medicine, University of Houston, Houston, TX, USA, United States

<sup>4</sup> Karches Center for Oncology Research, The Feinstein Institutes for Medical Research, Northwell Health, Manhasset, NY, USA / Department of Medicine, North Shore University Hospital and Long Island Jewish Medical Center, Northwell Health, Manhasset, NY, USA, United States

<sup>5</sup> Karches Center for Oncology Research, The Feinstein Institutes for Medical Research, Northwell Health, Manhasset, NY, USA, United States

<sup>6</sup> Servei de Patologia, Hospital del Mar, Barcelona, Spain; Grup de Recerca Translacional en Neoplàsies Hematològiques, Programa de Recerca en Càncer, Institut Hospital del Mar d'Investigacions Mèdiques (IMIM), Barcelona, Spain, Barcelona, Spain

<sup>7</sup> Donald & Barbara Zucker School of Medicine at Hofstra/Northwell, Lake Success, New York, United States

<sup>8</sup> Hospital del Mar Medical Research Institute (IMIM), Hospital del Mar, Barcelona, Spain, Spain

<sup>9</sup> Grup de Recerca Clínica Aplicada en Neoplàsies Hematològiques, Programa de Recerca en Càncer, Hospital del Mar-IMIM, Barcelona, Spain; Servei d'Hematologia, Hospital del Mar, Barcelona, Spain, Spain



<sup>10</sup> Servei de Patologia, Hospital del Mar, Barcelona, Spain; Grup de Recerca Translacional en Neoplàsies Hematològiques, Programa de Recerca en Càncer, Institut Hospital del Mar d'Investigacions Mèdiques (IMIM), Barcelona, Spain, Spain

<sup>11</sup> Karches Center for Oncology Research, The Feinstein Institutes for Medical Research, Northwell Health, Manhasset, NY, USA, New York, New York, United States

#### **1084574**

##### **Relation Between Serum Thymidine Kinase, Beta-2 Microglobulin and LDH with Tumor Mass and Distribution in B-Cell Chronic Lymphocytic Leukemia (B-CLL)**

MARIJA IVIC,<sup>1</sup>MARTINA SEDINIC,<sup>1</sup>BRANKICA SIMAC,<sup>1</sup>OZANA JAKSIC,<sup>2</sup>ENA SORIC,<sup>1</sup>DAVID CICIC,<sup>1</sup>ZDRAVKO MITROVIC,<sup>1</sup>RAJKO KUSEC,<sup>1</sup>VLATKO PEJSA,<sup>1</sup>OZREN JAKSIC,<sup>1</sup>

<sup>1</sup> University Hospital Dubrava, Zagreb, Croatia, Zagreb, Croatia

<sup>2</sup> School of Medicine, University of Zagreb, Croatia, Zagreb, Croatia

#### **1084582**

##### **Outcomes Beyond Progression in Ibrutinib-Treated Patients with Chronic Lymphocytic Leukemia**

PAUL HAMPEL,<sup>1</sup>KARI RABE,<sup>2</sup>TIMOTHY CALL,<sup>2</sup>WEI DING,<sup>2</sup>JOSE LEIS,<sup>2</sup>ASHER CHANAN-KHAN,<sup>3</sup>SAAD KENDERIAN,<sup>2</sup>ELI MUCHTAR,<sup>2</sup>YUCAI WANG,<sup>1</sup>SIKANDER AILAWADHI,<sup>4</sup>AMBER KOEHLER,<sup>2</sup>SUSAN SCHWAGER,<sup>2</sup>CURTIS HANSON,<sup>2</sup>MIN SHI,<sup>2</sup>DANIEL VAN DYKE,<sup>2</sup>ESTEBAN BRAGGIO,<sup>2</sup>SUSAN SLAGER,<sup>2</sup>NEIL KAY,<sup>5</sup>SAMEER PARIKH,<sup>2</sup>

<sup>1</sup> Mayo Clinic, Rochester, Minnesota, United States

<sup>2</sup> Mayo Clinic, United States

<sup>3</sup> Mayo Clinic Jacksonville, Jacksonville, Florida, United States

<sup>4</sup> Mayo Clinic Florida, Jacksonville, Florida, United States

<sup>5</sup> Mayo Clinic Rochester, Rochester, Minnesota, United States



**1084587**

**Novel Strategies for Three-Dimensional Culture of Chronic Lymphocytic Leukemia Cells**

HANA SVOZILOVÁ,<sup>1</sup>LUCY VOJTOVÁ,<sup>2</sup>DANIEL HORÁK,<sup>3</sup>RADANA STUDENÁ,<sup>4</sup>JANA DORAZILOVÁ,<sup>2</sup>Jiří BALOUN,<sup>4</sup>ZDENĚK PLICHTA,<sup>3</sup>VLADIMÍR PROKS,<sup>3</sup>MICHAEL DOUBEK,<sup>5</sup>ŠÁRKA POSPÍŠILOVÁ,<sup>6</sup>

<sup>1</sup> Center of Molecular Medicine, Central European Institute of Technology, Masaryk University Brno & Department of Internal Medicine-Hematology and Oncology, University Hospital Brno and Faculty of Medicine, Masaryk University Brno, Czech Republic, Brno, Czech Republic

<sup>2</sup> Advanced Biomaterials, Central European Institute of Technology, Brno University of Technology, Brno, Czech Republic, Czech Republic

<sup>3</sup> Institute of Macromolecular Chemistry, Czech Academy of Sciences, Prague, Czech Republic, Czech Republic

<sup>4</sup> Center of Molecular Medicine, Central European Institute of Technology, Masaryk University Brno, Czech Republic, Czech Republic

<sup>5</sup> Center of Molecular Medicine, Central European Institute of Technology, Masaryk University Brno & Department of Internal Medicine-Hematology and Oncology, University Hospital Brno and Faculty of Medicine, Masaryk University Brno, Czech Republic, Czech Republic

<sup>6</sup> Center of Molecular Medicine, Central European Institute of Technology, Masaryk University Brno & Department of Internal Medicine-Hematology and Oncology, University Hospital Brno and Faculty of Medicine, Masaryk University Brno, Czech Republic, Brno, Czech Republic

**1084593**

**Healthcare Team Burden Due To the Utilization of Novel Therapeutics for Chronic Lymphocytic Leukemia (CLL) and Lymphoid Malignancies**

MAISHARA MUQUITH,<sup>1</sup>HEATHER REVES,<sup>2</sup>FARRUKH AWAN,<sup>2</sup>

<sup>1</sup> The University of Texas Southwestern Medical Center, Dallas, Texas, United States

<sup>2</sup> The University of Texas Southwestern, United States

**1084598**

**Chronic Lymphocytic Leukemia Actively Induces T-Cell Dysfunction by Contact-Dependent Signaling**

J.A.C. VAN BRUGGEN,<sup>1</sup>F.S. PETERS,<sup>2</sup>E. ELDERING,<sup>1</sup>G.W.J. VAN DER WINDT,<sup>1</sup>ARNON KATER,<sup>3</sup>

**XIX International Workshop on CLL**

16 – 20 September 2021, Virtual

[www.iwcll2021.org](http://www.iwcll2021.org) • 1-888-476-9129



<sup>1</sup> Amsterdam UMC, Netherlands

<sup>2</sup> Amsterdam UMC, Amsterdam, Netherlands

<sup>3</sup> Amsterdam University Medical Centers, Amsterdam, on behalf of Hovon, Amsterdam, Netherlands

**1084599**

**RPS15 Mutation Impacts B-Cell Fate and Drives B-Cell Malignancy Through Myc Activation in a Murine Model**

CATHERINE GUTIERREZ,<sup>1</sup> PEYTON WADDICOR,<sup>2</sup> TAMARA OUSPENSKAIA,<sup>3</sup> DORIS FU,<sup>4</sup> ANAT BIRAN,<sup>5</sup> AVIV LIANI,<sup>6</sup> GREGORY LAZARIAN,<sup>7</sup> ELISA TEN HACKEN,<sup>5</sup> ELIZABETH WITTEN,<sup>5</sup> FARA FAYE REGIS,<sup>5</sup> HEATHER JOYAL,<sup>5</sup> LEAH BILLINGTON,<sup>5</sup> NATHAN DANGLE,<sup>5</sup> FABIENNE LUCAS,<sup>8</sup> MEI ZHENG,<sup>8</sup> BLAKE WELLS,<sup>9</sup> MARÍA HERNÁNDEZ-SÁNCHEZ,<sup>10</sup> SHUQIANG LI,<sup>5</sup> LILI WANG,<sup>11</sup> AZIZ AL'KHAFAJI,<sup>3</sup> KENNETH J. LIVAK,<sup>5</sup> DONNA S. NEUBERG,<sup>5</sup> FLORENCE CYMBALISTA,<sup>12</sup> RUBEN CARRASCO,<sup>5</sup> STIRLING SHAO,<sup>9</sup> AVIV REGEV,<sup>3</sup> CATHERINE WU,<sup>5</sup>

<sup>1</sup> Harvard Medical School, Boston, Massachusetts, United States

<sup>2</sup> Harvard Medical School, Massachusetts, United States

<sup>3</sup> Broad Institute of MIT and Harvard, United States

<sup>4</sup> Massachusetts Institute of Technology, United States

<sup>5</sup> Dana Farber Cancer Institute, United States

<sup>6</sup> Northeastern University, United States

<sup>7</sup> APHP Hôpital Avicenne, United States

<sup>8</sup> Brigham and Women's Hospital, United States

<sup>9</sup> Harvard Medical School, United States

<sup>10</sup> University of Salamanca, IBSAL, IBMCC, CSIC, Cancer Research Center. Department of Hematology, University Hospital of Salamanca, Salamanca, Spain

<sup>11</sup> City of Hope, United States

<sup>12</sup> Laboratoire d'Hématologie, Hôpital Avicenne, APHP, Bobigny, France, France





**1084604**

**Mono-Therapy of Ibrutinib Effectively Reduced the Incidence of Richter Transformation in Secondary but Not Primary Lymphoid Organs and Failed in Treating Transformed Lymphoma in Pre-Clinical Mouse Models**

SHIH-SHIH CHEN,<sup>1</sup>JACQUELINE BARRIENTOS,<sup>2</sup>XIAO-JIE YAN,<sup>3</sup>UWE WIRTZ,<sup>4</sup>EDITH SZAFER-GLUSMAN,<sup>4</sup>KANTI R. RAI,<sup>5</sup>NICHOLAS CHIORAZZI,<sup>3</sup>

<sup>1</sup> Feinstein Institute for Medical Research, United States

<sup>2</sup> Donald & Barbara Zucker School of Medicine at Hofstra/Northwell, Lake Success, New York, United States

<sup>3</sup> The Feinstein Institute for Medical Research, New York, United States

<sup>4</sup> Pharmacyclics, United States

<sup>5</sup> Karches Center for Oncology Research, The Feinstein Institutes for Medical Research, Northwell Health, Manhasset, NY, USA / Department of Medicine, North Shore University Hospital and Long Island Jewish Medical Center, Northwell Health, Manhasset, NY, USA, United States

**1084612**

**Severe Neutropenia in Chronic Lymphocytic Leukemia (CLL) Patients Treated with Ibrutinib**

AMBER KOEHLER,<sup>1</sup>WILLIAM ARCHIBALD,<sup>1</sup>TIMOTHY CALL,<sup>1</sup>KARI RABE,<sup>1</sup>SARA ACHENBACH,<sup>1</sup>WEI DING,<sup>1</sup>SAAD KENDERIAN,<sup>1</sup>JOSE LEIS,<sup>1</sup>YUCAI WANG,<sup>2</sup>ELI MUCHTAR,<sup>1</sup>LINDSEY KLUCK,<sup>1</sup>PAUL HAMPEL,<sup>2</sup>SUSAN SCHWAGER,<sup>1</sup>SUSAN SLAGER,<sup>1</sup>NEIL KAY,<sup>3</sup>SAMEER PARIKH,<sup>1</sup>

<sup>1</sup> Mayo Clinic, United States

<sup>2</sup> Mayo Clinic, Rochester, Minnesota, United States

<sup>3</sup> Mayo Clinic Rochester, Rochester, Minnesota, United States

**1084672**

**Positive effects on Quality of Life in Patients with Chronic Lymphocytic Leukemia treated with Ibrutinib. Interim analysis of a Real-World Study**

MARIA JOSE MELA OSORIO,<sup>1</sup>ASTRID PAVLOVSKY,<sup>2</sup>CAROLINA PAVLOVSKY,<sup>2</sup>ISOLDA FERNÁNDEZ,<sup>2</sup>CLAVIJO MANUELA,<sup>3</sup>AUGUSTO MIROLI,<sup>4</sup>

**XIX International Workshop on CLL**

16 – 20 September 2021, Virtual

[www.iwcll2021.org](http://www.iwcll2021.org) • 1-888-476-9129



FEDERICO SACKMANN MASSA,<sup>2</sup>GUILLERMINA REMAGGI,<sup>5</sup>LUCIANA FERRARI,<sup>2</sup>MARIANA JUNI,<sup>2</sup>MAXIMILIANO RIDDICK,<sup>6</sup>MIGUEL A PAVLOVSKY,<sup>2</sup>

<sup>1</sup> FUNDALEU, Buenos Aires, Argentina

<sup>2</sup> Fundaleu, Argentina

<sup>3</sup> Hospital Aleman, Argentina

<sup>4</sup> Policlínico del Docente OSPLAD. Complejo Médico Churruca-Visca., Argentina

<sup>5</sup> Fundaleu, United States

<sup>6</sup> Departamento de Matemática, Facultad de Ciencias Exactas, UNLP, CONICET. INIFTA, Facultad de Ciencias Exactas, UNLP., Argentina

#### **1085354**

**Prognostic value of PET/CT in the prediction of Time to First Treatment in Chronic Lymphocytic Leukemia/ Small Lymphocytic Leukemia patients at diagnosis**

HUAYUAN ZHU,<sup>1</sup>YEQIN SHA,<sup>2</sup>CHONGYANG DING,<sup>1</sup>WEI WU,<sup>1</sup>YI XIA,<sup>1</sup>YI MIAO,<sup>2</sup>SHUCHAO QIN,<sup>1</sup>LI WANG,<sup>2</sup>LEI FAN,<sup>2</sup>WEI XU,<sup>2</sup>JIANYONG LI,<sup>1</sup>

<sup>1</sup> Jiangsu Province Hospital, The First Affiliated Hospital of Nanjing Medical University, China (People's Republic)

<sup>2</sup> Jiangsu Province Hospital, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China (People's Republic)

#### **1085379**

**BTK Inhibitor Ibrutinib/Zanubrutinib Plus Bendamustine and Rituximab as the Initial Treatment for Chronic Lymphocytic Leukemia/Small Lymphocytic Leukemia: A Single Arm Real-World Study**

HUAYUAN ZHU,<sup>1</sup>WEI WU,<sup>1</sup>ZE JIN,<sup>1</sup>YEQIN SHA,<sup>2</sup>CHONGYANG DING,<sup>1</sup>ZHEN WANG,<sup>1</sup>YILIAN YANG,<sup>1</sup>JINGYAN QIU,<sup>1</sup>HONGLING BEI,<sup>1</sup>CHEN PENG,<sup>1</sup>RUIZE CHEN,<sup>1</sup>LI WANG,<sup>2</sup>LEI FAN,<sup>2</sup>WEI XU,<sup>2</sup>JIANYONG LI,<sup>3</sup>

<sup>1</sup> Jiangsu Province Hospital, The First Affiliated Hospital of Nanjing Medical University, China (People's Republic)

**XIX International Workshop on CLL**

16 – 20 September 2021, Virtual

[www.iwcll2021.org](http://www.iwcll2021.org) • 1-888-476-9129



<sup>2</sup> Jiangsu Province Hospital, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China (People's Republic)

<sup>3</sup> Jiangsu Province Hospital, The First Affiliated Hospital of Nanjing Medical University, United States

## **LATE BREAKERS**

### **1107620**

#### **Expression of 14q32 miRNAs Correlate with Gene Expression Changes in CLL Cases Defined by IGHV Mutational Status and BCR Signalling Capacity, with a Putative Role in the Regulation of GAB1**

DEAN BRYANT,<sup>1</sup>LINDSAY SMITH,<sup>2</sup>KARLY-RAI ROGERS-BROADWAY,<sup>2</sup>JEONGMIN WOO,<sup>2</sup>RACHEL FELL,<sup>2</sup>LAURA KARYDIS,<sup>2</sup>MATTHEW BLUNT,<sup>2</sup>HELEN PARKER,<sup>2</sup>LARA BUERMANN,<sup>2</sup>FREDA STEVENSON,<sup>1</sup>FRANCESCO FORCONI,<sup>1</sup>PACKHAM GRAHAM,<sup>1</sup>ANDREW STEELE,<sup>3</sup>JONATHAN STREFFORD,<sup>2</sup>

<sup>1</sup> University of Southampton, Southampton, United Kingdom

<sup>2</sup> University of Southampton, United Kingdom

<sup>3</sup> Janssen Pharmaceutical Companies of Johnson and Johnson, Southampton, Pennsylvania, United States

### **1109564**

#### **Gain-of-Function Variants of Complement C2 Support Cytocidal Activity of Anticancer Monoclonal Antibodies**

ALEKSANDRA URBAN,<sup>1</sup>ALAN MAJERANOWSKI,<sup>2</sup>GRZEGORZ STASHOJÓ,<sup>3</sup>PATRYCJA KOSZAŁKA,<sup>3</sup>ANNA FELBERG,<sup>3</sup>MICHAŁ TASZNER,<sup>4</sup>JAN ZAUCHA,<sup>4</sup>MARCIN OKRÓJ,<sup>5</sup>

<sup>1</sup> Department of Cell Biology and Immunology, Intercollegiate Faculty of Biotechnology, University of Gdańsk and Medical University of Gdańsk, Gdansk, Poland

<sup>2</sup> Department of Cell Biology and Immunology, Intercollegiate Faculty of Biotechnology, University of Gdańsk and Medical University of Gdańsk; Department of Hematology and Transplantology, Medical University, Gdansk, Poland, Gdansk, Poland

<sup>3</sup> Department of Cell Biology and Immunology, Intercollegiate Faculty of Biotechnology, University of Gdańsk and Medical University of Gdańsk, Poland

<sup>4</sup> Department of Hematology and Transplantology, Medical University of Gdańsk, Poland

<sup>5</sup> Department of Cell Biology and Immunology, Intercollegiate Faculty of Biotechnology, University of Gdańsk, Poland

**XIX International Workshop on CLL**

16 – 20 September 2021, Virtual

[www.iwcll2021.org](http://www.iwcll2021.org) • 1-888-476-9129